

Applicants : Naldini et al.,  
USSN : 10/554,181  
Filed : 12/27/2005  
Examiner : David Guzo  
Page : 6

Atty. Dkt. No. : 1130-PCT-US  
Art Unit : 1636  
Date of office action : 11/16/2007  
Date of response : 03/17/2008

### REMARKS

#### Claim Status

Claims 1-18 are pending. Applicants have canceled claim 2 without prejudice to pursue the subject matter in a future application. Claims 1, 3, 12, 14, 15 and 16 have been amended.

#### Support for the amendments to the claims

Support for amended claim 1 may be found *inter alia* on page 17 of the Specification, lines 15-27; claim 1 and claim 2 as filed.

Support for amended claim 3 may be found *inter alia* on page 17 of the Specification, lines 21-24.

Support for amended claim 12 may be found *inter alia* on page 5 of the Specification, line 10.

Support for amended claims 13-16 may be found *inter alia* in claims 13-16 as filed.

Applicants respectfully request the entry of this Amendment. Upon entry, Claims 1, 3-18 are pending and under examination.

#### Rejections Under 35 U.S.C. §112

Claims 12-13 are rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The rejection is respectfully traversed.

Claim 12 has been amended to recite that the tissue animal cells are brain neurons. Claim 13 has been amended to clarify that the aim is to express the sequences in an animal cell. Applicants submit that claim 12 and 13 have been amended to obviate the rejection. Accordingly, Applicants respectfully

Applicants : Naldini et al.,	Atty. Dkt. No.	: 1130-PCT-US
USSN : 10/554,181	Art Unit	: 1636
Filed : 12/27/2005	Date of office action	: 11/16/2007
Examiner : David Guzo	Date of response	: 03/17/2008
Page : 7		

request that the rejection of claims 12-13 under 35 U.S.C. §112, second paragraph, be withdrawn.

#### **Rejections Under 35 U.S.C. §102**

Claims 1-4 and 6-15 are rejected under 35 U.S.C. §102(e) as being anticipated by Chtarto et al. The rejection is respectfully traversed.

Chtarto et al. is directed exclusively to a vector comprising a bi-directional antibiotic controlled activator-responsive promoter. In particular, the promoter comprises a tetracycline (Tet) responsive element.

The **Tet responsive promoter** is a synthetic sequence composed of 7 repetitions of an 8 nucleotide-long **prokaryotic sequence**. Such promoter is not able to exploit the endogenous mammalian transcriptional machinery in order to work properly. Therefore, to render this promoter functional, it is necessary to express an **additional** transgene encoding for a chimeric transcriptional activator composed of two halves, the first one being of **prokaryotic** origin and the second one being of **viral or human** origin.

A fundamental feature of the tetracycline-responsive expression system is that the promoters used must be insulated from nearby competing enhancers in order to prevent inappropriate transactivation and preserve integrity of modulation by doxycycline. Therefore, only minimal promoters have been so far used in this system. Moreover, the Tet-regulated system depends on the expression (or exogenous administration) of transactivators, whose expression (or administration) may encounter problems in vivo.

Applicants : Naldini et al.,  
USSN : 10/554,181  
Filed : 12/27/2005  
Examiner : David Guzo  
Page : 8

Atty. Dkt. No. : 1130-PCT-US  
Art Unit : 1636  
Date of office action : 11/16/2007  
Date of response : 03/17/2008

In contrast, the present invention is directed to **synthetic eukaryotic bidirectional promoters**, based on the juxtaposition of a core promoter element placed upstream and in opposite orientation to an efficient promoter, that exploits the endogenous transcriptional machinery available to most animal cells types to drive robust expression of two divergent transcripts. The fact that the bidirectional promoter of the present invention comprises a minimal viral promoter and a **full length animal** promoter represents a fundamental difference over the prior art in general, and over Chtarto et al. in particular.

It is well known in this art that the eukaryotic and prokaryotes promoters act differently. For example,

*The promoter contains specific DNA sequences, response elements, that are recognized by proteins known as transcription factors. These factors bind to the promoter sequences, recruiting RNA polymerase, the enzyme that synthesizes the RNA from the coding region of the gene.*

- In prokaryotes, the promoter is recognized by RNA polymerase and an associated sigma factor, which in turn are brought to the promoter DNA by an activator protein binding to its own DNA sequence nearby.*
- In eukaryotes, the process is more complicated, and at least seven different factors are necessary for the transcription of an RNA polymerase II promoter."*

See Exhibit A, 5 pages.

In addition, it is well known from general biology text books that a promoter of a prokaryote organism cannot work in the environment of an eukaryote organism and vice versa.

The bidirectional promoter of the present invention can be based on any eukaryotic promoter: ubiquitous, constitutive, tissue specific or endogenously regulated.

Applicants : Naldini et al.,  
USSN : 10/554,181  
Filed : 12/27/2005  
Examiner : David Guzo  
Page : 9

Atty. Dkt. No. : 1130-PCT-US  
Art Unit : 1636  
Date of office action : 11/16/2007  
Date of response : 03/17/2008

In nature, few instances of bidirectional promoters have been documented and only very recently recent surveys of the human genome have indicated an abundance of divergently transcribed gene pairs representing more than 10% of the human genome, whose transcriptional start sites are separated by less than 1 kb. In addition, it has been suggested that more than half of the human promoters does not exhibit strong directionality in transcript initiation and can function in a bidirectional fashion. Thus, the synthetic bidirectional promoters of the present invention may mimic a well-represented and evolutionary conserved feature of eukaryotic transcription, providing a structural basis for their robust performance.

More specifically, Chtarto et al. require the use of a transactivator factor encoded by a reverse antibiotic controlled transactivator nucleotide sequence for activating the bi-directional promoter. See, for instance, Chtarto et al. column 5, lines 12-16:

*In said construct or system the bi-directional antibiotic controller activator responsive promoter/operator sequence 4 is advantageously activated by the transactivator factor 7, encoded by the reverse antibiotic controlled transactivator 7, encoded by the reverse antibiotic controlled transactivator nucleotide sequence 6 in the presence of said antibiotic 5.*

That Chtarto et al. is only directed to an antibiotic inducible/repressible genetic construct is clear throughout the document. See further Fig. 6, column 4, lines 42-43, column 5, lines 22-32.

The present invention offers the construction of a bidirectional promoter comprising a minimal viral promoter and a full length eukaryotic promoter. See, for instance, description page 7, lines 3-8:

Applicants : Naldini et al.,  
USSN : 10/554,181  
Filed : 12/27/2005  
Examiner : David Guzo  
Page : 10

Atty. Dkt. No. : 1130-PCT-US  
Art Unit : 1636  
Date of office action : 11/16/2007  
Date of response : 03/17/2008

*A bidirectional promoter made by minimal core promoter elements from the human cytomegalovirus (mCMV) joined upstream, and in opposite orientation, to an efficient promoter, derived from the human phosphoglycerate kinase (PGK) or poly-ubiquitin UBI-C gene, was driving divergent transcription of two RNAs.*

In conclusion, Chtarto et al. do not anticipate the present invention because Charto et al. do not teach each and every aspect of the present invention. Accordingly, Applicants respectfully request that the rejection of claims 1-4 and 6-15 under 35 U.S.C. §102(e) be withdrawn.

Claims 1-4 and 6-11 and 13-18 are rejected under 35 U.S.C. §102(e) as being anticipated by Itoh et al. The rejection is respectfully traversed.

Itoh et al. is directed exclusively to a vector comprising a low molecular weight compound-responsive bidirectional promoter and a DNA encoding a low molecular weight compound-controlled transactivator. In particular, the low molecular weight compound is tetracycline or doxycycline and the low molecular weight compound-controlled transactivator is a reverse tetracycline transactivator.

Therefore, arguments presented above concerning Chtarto et al. are also valid in respect to Itoh et al.

In conclusion, Itoh et al. do not anticipate the present invention because Itoh et al. do not teach each and every aspect of the present invention. Accordingly, Applicants respectfully request that the rejection of claims 1-4 and 6-11 and 13-18 under 35 U.S.C. §102(e) be withdrawn.

Applicants : Naldini et al.,	Atty. Dkt. No.	: 1130-PCT-US
USPN : 10/554,181	Art Unit	: 1636
Filed : 12/27/2005	Date of office action	: 11/16/2007
Examiner : David Guzo	Date of response	: 03/17/2008
Page : 11		

Claims 1-4, 7-8, 10 and 14 are rejected under 35 U.S.C. §102(b) as being anticipated by Fux et al. The rejection is respectfully traversed.

Fux et al. discloses the construction of two vectors, pDuoRex7 and pDuoRex8 (see page 114, left column, last paragraph) which contain two antibiotic-responsive expression units in divergent orientation. Such pDuoRex-based dual regulated expression requires concomitant production of tTA and PIT (see page 114, right column, first paragraph).

Thus, arguments presented above concerning Chtarto et al. are also valid in respect to Fux et al.

In conclusion, Fux et al. do not anticipate the present invention because Fux et al. do not teach each and every aspect of the present invention. Accordingly, Applicants respectfully request that the rejection of claims 1-4, 7-8, 10 and 14 under 35 U.S.C. §102(b) be withdrawn.

It should be noted that none of the cited prior art documents discloses a bidirectional promoter comprising a minimal viral promoter and a full length animal promoter. Therefore none of the cited documents anticipate the present invention.

Moreover, starting from the teaching of Chtarto et al., or Itoh et al. or Fux et al. and due to the evolutionary distance between prokaryotes and mammals and to their differences in the transcriptional machinery, the person skilled in the art would not predict and foresee that mammalian promoters could be also exploited for building a bidirectional promoter. Therefore, the invention is not obvious in respect to such cited prior art documents.

Applicants : Naldini et al.,  
USSN : 10/554,181  
Filed : 12/27/2005  
Examiner : David Guzo  
Page : 12

Atty. Dkt. No. : 1130-PCT-US  
Art Unit : 1636  
Date of office action : 11/16/2007  
Date of response : 03/17/2008

**Rejections Under 35 U.S.C. §103**

Claim 5 is rejected under 35 U.S.C. §103(a) as being unpatentable over Chtarto et al. or Itoh et al., in view of Hope et al. (US 6,136,597).

Chtarto et al. and Itoh et al. have been discussed above. Hope et al. disclose an RNA export element which mediates efficient transport of RNA from the nucleus to the cytoplasm. This RNA export element is referred to as WPRE. WPRE is a post transcriptional regulatory element. Hence, Hope et al. teach using WPRE to increase transgene expression.

Therefore, even though assuming it is appropriate to combine Chtarto et al., and Hope et al., or Itoh et al., and Hope et al., (which the Applicants do not concede), such combination would not teach or suggest all of the features of dependent claim 5. In particular, the combined teaching of Chtarto, Itoh and Hope does not teach or suggest constructing a bidirectional promoter comprising a minimal viral promoter and a full length animal promoter.

Accordingly, Applicants respectfully request that the rejection of claim 5 under 35 U.S.C. §103(a) be withdrawn.

For the Examiner's information, the corresponding **European Application** of this subject application has been granted and is attached hereto as **Exhibit B, 71 pages**.

Applicants : Naldini et al.,  
USSN : 10/554,181  
Filed : 12/27/2005  
Examiner : David Guzo  
Page : 13


Atty. Dkt. No. : 1130-PCT-US  
Art Unit : 1636  
Date of office action : 11/16/2007  
Date of response : 03/17/2008

**Conclusion**

In summary, Applicants believe that all grounds of rejections have been addressed and earnestly request the Examiner to place this application in condition for allowance.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below. If any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,



Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicants  
Law Offices of Albert Wai-Kit  
Chan, PLLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, NY 11357  
Tel: (718) 799-1000  
Fax: (718) 357-8615  
e-mail: chank@kitchanlaw.com

# **EXHIBIT A**

# Promoter

From Wikipedia, the free encyclopedia

In biology, a **promoter** is a regulatory region of DNA located upstream (towards the 3' region of the anti-sense strand) of a gene, providing a control point for regulated gene transcription.

## Contents

- 1 Overview
- 2 Identification of relative location
- 3 Promoter elements
  - 3.1 Prokaryotic promoters
    - 3.1.1 Probability of occurrence of each nucleotide
  - 3.2 Eukaryotic promoters
- 4 Detection of promoters
- 5 Evolutionary change
- 6 Binding
- 7 Diseases associated with aberrant promoter function
- 8 Canonical sequences and wild-type
- 9 Diseases associated with promoter elements
- 10 References
- 11 External links

## Overview

The promoter contains specific DNA sequences, response elements, that are recognized by proteins known as transcription factors. These factors bind to the promoter sequences, recruiting RNA polymerase, the enzyme that synthesizes the RNA from the coding region of the gene.

- In prokaryotes, the promoter is recognized by RNA polymerase and an associated sigma factor, which in turn are brought to the promoter DNA by an activator protein binding to its own DNA sequence nearby.
- In eukaryotes, the process is more complicated, and at least seven different factors are necessary for the transcription of an RNA polymerase II promoter.

Promoters represent critical elements that can work in concert with other regulatory regions (enhancers, silencers, boundary elements/insulators) to direct the level of transcription of a given gene.

It is worth noting that promoters are not DNA specific, and can in fact locate upstream towards the 3' end of an RNA genome, e.g. Respiratory Syncytial Virus (RSV).

## Identification of relative location

As promoters are typically immediately adjacent to the gene in question, positions in the promoter are designated relative to the transcriptional start site, where transcription of RNA begins for a particular

gene (i.e., positions upstream are negative numbers counting back from -1, for example -100 is a position 100 base pairs upstream).

## Promoter elements

- Core promoter - the minimal portion of the promoter required to properly initiate transcription
  - Transcription Start Site (TSS)
  - Approximately -34
  - A binding site for RNA polymerase
    - RNA polymerase I: transcribes genes encoding ribosomal RNA
    - RNA polymerase II: transcribes genes encoding messenger RNA and certain small nuclear RNAs
    - RNA polymerase III: transcribes genes encoding tRNAs and other small RNAs
  - General transcription factor binding sites
- Proximal promoter - the proximal sequence upstream of the gene that tends to contain primary regulatory elements
  - Approximately -250
  - Specific transcription factor binding sites
- Distal promoter - the distal sequence upstream of the gene that may contain additional regulatory elements, often with a weaker influence than the proximal promoter
  - Anything further upstream (but not an enhancer or other regulatory region whose influence is positional/orientation independent)
  - Specific transcription factor binding sites

## Prokaryotic promoters

In prokaryotes, the promoter consists of two short sequences at -10 and -35 positions *upstream* from the transcription start site. Sigma factors not only help in enhancing RNAP binding to the promoter but helps RNAP target which genes to transcribe.

- The sequence at -10 is called the Pribnow box, or the -10 element, and usually consists of the six nucleotides TATAAT. The Pribnow box is absolutely essential to start transcription in prokaryotes.
- The other sequence at -35 (the -35 element) usually consists of the six nucleotides TTGACA. Its presence allows a very high transcription rate.
- Both of the above consensus sequences, while conserved on average, are not found intact in most promoters. On average only 3 of the 6 base pairs in each consensus sequence is found in any given promoter. No promoter has been identified to date that has intact consensus sequences at both the -10 and -35; it is thought that this would lead to such tight binding by the sigma factor that the polymerase would be unable to initiate productive transcription.
- Some promoters contain a UP element (consensus sequence 5'-TGNTATAAT-3') upstream of the -35 element; the presence of the -35 element appears to be unimportant for transcription from the UP element-containing promoters.

It should be noted that the above promoter sequences are only recognized by the sigma-70 protein that interacts with the prokaryotic RNA polymerase. Complexes of prokaryotic RNA polymerase with other sigma factors recognize totally different core promoter sequences.

(note that the optimal spacing between the -35 and -10 sequences is 17 nt)

for -10 sequence					
T	A	T	A	A	T
77%	76%	60%	61%	56%	82%

for -35 sequence					
T	T	G	A	C	A
69%	79%	61%	56%	54%	54%

Eukaryotic promoters are extremely diverse and are difficult to characterize. They typically lie upstream of the gene and can have regulatory elements several kilobases away from the transcriptional start site. In eukaryotes, the transcriptional complex can cause the DNA to bend back on itself, which allows for placement of regulatory sequences far from the actual site of transcription. Many eukaryotic promoters, but by no means all, contain a TATA box (sequence TATAAA), which in turn binds a TATA binding protein which assists in the formation of the RNA polymerase transcriptional complex.<sup>[1]</sup> The TATA box typically lies very close to the transcriptional start site (often within 50 bases).

Eukaryotic promoter regulatory sequences typically bind proteins called transcription factors which are involved in the formation of the transcriptional complex. An example is the E-box (sequence CACGTG), which binds transcription factors in the basic-helix-loop-helix (bHLH) family (e.g. BMAL1-Clock, cMyc).<sup>[2]</sup>

A wide variety of algorithms have been developed to facilitate detection of promoters in genomic sequence, and promoter prediction is a common element of many gene prediction methods.

A major question in evolutionary biology is how important tinkering with promoter sequences is to evolutionary change, for example, the changes that have occurred in the human lineage after separating from chimps.

Some evolutionary biologists, for example Allan Wilson, have proposed that evolution in promoter or regulatory regions may be more important than changes in coding sequences over such time frames.

<http://en.wikipedia.org/wiki/Promoter>

The binding of a promoter sequence (P) to a sigma factor-RNAP complex (R) is a two-step process:

1.  $R+P \leftrightarrow RP(\text{closed}), K = 10^7$
2.  $RP(\text{closed}) \rightarrow RP(\text{open}), K = 10^{-2}$

## Diseases associated with aberrant promoter function

Though OMIM is a major resource for gathering information on the relationship between mutations and natural variation in gene sequence and susceptibility to hundreds of diseases, it requires a sophisticated search strategy to extract those diseases that are associated with defects in transcriptional control where the promoter is believed to have direct involvement.

This is a list of diseases that evidence suggests have some involvement of promoter malfunction, either through direct mutation of a promoter sequence or mutation in a transcription factor or transcriptional co-activator.

Keep in mind that most diseases are heterogeneous in etiology, meaning that one "disease" is often many different diseases at the molecular level, though the symptoms exhibited and the response to treatment might be identical. How diseases respond differently to treatment as a result of differences in the underlying molecular origins is partially addressed by the discipline of pharmacogenomics.

Not listed here are the many kinds of cancers that involve aberrant changes in transcriptional regulation owing to the creation of chimeric genes through pathological chromosomal translocation.

## Canonical sequences and wild-type

The usage of canonical sequence for a promoter is often problematic, and can lead to misunderstandings about promoter sequences. Canonical implies perfect, in some sense.

In the case of a transcription factor binding site, then there may be a single sequence which binds the protein most strongly under specified cellular conditions. This might be called canonical.

However, natural selection may favor less energetic binding as a way of regulating transcriptional output. In this case, we may call the most common sequence in a population, the wild-type sequence. It may not even be the most advantageous sequence to have under prevailing conditions.

Recent evidence also indicates that several genes (including the proto-oncogene c-myc) have G-quadruplex motifs as potential regulatory signals.

## Diseases associated with promoter elements

- Asthma<sup>[3][4]</sup>
- Beta thalassemia<sup>[5]</sup>
- Rubinstein-Taybi syndrome<sup>[6]</sup>

## References

- <sup>^</sup> Smale ST, Kadonaga JT (2003). The RNA polymerase II core promoter. *Annu Rev Biochem.* 72, 449-479. PMID 12651739 PDF
- <sup>^</sup> Levine M, Tjian R (2003). Transcription regulation and animal diversity. *Nature.* 424(6945), 147-151. PMID 12853946 PDF
- <sup>^</sup> population genetics study: Hobbs, K.; Negri, J.; Klinnert, M.; Rosenwasser, L.J.; and Borish, L. (1998). Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. *Am J Respir Crit Care Med.* **158** (6), 1958-1962. PMID 9847292
- <sup>^</sup> population genetics study: Burchard, E.G.; Silverman, E.K.; Rosenwasser, L.J.; Borish, L.; Yandava, C.; Pillari, A.; Weiss, S.T.; Hasday, J.; Lilly, C.M.; Ford, J.G.; and Drazen, J.M. (1999). Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. *Am J Respir Crit Care Med.* **160** (3), 919-922. PMID 10471619
- <sup>^</sup> Kulozik, A.E.; Bellan-Koch, A.; Bail, S.; Kohne, E.; and Kleihauer, E. (1991). Thalassemia intermedia: moderate reduction of beta globin gene transcriptional activity by a novel mutation of the proximal CACCC promoter element. *Blood.* **77** (9), 2054-2058. PMID 2018842
- <sup>^</sup> Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, et al. (1995). Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. *Nature.* **376** (6538), 348-351. PMID 7630403

## External links

- *Directory of computational tools for detecting promoters in sequence data*: BioDirectory (Directory). *BioDirectory*. Oxford Informatics. Retrieved on 2006-12-11.
- ORegAnno - Open Regulatory Annotation Database
- MeSH *Promoter Regions (Genetics)*
- SwitchDB - An online database used to analyze promoters and transcription start sites (TSSs) throughout the human genome.
- Pleiades Promoter Project - a research project with an aim to generate 160 fully characterized, human DNA promoters of less than 4 kb (MiniPromoters) to drive gene expression in defined brain regions of therapeutic interests.

Retrieved from "<http://en.wikipedia.org/wiki/Promoter>"

Categories: Gene expression

Hidden categories: Articles with unsourced statements since January 2007 | All articles with unsourced statements

- This page was last modified on 4 March 2008, at 14:27.
- All text is available under the terms of the GNU Free Documentation License. (See **Copyrights** for details.)  
Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a U.S. registered 501(c)(3) tax-deductible nonprofit charity.

# EXHIBIT B

(19)



(11)

**EP 1 616 012 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**19.12.2007 Bulletin 2007/51**

(51) Int Cl.:  
**C12N 15/79 (2006.01)**

(21) Application number: **04728627.3**

(86) International application number:  
**PCT/IT2004/000227**

(22) Date of filing: **21.04.2004**

(87) International publication number:  
**WO 2004/094642 (04.11.2004 Gazette 2004/45)**

**(54) SYNTHETIC BI-DIRECTIONAL PROMOTERS AND USES THEREOF**

SYNTHETISCHE BIDIREKTIONALE PROMOTOREN UND DEREN VERWENDUNGEN

PROMOTEURS BIDIRECTIONNELS DE SYNTHÈSE, ET LEURS UTILISATIONS

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **24.04.2003 US 465080 P**

(43) Date of publication of application:  
**18.01.2006 Bulletin 2006/03**

(73) Proprietor: **FONDAZIONE CENTRO SAN  
RAFFAELE DEL MONTE TABOR  
20132 Milano (IT)**

(72) Inventors:  
• **NALDINI, Luigi**  
20132 Milano (IT)  
• **AMENDOLA, Mario**  
20132 Milano (IT)  
• **VIGNA, Elisa**  
20132 Milano (IT)

(74) Representative: **Capasso, Olga et al  
de Simone & Partners SpA  
Via V.Bellini 20  
00198 Roma (IT)**

(56) References cited:  
**WO-A-03/087294 US-B1- 6 630 324**

- **YU XIAOBING ET AL: "Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells." MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. JUN 2003, vol. 7, no. 6, June 2003 (2003-06), pages 827-838, XP002303041 ISSN: 1525-0016**

- **FUX CORNELIA ET AL: "Bidirectional expression units enable streptogramin-adjustable gene expression in mammalian cells." BIOTECHNOLOGY AND BIOENGINEERING. 5 SEP 2003, vol. 83, no. 5, 5 September 2003 (2003-09-05), pages 618-625, XP002303042 ISSN: 0006-3592**
- **FUX CORNELIA ET AL: "Toward higher order control modalities in mammalian cells: Independent adjustment of two different gene activities." BIOTECHNOLOGY PROGRESS, vol. 19, no. 1, 18 January 2003 (2003-01-18), pages 109-120, XP002305563 ISSN: 8756-7938**
- **UNSINGER J ET AL: "Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes." MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. NOV 2001, vol. 4, no. 5, November 2001 (2001-11), pages 484-489, XP002258698 ISSN: 1525-0016**
- **UNSINGER J ET AL: "Stable and strictly controlled expression of LTR-flanked autoregulated expression cassettes upon adenoviral transfer" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 319, no. 3, 2 July 2004 (2004-07-02), pages 879-887, XP004512521 ISSN: 0006-291X**
- **XIE M.; HE Y.; GAN S.: 'Bidirectionalization of polar promoters in plants.' NATURE BIOTECHNOL. vol. 19, July 2001, pages 677 - 679, XP002390685**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 616 012 B1**

**Description**

**[0001]** The present invention relates to bidirectional promoters allowing efficient and coordinate expression of two or more genes, to gene transfer vectors containing these promoters, to particles transducing said vectors into a cell, to the use of said vectors for the delivery and expression of multiple genes in target cells, also for gene therapy, and for the manufacturing of medicaments.

**TECHNICAL BACKGROUND**

**[0002]** Expression of multiple transgenes within the same target cells is required for several gene transfer and therapy applications<sup>1</sup>. Gene-function studies are best performed by expressing cDNAs together with a marker gene; by this approach, genetically-modified cells can be identified and monitored in vitro and in vivo. Similarly, gene therapy applications can be improved by purification of gene-corrected cells before in vivo administration, taking advantage of coordinate expression of selectable markers. Genetically-modified cells can be amplified ex vivo or in vivo by introducing growth-promoting or drug-resistance genes together with the therapeutic gene, as recently shown by MGMT-mediated selection of transduced Hematopoietic Stem Cells (HSC)<sup>2</sup>; using this approach, the efficacy of gene therapy can be increased, and its application potentially extended to a wide spectrum of diseases<sup>3,4</sup>.

**[0003]** Conversely, genetically-modified cells expressing conditionally cytotoxic genes, together with the therapeutic gene, can be eliminated in vivo, if adverse events occur; this approach is used to control graft-versus-host disease following donor T-lymphocytes infusion to treat leukemia relapse<sup>5</sup>; it may also provide an important safety provision in HSC gene transfer, given the recent occurrence of leukemia related to vector integration in a successful clinical trial of X-linked Severe Combined ImmunoDeficiency<sup>6</sup>. Coordinate expression of more than one transgene is essential when the activity to be reconstituted by gene transfer depends on multiple subunits encoded by different genes, or requires the synergism of separate molecules. For instance, reconstitution of the dopamine biosynthetic pathway in striatal neurons of Parkinson's disease patients requires co-expression of tyrosine hydroxylase with GTP-cyclohydrolase I and/or DOPA decarboxylase<sup>7</sup>; cancer gene therapy may require co-expression of multiple antigens and/or cytokines in antigen-presenting cells for immunotherapy, and of two T-cell receptor chains in T-cells engineered for adoptive transfer<sup>8</sup>.

**[0004]** In spite of such well-recognized needs, reaching coordinate, high-level expression of multiple transgenes in the majority of target cells has been a significant challenge for gene transfer technology. Two different transgenes have been expressed by two separate vectors; yet, only a fraction of target cells was transduced by both vectors and a heterogeneous population of cells was obtained that expressed either one or two genes in different ratios, preventing reliable studies and/or efficacious applications. Alternatively, two or more transgenes have been expressed by different promoters within the same vector<sup>9</sup>; yet, different tissue specificity and mutual interference between promoters often prevented efficient co-expression in the same target cells<sup>10</sup>. Differential splicing generates multiple transcripts from the same promoter, but it has proven difficult to adapt to viral delivery of multiple transgenes<sup>11</sup>. Chimeric polyproteins that self-process co-translationally into separate components have been generated using the self-cleaving peptide of the Foot and Mouth Disease Virus 2A<sup>12, 13</sup>; however, application of this technology to multiple gene transfer has been limited until now because it requires sophisticated engineering, restricts both proteins to the same cellular compartment, and introduces sequence changes that may affect protein activity, stability, and immunogenicity.

**[0005]** The most satisfactory approach to multiple gene transfer until now has relied on using internal ribosome entry sites (IRES's)<sup>14</sup>. These sequences, identified in viral and cellular transcripts, control translation in a mRNA-Cap-independent manner and, when inserted between two genes in a bicistronic messenger RNA, allow translation of the downstream gene. The authors tested the performance of different IRES's in the context of self-inactivating (SIN) lentiviral vectors (LVs), and found significant limitations of this approach.

**[0006]** WO 02/064804 describes bi-directional dual promoter complexes that are effective for enhancing transcriptional activity of transgenes in plants.

**[0007]** The bi-directional promoters of the invention include a modified enhancer region with at least two core promoters on either side of the modified enhancer in a divergent orientation. The application refers to gene expression in plants. In addition, the approach requires the duplication of tandem oriented enhancer sequences in a modified internal region of the construct, to be joined by two identical or homologous minimal promoters on either sides. The instant invention does not require duplication of enhancer or any other sequences in the efficient promoter of the bi-directional construct, nor are need that the core promoters on either sides of it to share at least 30% identity. Finally, tandem duplication may be incompatible with retro/lentiviral delivery.

**[0008]** US 6,388,170 discloses plant vectors, having bi-directional promoters, comprising a minimal promoter and a common promoter, wherein said minimal promoters is operably linked to said common promoter, in opposite orientation to said common promoter, and 5' to said common promoter. Promoter sequences derived from plants and plant-infecting viruses are disclosed and tested in plant cells or plant parts.

**[0009]** Given the substantial evolutionary distance between plants and animals, US 6,388,170 does not teach how to

engineer animal promoters for bidirectional activity and whether bi-directional promoters may effectively work in animal cells. In addition, US 6,388,170 does not teach how to engineer bi-directional promoters for gene expression in animals and in animal cells using the available gene transfer methods.

**[0010]** WO01/34825 discloses cell lines, plasmids and vectors useful for the production of recombinant viruses such as adenoviruses, which are useful in gene therapy. The cell lines, plasmids and vectors comprise inducible promoters, such as bi-directional promoters for the coordinate expression of bidirectionally cloned gene. However only bi-directional Tet-regulated constructs are disclosed.

**[0011]** Thus, the authors explored novel strategies to take full advantage of gene transfer systems, such as LV, that allow efficient ex vivo transduction and direct in vivo administration.

#### DESCRIPTION OF THE INVENTION

**[0012]** The authors developed a novel vector design in which synthetic bi-directional promoters mediated coordinate transcription of two divergent RNAs. The authors show that LVs carrying bi-directional promoters coordinately expressed two transgenes in the vast majority of transduced cells clearly outperforming the bicistronic vectors. The efficient performance of the new bi-directional LVs in primary hematopoietic cells, assayed ex vivo and after transplantation, and in several tissues in vivo, after direct vector delivery or transgenesis was established. The invention overcomes a long-standing hurdle in the quest for improved gene-expression tools and are expected to advance the reach and safety of gene therapy.

**[0013]** It is therefore an object of the instant invention a bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells comprising 5' end to 3' end:

a) a first minimal promoter sequence derived from cytomegalovirus (CMV) or mouse mammary tumor virus (MMTV) genomes;

b) a full efficient promoter sequence derived from an animal gene;

the two promoter sequences driving a coordinate transcription of said coding sequences in the opposite orientation.

**[0014]** In the ambit of the instant invention a full efficient promoter sequence means a sequence driving an efficient transcription of primary transcript. Preferably It comprises an enhancer region and a minimal promoter sequence, either distinct or overlapping. More preferably the full efficient promoter sequence derives from the phosphoglycerate kinase or from the ubiquitin promoter.

**[0015]** It is an object of the invention a bidirectional expression cassette essentially comprising the bidirectional promoter as above disclosed, convenient insertion sites positioned downstream to each promoter, and polyadenylation sites positioned downstream to each insertion site.

**[0016]** Preferably the bidirectional expression cassette further comprises at least one post-transcriptional regulatory element positioned upstream to one or each polyadenylation site. More preferably the bidirectional expression cassette further comprises at least one internal ribosome entry site (IRES) sequence to express three or more genes.

**[0017]** It is an object of the invention an expression construct containing the bidirectional promoter, as above disclosed.

**[0018]** It is an object of the invention an expression construct containing the bidirectional expression cassette, as above disclosed.

**[0019]** It is an object of the invention a gene transfer expression vector containing the expression construct as above disclosed further comprising lentiviral or retroviral sequences.

**[0020]** It is an object of the invention the use of the gene transfer expression vector for the preparation of a delivery and expression system in animal cells, preferably in vivo tissue animal cells, more preferably, brain neurons.

**[0021]** It is an object of the invention an in vitro method for the coordinate expression of two exogeneous coding sequences into an animal cell comprising the following steps:

a) cloning said coding sequences into the gene transfer expression vector according to claim 8, each coding sequence under the control of one of the two promoters of the bidirectional promoter;

b) transforming animal cells by means of said vectors;

c) allowing the expression of the vector.

**[0022]** Preferably the animal cell is an human cell, more preferably the human cell is a retransplantable human cell, even more preferably the retransplantable human cell is an hematopoietic cell.

**[0023]** Alternatively, the transformation of tissue cells in vivo may be performed by direct delivery of the vector, such as into brain neurons.

**[0024]** It is an object of the invention a method for generating a transgenic non human organism comprising the step of transforming appropriate cells by means of the gene transfer expression vector as disclosed above.

[0025] The vectors of the invention can be advantageously utilized for gene function and target validation studies in vitro and in vivo; gene therapy; expression of multiple genes in animal cells; generation of transgenic animals and eventually knock down of multiple genes; and for manufacturing of medicaments, as well.

## FIGURE LEGENDS

[0026] The invention will be now described with reference to following Figures:

**Fig. 1.** Gene transfer performance of bicistronic lentiviral vectors. (a) Scheme of the proviral vector form. A bicistronic expression cassette containing an internal ribosome entry site (IRES) derived either from the encephalomyocarditis virus (EMCV), with wild-type (wt) or mutated (mut) translation start site, or from the 5' untranslated NF- $\kappa$ B repressing factor mRNA (NRF) was driven by the human immediate early cytomegalovirus (CMV) or phosphoglycerate kinase (PGK) promoter.  $\Delta$ U3, R and U5, LTR regions with deletion in U3; SD and SA, splice donor and acceptor site;  $\psi$ , encapsidation signal including the 5' portion of the gag gene (GA); RRE, Rev-response element; cPPT, central polypurine tract; WPRE, woodchuck hepatitis virus post-transcription regulatory element. (b) Southern blot analysis of HeLa cells transduced by the indicated monocistronic (CMV) or bicistronic vectors expressing luciferase (gene 1) and GFP (gene 2) from the CMV promoter, probed for the WPRE sequence. All vector integrated with the expected length of DNA. Vector copy number was determined relative to a plasmid standard curve and used to normalize vector stocks and ensure similar levels of integration for each vector in a given target cell type in the experiments shown in c-f. (c-f) Luciferase and GFP expression in human HeLa cells (c), umbilical vein endothelial cells (HUVEC, d), peripheral blood lymphocytes (PBL, e), and cord blood-derived CD34+ progenitors (f) transduced 5-7 days before with a monocistronic ( $\square$ , CMV) or the indicated bicistronic CMV-luciferase-GFP vector. Left column, histograms representing net luciferase activity in cells extracts, mean  $\pm$  SD. Right panel, dot plots representing GFP expression by FACS analysis, the frequency and the mean fluorescence intensity (MFI, X) of GFP+ cells is indicated. The control monocistronic vector expressed luciferase in the histogram ( $\square$ ), and GFP in the leftmost dot plot (CMV) for each cell type. (g, h) FACS analysis of  $\Delta$ NGFR and GFP expression in 293T cells (g) and CD34+ progenitors (h) transduced by a EMCV wt IRES vector expressing  $\Delta$ NGFR and GFP from the PGK promoter. Histograms in panel (h) show the distribution of  $\Delta$ NGFR expression in all viable cells analysed (left), and of GFP expression in the gated (M1)  $\Delta$ NGFR+ cells (right). Experiments shown are representative of at least three performed with similar results.

**Fig. 2.** Gene transfer performance of bidirectional lentiviral vectors. (a) Scheme of the proviral vector form. A bidirectional promoter made by minimal core promoter elements from the human cytomegalovirus (mCMV) joined upstream, and in opposite orientation, to an efficient promoter, derived from the human phosphoglycerate kinase (PGK) or poly-ubiquitin UBI-C gene, was driving divergent transcription of two RNAs. CTE, constitutive transport element from the Mason-Pfizer monkey virus; pA, polyadenylation site A from the Simian Virus 40. Other vector features as in the legend to figure 1. (b) Net luciferase activity and (c-e) GFP expression in HeLa cells transduced 5-7 days before with LVs carrying the indicated bi-directional or control expression cassettes. The frequency and MFI (X) of GFP+ cells at FACS analysis is indicated in the dot plots to the right. Luciferase activity was determined for the two marked vectors ( $\square$ ,  $\blacksquare$ ). (f-j)  $\Delta$ NGFR and GFP expression in HeLa cells transduced 5-7 days before with serial 10-fold dilutions of LVs carrying the indicated expression cassette. The frequency of  $\Delta$ NGFR+ (upper left region) and  $\Delta$ NGFR/GFP double positive (upper right region) cells, with the respective MFI of  $\Delta$ NGFR (Y) and GFP (X), are indicated in the FACS dot plots. Experiments shown are representative of at least three performed with similar results.

**Fig. 3.** Comparison of bi-directional and bicistronic lentiviral vectors performance.  $\Delta$ NGFR and GFP expression in 293T cells transduced 3 weeks before with serial 10-fold dilutions of LVs carrying the indicated expression cassette. The total percentage of  $\Delta$ NGFR-expressing cells and of  $\Delta$ NGFR/GFP double positive cells (in brackets) are indicated above the FACS dot plots. The average number of vector Copies per Cell (CpC) is indicated in each plot, with the expected frequency of transduced cells according to the Poisson's distribution of random independent events. Although virtually all integrated vectors expressed  $\Delta$ NGFR, its level of expression and the fraction of transduced cells co-expressing GFP were much higher for the two bi-directional vectors tested (MA1 and MA4) as compared to the EMCV wt IRES bicistronic vector.

**Fig. 4.** Dual-gene transfer in hematopoietic cells by bi-directional vectors. (a-c) Human cord blood CD34+ progenitors were transduced by the GFP- $\Delta$ NGFR MA1 vector in the presence of early acting cytokines as described<sup>23</sup>, and analysed either after 7 days of culture in the same medium (a), and after additional 10 days in medium promoting myeloid differentiation (b), or after seeding in methylcellulose-based clonogenic medium. For (a) and (b), a dot plot showing  $\Delta$ NGFR and GFP expression by FACS analysis is shown, together with histograms showing the distribution of  $\Delta$ NGFR expression in all viable cells analysed (top), and of GFP expression in the gated (M1)  $\Delta$ NGFR+ cells (bottom). The percentage of immature progenitors expressing CD34, and of differentiating cells expressing the CD 13 myeloid marker at the time of analysis is indicated. For (c), representative light (left) and fluorescent (right)

micrograph of the indicated type of CFC are shown. (d, e) Human peripheral blood lymphocytes were transduced either after 2-day activation with anti-CD3 and anti-CD28 antibodies (d), or after 4-day treatment with interleukin-7, as described<sup>24</sup>, (e), and analyzed for ΔNGFR and GFP expression as described above. (f, g) Purified (lin-) murine bone marrow progenitors were transduced without cytokine stimulation as described<sup>48</sup>, and analyzed for ΔNGFR and GFP expression after 7 days in liquid culture (f), or immediately transplanted into lethally-irradiated syngenic recipients. FACS analysis of the peripheral blood of a representative mouse 2 months after transplant is shown in g. Experiments shown are representative of three performed with similar results. In d-f, cells transduced to low vector copy numbers are shown for more stringent performance analysis.

**Fig. 5** In vivo dual-gene transfer by bi-directional vectors. High-titer of GFP-ΔNGFR MA1 LV were stereotactically injected into the striatum of adult mice. Cryostatic brain sections were obtained two months after injection and analyzed by immunofluorescence and confocal microscopy. Representative pictures of the injected area are shown, after immunostaining for ΔNGFR (red), GFP (green), and TO-PRO3 staining for nuclear DNA (blue). Fluorescent signals were sequentially acquired from single optical sections and are shown individually and after merging (merge). Original magnification 200X (Scale bar = 120 μm)

**Fig. 6** Dual-transgenesis by bi-directional vector. Transgenic mouse lines were generated by direct injection of GFP-ΔNGFR MA1 LV into the perivitelline space of single-cell embryos, as described<sup>19</sup>, and the indicated tissues were analyzed for ΔNGFR (red) and GFP (green) expression by immunofluorescence and confocal microscopy on cryostatic sections. Nuclei were stained by TO-PRO3 (blue). Fluorescent signals were sequentially acquired from single optical sections and are shown individually and after merging (merge). The pictures shown were obtained from an F1 mouse carrying two vector genomes integrated into the germ-line. Similar pictures were obtained from other transgenic mice analyzed that carried similar or higher number of vector copies. Original magnification 200X (spleen, lung), 400X (heart, kidney, brain, liver), 630X (gut) (Scale bar = 120 μm)

**Fig. 7a** Map of the plasmid containing the lentiviral vector construct RRL-MA1-lucif/GFP.

**Fig. 7b** Sequence of the plasmid containing the lentiviral vector construct RRL-MA1-lucif/GFP.

**Fig. 8a** Map of the plasmid containing the lentiviral vector construct CCL-MA1-GFP/deltaLNGFR.

**Fig. 8b** Sequence of the plasmid containing the lentiviral vector construct CCL-MA1-GFP/deltaLNGFR.

**Fig. 9a** Map of the plasmid containing the lentiviral vector construct RRL-MA2-lucif/GFP.

**Fig. 9b** Sequence of the plasmid containing the lentiviral vector construct RRL-MA2-lucif/GFP.

**Fig. 10a** Map of the plasmid containing the lentiviral vector construct CCL-MA3-GFP/deltaLNGFR.

**Fig. 10b** Sequence of the plasmid containing the lentiviral vector construct CCL-MA3-GFP/deltaLNGFR.

**Fig. 11a** Map of the plasmid containing the lentiviral vector construct CCL-MA4-GFP/deltaLNGFR.

**Fig. 11b** Sequence of the plasmid containing the lentiviral vector construct CCL-MA4-GFP/deltaLNGFR.

## EXAMPLE 1

### MATERIALS AND METHODS

#### Plasmid construction

**[0027]** All transfer vectors were built from plasmid pCCL.sin.cPPT.PGK.GFP.WPRE<sup>15</sup> using the following previously described sequence elements: EMCV IRES's with the downstream gene coding sequence starting at the 11<sup>th</sup> ATG of the IRES (wt) or with the 11<sup>th</sup> ATG of IRES mutated to create a HindIII cloning site and allow translation initiation at the downstream transgene ATG<sup>16</sup>(EMCMut), the NRF IRES<sup>18</sup>, the MPMV CTE<sup>21</sup>, a minimal CMV core promoted<sup>20</sup>, a 1226 bp fragment from the Ubiquitin-C promoter<sup>19</sup>.

#### Construction of lentiviral vector with bi-directional promoters

**[0028]** To generate the lentiviral construct **RRL-MA1**, an XhoI-XhoI fragment containing the SV40polyA.CTE.Luciferase.minhCMV elements (derived from the lentiviral construct

**[0029]** pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minhCMV.TetO7.minMMTV.eGFP) was cloned into the lentiviral vector construct pRRL.sin.cPPT.hPGK.eGFP.Wpre (Follenzi et al., 2000) cut with the same enzyme to obtain RRL-MA1-lucif/GFP (pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minhCMV.hPGK.eGFP.Wpre).

**[0030]** To generate the lentiviral construct **CCL-MA1**, two fragments were cloned into the lentiviral construct pRRL.sin.cPPT.hPGK.ΔLNGFRWpre first cut with KpnI, blunted and then cut with XhoI, the first fragment containing the minhCMV.eGFP elements was derived from the lentiviral construct pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minMMTV.TetO7.minhCMV.eGFP cut with KpnI, blunted and then with XhoI and the second derived from the construct pRRL.sin.cPPT.SV40polyA.CTE.tTA2.Wpre cut with BamHI, blunted and then cut with NotI. The resulting lentiviral construct pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.minMMTV.TetO7.minhCMV.eGFP was cut with NotI and AvrII

and the fragment containing the cPPT.SV40polyA.CTE.eGFP.minhCMV.hPGK.  $\Delta$ LNGFRWpre was cloned into the lentiviral construct pCCL.sin.cPPT.hPGK.eGFP.Wpre cut with the same enzymes to obtain CCL-MA1-GFP/ $\Delta$ LNGFR (pCCL.sin.cPPT.SV40polyA.CTE.eGFP.minhCMV.hPGK.  $\Delta$ LNGFRWpre).

**[0031]** To generate the lentiviral construct **RRL-MA2**, a HindIII-BamHI fragment containing the hFGK.Luciferase elements (derived from the lentiviral vector construct pRRL.sin.cPPT.hPGK.Luciferase.IRES.Wpre) was cloned into the retroviral construct SF2-clCM2G (obtained from Rainer Loew, University of Heidelberg, FRG) cut with the same enzymes to obtain the construct cPPT.SV40polyA.CTE.Luciferase.hPGK.minMIVITV.eGFP. This construct was first cut with Sall, blunted and then cut with BamHI and the fragment containing the Luciferase.hPGK.minMMTV.eGFP elements was cloned into the lentiviral vector construct pRRL.sin.cPPT.SV40polyA.CTE.tTA2.Wpre cut in the same way, to obtain RRL-MA2-lucif/GFP (pRRL.sin.cPPT.SV40polyA.CTE.Luciferase.hPGK.minMMTV.eGFP.Wpre).

**[0032]** To generate the lentiviral construct **CCL-MA3**, two fragments were cloned into the pBLKS+ cut with HindIII and XhoI, the first fragment containing the CTE.SV40polyA elements was derived from the lentiviral vector construct pRRL.sin.cPPT.SV40polyA.CTE.tTA2 cut with HindIII and XbaI and the second fragment containing the minMMTV.GFP elements derived from the construct cPPT.SV40polyA.CTE.Luciferase.hPGK.minMMTV.eGFP cut with XhoI and XbaI to obtain the construct pBLKS+ minMMTV.GFP.CTE.SV40polyA. The resulting construct was cut with EcoRV and XhoI and the fragment containing the minMMTV.GFP.CTE.SV40polyA was cloned into the lentiviral vector construct pCCL.sin.cPPT.hPGK.  $\Delta$ NGFR.Wpre cut with the same enzymes, to obtain the final lentiviral vector construct CCL-MA3-GFP/ $\Delta$ NGFR (pCCL.sin.cPPT.SV40polyA.CTE.GFP.minMMTV.hPGK.  $\Delta$ NGFR.Wpre).

**[0033]** To generate the lentiviral construct **CCL-MA4** the fragment derived from pHR'.UBI-C.eGFP cut with PacI, blunted and cut with PstI, containing the UBI-C promoter sequence, was inserted into the place of the PGK promoter into construct pCCL.sin.cPPT.SV40polyA.CTE.GFP.minCMV.PGK. $\Delta$ NGFR.Wpre cut with EcoRV and PstI to obtain the final lentiviral vector construct CCL-MA4-GFP/ $\Delta$ NGFR (pCCL.sin.cPPT.SV40polyA.CTE.GFP.minCMV.UBI-C.  $\Delta$ NGFR.Wpre).

**[0034]** The maps and the nucleotide sequences of the RRL-MA1-lucif/GFP, CCL-MA1-GFP/ $\Delta$ LNGFR, RRL-MA2-lucif/GFP; CCL-MA3-GFP/ $\Delta$ LNGFR; CCL-MA4-GFP/ $\Delta$ LNGFR constructs are shown respectively in figures 7a-11a and figures 7b-11b.

#### *Vector production and titration*

**[0035]** VSV-pseudotyped third-generation LV were produced by transient 4-plasmid co-transfection into 293T cells and purified by ultracentrifugation as described<sup>15</sup>, with the modification that 1 mM NaButyrate was added to the cultures for vector collection<sup>47</sup>. Expression titer of GFP or  $\Delta$ LNGFR vectors were estimated on HeLa cells by limiting dilution. Vector particle was measured by HIV-1 gag p24 antigen immunocapture (NEN Life Science Products). Vector infectivity was calculated as the ratio between titer and particle for the vector expressing GFP or  $\Delta$ NGFR. Vector expression titer in the 293T supernatant ranged from 0.7 to  $1 \times 10^7$  Transducing Units<sup>HeLa</sup>(TU)/ml for monocistronic CMV or PGK vector, from 3 to  $8 \times 10^6$  TU/ml for bicistronic vectors and bi-directional vectors. Vector infectivity ranged from 0.5 to  $1 \times 10^5$  TU/ng of p24 for monocistronic CMV or PGK vector, and from 2 to  $6 \times 10^4$  TU/ng of p24 for bicistronic and bi-directional vectors.

#### *Cell cultures*

**[0036]** Continuous cultures of HeLa and 293T cells were maintained in Iscove's modified Dulbecco's medium (IMDM; Sigma, Milan, Italy) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen Corporation, UK) and a combination of penicillin-streptomycin and glutamine. Primary cultures of human umbilical vein endothelial cells (HCTVECs), peripheral blood lymphocytes, and cord blood CD34+ progenitors were obtained and maintained as described<sup>15</sup>. CD34+ progenitors were transduced with  $5 \times 10^7$  TU/ml of LV and cultured for at least 7 days in the presence of recombinant human interleukin 6 (rhIL6, 20 ng/ml), recombinant human stem cell factor (rhSCF, 100 ng/ml), recombinant human FLT-3 ligand (rhFLT-3 ligand, 100ng/ml), all from PeproTech (Rocky Hill, NJ), and recombinant human thrombopoietin (rhTPO, 20 ng/ml; Amgen, Thousand Oaks, CA) as described<sup>23</sup>. For differentiating conditions, transduced progenitors were cultured for 10 days in the presence of rhSCF, 50 ng/ml, recombinant human granulocyte monocyte-colony stimulating factor (rhGM-CSF, 20 ng/ml), recombinant human monocyte-colony stimulating factor (rhG-CSF, 20 ng/ml), all from PeproTech. For clonogenic assays, transduced cells were plated at a density of 800 cells/ml in human complete MethoCult medium (StemCell Technologies, Vancouver, CA) and were scored by light and fluorescence microscopy 14 days later.

**[0037]** Human peripheral blood lymphocytes were purified by Ficoll gradient and transduced with  $0.5-5 \times 10^7$  TU/ml of vector either after 2-day activation with 30ng/ml anti-CD3 antibodies (Orthoclone, Milan, Italy) plus 1 $\mu$ g/ml anti-CD28 antibodies (PharMingen, San Diego, CA), or after 4-day treatment with 5ng/ml interleukin-7 (Boehringer Mannheim-Roche GmbH, Mannheim, Germany), as described<sup>24</sup>.

**[0038]** Purification of lineage marker-negative cells from C57BL/6 mouse bone marrow with a magnetic cell depletion

technique (StemCell Technologies, Vancouver, CA), *ex vivo* transduction in serum-free StemSpan medium (StemCell Technologies, Vancouver, CA) with  $0.5-2 \times 10^7$  TU/ml of vector, and transplantation into lethally irradiated syngenic recipients were performed as described<sup>48</sup>.

5 *Mice*

**[0039]** CD1, C57BL/6 and FVB mice were purchased from Charles Rivers Laboratories (Calco, Italy) and maintained in SPF conditions. All animal procedures were performed according to protocols approved by the Hospital San Raffaele Institutional

10 **[0040]** Animal Care and Use Committee.

*DNA analysis: Southern and real time PCR*

**[0041]** Vector copies per genome were quantified by Real-Time PCR from 300 ng template DNA extracted from cells by a commercial kit (Qiagen), using one set of primers and probe to detect the LV backbone:

LV forward primer, 5'-TGAAAGCGAAAGGGAAACCA-3';

LV reverse primer, 5'-CCGTGCGCGCTTCAG-3';

LV probe, 5'-(VIC)-CTCTCTCGACGCAGGACT-(TAMRA)-3'.

20

**[0042]** Reactions were carried out according to manufacturer instructions and analysed using the ABI Prism 7700 sequence detection system (PE-Applied Biosystem). For Southern blot, DNA was extracted from transduced cells, digested with Afl-II to release the expression cassette from integrated vector DNA and analysed with a WPRE probe to detect vector sequences. The average number of integrated vector copies was determined relative to a plasmid standard curve.

25

**[0043]** These numbers were used to calculate vector integration titer and normalize vector stocks for all subsequent transduction experiments to ensure similar levels of integration for each vector tested.

*Experimental Design and Stereotactic Injection.*

30

**[0044]** Nine weeks-old C57BL/6 mice were anesthetized with intraperitoneal injection of Tribromoethanol 1.25% (SIG-MA), positioned in a stereotactic frame (David Kopf Instruments, Tujunga, CA) and the skull exposed by a small incision. Two  $\mu$ l of vector concentrate ( $2 \times 10^6$  TU/ $\mu$ l) was injected by a Hamilton syringe with a 33G blunt tip needle (Hamilton; Reno, NV) into the left hemisphere striatum (stereotactic coordinates in mm from bregma: AP=+0.74, ML=-1.9 and DV=-3.5 from skull surface) at a rate of 0.2  $\mu$ l/min. The needle was left in place for additional 5 minutes before slow removal.

35

*Transgenesis*

**[0045]** Transgenic mice were generated using LV as described by Lois et al.<sup>19</sup>. Briefly, female FVB mice were super-ovulated with a combination of pregnant mare serum and human chorionic gonadotropin. On average between 20 and 30 embryos were collected per female and microinjected into the perivitelline space with  $10-100$  pL of  $5 \times 10^7$  TU/ml LV stock on the same day. Manipulated embryos were immediately implanted into the oviduct of pseudopregnant CD1 mice. Pups were genotyped for the presence of the GFP sequence by PCR analysis as described<sup>49</sup>. Positive mice were bred to test germ-line transmission of the transgene. DNA was extracted from the tail and used to quantify vector copy number by real time PCR in founder and F1 progeny mice.

45

*Flow cytometry and Luciferase assay*

**[0046]** Transduced cells were grown for at least 4 days before FACS analysis to reach steady state GFP expression and to rule out pseudotransduction. Before FACS analysis, adherent cells were detached with 0.05% trypsin-EDTA, washed, and fixed in phosphate buffer saline (PBS) containing 1% paraformaldehyde (PAF) and 2% FBS. Cells grown in suspension were washed and resuspended in PBS containing 2  $\mu$ g/ml propidium iodide (PI) (BD Bioscience PharMingen, San Diego, CA) and 2% FBS. For immunostaining,  $10^5$  cells were blocked in PBS 5% mouse serum, 5% human serum, 2% FBS for 15 min at 4°C. After blocking, 10  $\mu$ l of R-phycoerythrin (RPE)-conjugated antibodies (anti-CD34 and anti-CD13, Dako, Glostrup, Denmark, and anti- $\Delta$ LNGFR, BD Bioscience PharMingen, San Diego, CA) were added and the cells were incubated for 30 min at 4°C, washed, stained with PI, and analyzed by three-color flow cytometry. Only viable, PI-negative cells were used for the analysis.

55

**[0047]** Luciferase was assayed in cell lysates prepared as described by the manufacturer (luciferase assay system;

Promega). RLU were measured with a Lumat LB9507 luminometer (Berthold) after mixing cell lysates (normalized for protein content measured by BCA Protein Assay Reagent kit Pierce) with Luciferase Substrate (Promega).

#### Tissue analysis

**[0048]** Anesthetized mice were perfused with 0.9% NaCl followed by 4% PAF in PBS. Tissue samples were collected, equilibrated in 20% sucrose in PBS for 48 h at 4°C, and embedded in optimal-cutting-temperature compound (OCT) for quick freezing. 10  $\mu$ m (for transgenic mice) and 20  $\mu$ m (for stereotactically injected mice) thick cryostatic sections were post-fixed in PAF and frozen at -80 °C. Sections were blocked with 5% goat serum (Vector Laboratories) in PBS containing 1% bovine serum albumine (BSA) and 0.1% Triton X-100 (PBS-T), and incubated with rabbit affinity-purified GFP antibody (Molecular Probes) and R-phycoerythrin (RPE)-conjugated  $\Delta$ LNFR monoclonal antibody (BD Bioscience Pharmingen, San Diego, CA) for 1 h, washed and stained with AlexaFluor488-conjugated goat anti-rabbit antibody (Molecular Probes) in PBS-T and 1% BSA for 1 h. Cell nuclei were stained with TOPRO-3 after 1 h of RNase treatment (Molecular Probes). Sections were mounted and analyzed by three-laser confocal microscope (Radiance 2100; BioRad). Fluorescent signals from single optical sections were sequentially acquired and analyzed by PhotoShop 7.0 (Adobe).

## RESULTS

### Bicistronic LVs

**[0049]** In order to express more than one transgene from a single vector, the authors first evaluated the performance of different IRES's in the context of late-generation self-inactivating LVs<sup>15</sup>. They used the strong CMV and PGK promoters to drive expression of bicistronic transcripts encoding, from the 5' to the 3' end, the luciferase reporter, an IRES, and the cell-associated GFP marker (fig. 1a). Two IRES's were derived from the Encephalomyocarditis virus; a wild-type (EMCVwt) and a mutant (EMCVmut) form<sup>16, 17</sup>, that differed for the ATG from which downstream translation started. Another IRES was derived from the 5' untranslated sequence of the NF- $\kappa$ B transcription Repressing Factor (NRF) mRNA<sup>18</sup>.

**[0050]** They generated high-titer VSV-pseudotyped stocks of all bicistronic and control monocistronic vectors, and normalized them for transducing activity measuring integration in HeLa cells by Southern blot (fig. 1b). They then compared gene expression in cells transduced to equal vector copy numbers (Fig. 1c-f). Although luciferase activity was similar in HeLa cells transduced by CMV-luciferase vector and in cells transduced by the best performing bicistronic vector, only a small fraction of the latter cells expressed the IRES-dependent GFP gene, with a ten-fold decrease in expression titer as compared to cells transduced by the control CMV-GFP vector (Fig. 1c). Moreover, the GFP mean fluorescence intensity (MFI) was significantly lower in cells expressing the protein from the IRES's than in cells expressing it from the mRNA<sup>Cap</sup>. They then tested bicistronic LVs in primary human cells, including umbilical vein endothelial cells, peripheral blood lymphocytes, and CD34+ cord blood hematopoietic progenitors (HPC) (Fig. 1d-f). All cell types were transduced efficiently, as indicated by the frequency of GFP-positive cells in cultures transduced by control CMV-GFP vector, but IRES-dependent GFP expression was only observed in a fraction of cells transduced by bicistronic vectors. IRES activity varied extensively with the target cell type; the NRF IRES was the only one reaching detectable downstream gene expression in lymphocytes, while the EMCVwt IRES was the most efficient in the other cell types. In addition, all IRES's decreased, in some cases more than one log, upstream gene expression, as compared to the control CMV-luciferase vector.

**[0051]** They also evaluated IRES-based vectors by expressing two cell-associated markers, GFP and a truncated version of the low-affinity NGF receptor ( $\Delta$ LNFR) (Fig. 1g,h). Among HeLa cells transduced by a low dose of the best-performing bicistronic vector, only the cells expressing high levels of  $\Delta$ LNFR also expressed GFP, with an average of one out of four  $\Delta$ LNFR-positive cells expressing GFP to detectable levels (Fig. 1g). Similarly, only a small fraction of transduced CD34+ progenitors expressing  $\Delta$ LNFR also expressed GFP to detectable levels (Fig. 1h). Overall, these results indicated that IRES-based bicistronic vectors failed to ensure coordinate expression of two transgenes in most target cell types tested, and that multi-copy transduction or selection of transduced cells for downstream gene expression were required to obtain a population expressing both transgenes in the majority of cells. *Bidirectional LVs*

**[0052]** To overcome the limitations of bicistronic vectors, the authors explored a new promoter design for coordinate transgene expression. They joined a minimal core promoter upstream, and in opposite orientation, to an efficient promoter. Rationale of this design was that upstream elements in the efficient promoter, when closely flanked by core promoters on both sides, may drive transcriptional activity in both directions. If such bi-directional activation occurred, expression of both transcripts would be coordinately regulated. They tested two ubiquitously expressed promoters, previously shown to drive robust and efficient transgene expression in LV; the above mentioned 516 bp fragment from the human phosphoglycerate kinase promoter (PGK)<sup>15</sup> and a 1226 bp fragment from the human ubiquitin C promoter (UBI C)<sup>19</sup>. They joined them to a minimal core promoter derived from the cytomegalovirus (minCMV) that was previously developed to

couple initiation of eukaryotic transcription to tetracycline (Tc)-dependent operators<sup>20</sup>. They flanked the bi-directional promoter with two expression cassettes optimized for LV-mediated gene delivery (fig. 2a). The upstream cassette - in anti-sense orientation relative to the vector LTR - included the constitutive transport element (CTE) of the Mason-Pfizer virus<sup>21</sup>, and a polyadenylation site from the Simian Virus 40 (SV40). The downstream cassette included the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE)<sup>22</sup> and the SIN HIV-1 LTR polyadenylation site.

**[0053]** As described above for bicistronic LVs, they verified correct transfer and normalized transduction of each vector by Southern blot analysis and real-time PCR of transduced cells. LV carrying bi-directional expression cassettes were produced to high titer and infectivity, similar to those obtained with standard vectors (see Methods). The bi-directional design significantly enhanced transcription from the upstream minimal promoter without affecting downstream expression from the efficient promoter (fig. 2b-h). Luciferase expression from the minCMV promoter, for instance, was increased at least one log when fused upstream to the PGK promoter (fig. 2b). Remarkably, the bi-directional PGK promoter allowed detecting GFP (or  $\Delta$ LNFR, not shown) to the same frequency and to similar expression levels in cells transduced by the bi-directional vector and expressing the protein from either side of the promoter (fig. 2c,d), as in cells transduced by the control PGK vector (fig. 2e). Using two cell-associated markers,  $\Delta$ LNFR and GFP, they showed stable, efficient and coordinate expression of bi-directional LVs, both at high and low vector copy number (fig. 2f). At high vector input, they reached high-level expression of both transgenes in virtually every target cell. At low vector input, when most transduced cells carried one proviral copy, they showed transgene co-expression in virtually every labeled cell, indicating the occurrence of divergent transcription from the bi-directional promoter. In both conditions, transgene expression was maintained to similar levels in cells analyzed at early and late times post-transduction (not shown, and Fig. 3 below). Transgene-expressing cells tended to distribute along a diagonal line in the two-color FACS plot, indicating that expression of the two transgenes was coordinately regulated.

**[0054]** Intriguingly, they observed coordinate bi-directional expression, although to significantly lower efficiency on the upstream side than the downstream side, when they tested the sole PGK promoter in the context of the bi-directional expression cassette that they developed (fig. 2g). They reproduced this finding after swapping the position of the two transgenes on each sides of the PGK promoter (not shown). These results indicated that transcription-activating elements in the PGK promoter are intrinsically capable of triggering divergent transcription and thus provide the main driving force for dual-gene expression in the new LV, ensuring coordinate regulation of transcription on both sides of the bi-directional promoter. Apposition of the minCMV core promoter, which had a very low activity per se (fig. 2h, and 2b above), enhanced upstream transcription from the PGK promoter possibly because of more efficient initiation (compare fig. 2g and 2f). When they changed the driving promoter in bi-directional vectors from PGK to UBI-C, they reproduced the findings observed with the PGK promoter (fig. 2i). They revealed an intrinsic bi-directional activity of the UBI-C promoter (fig. 2j) that was significantly enhanced by the upstream addition of the minCMV promoter.

**[0055]** They then compared directly the performance of bi-directional and bicistronic vectors in relation to the number of integrated copies, as measured by real-time PCR (Fig. 3). By analyzing 293T cells transduced with increasing vector doses, they proved that the vast majority of integrated bi-directional vectors based on the PGK (MA1) or UBI-C (MA4) promoter efficiently expressed both transgenes, clearly outperforming the best IRES-based bicistronic vector.

#### *Ex Vivo and In Vivo Dual-Gene Transfer*

**[0056]** They then assessed the performance of the bi-directional MA1 LV in more relevant targets for gene therapy applications and by different delivery strategies. They transduced human cord-blood HPC and PBL with  $\Delta$ LNFR-GFP MA1 LV *ex vivo*, according to previously optimized protocols<sup>23, 24</sup> (Fig.4). Both gene products were coordinately expressed to high-levels in a large fraction of HPC scored both as immature cells grown in the presence of early-acting cytokines (Fig. 4a), and after differentiation in liquid culture (Fig. 4b) or clonogenic assay (Fig. 4c, GFP only). Similarly, they obtained coordinate  $\Delta$ LNFR and GFP expression in PBL transduced in standard conditions of proliferation, triggered by CD3/CD28 co-stimulation (Fig. 4d), and as non-proliferating cells, treated only with IL-7 to maintain naïve cell properties (Fig. 4e). They also performed transplantation studies with transduced murine HPC, enriched from the bone marrow by negative selection, to prove stable dual-transgene expression in the progeny of long-term repopulating HSC (Fig 4f).  $\Delta$ LNFR and GFP were coordinately expressed to similar levels in the *ex vivo* transduced cells, before transplantation, and in the white blood cells of long-term engrafted mice. Overall, these results validated the new LV for proficient dual gene transfer in primitive, committed, and differentiated hematopoietic cells.

**[0057]** They injected concentrated  $\Delta$ LNFR-GFP MA1 LV in the striatum of adult mice and scored transgene expression 4 weeks after injection by confocal microscopy of brain sections immuno-stained for GFP and  $\Delta$ LNFR (fig. 5). They observed robust co-expression of both transgenes in the brain tissue surrounding the injection site. As previously reported after striatal injection of VSV-pseudotyped LV<sup>25-27</sup>, the vast majority of cells expressing the markers had the typical morphology of striatal neurons. Thus, the new bi-directional LV enabled efficient *in vivo* dual-gene transfer.

*Dual-Transgenesis*

**[0058]** They evaluated whether the new bi-directional LV allowed generation of dual-transgenic mouse lines. As previously described by Lois et al<sup>19</sup>, they microinjected the  $\Delta$ NGFR-GFP LV into the perivitelline space of single-cell embryos, and implanted them into pseudopregnant females. We obtained transgenic mice to high frequency, as assessed by the presence of vector DNA (more than 50% of newborns), and proved vector integration in the germ line by crossing some founder mice and analyzing their progeny for vector DNA content and transgene expression (Fig. 6). In the two F1 mice analyzed, carrying 2 and 5 vector copies in the genome, they found remarkably consistent expression of both transgenes in virtually every cell in the tissues studied, which included brain, liver, spleen, gut, heart, skeletal muscle, and kidney. Vector expression was also well detectable in the bone marrow and peripheral blood of the same mice, although in less than 100% of the cells, and more clearly for  $\Delta$ NGFR than GFP (not shown). These data indicated that bi-directional LV transgenesis is a rapid and efficient method to obtain robust, stable and coordinate expression of two transgenes in genetically-engineered mice. In addition, they show that the minCMV-PGK bi-directional promoter that they developed governs dual transgene expression in the majority of differentiated tissues of the mouse, and maintains expression after inheritance through the germ-line.

## DISCUSSION

**[0059]** In the pursuit of strategies enabling efficient dual-gene transfer, they initially faced significant limitations of IRES-based approaches. When tested in the context of bicistronic LV, IRES-dependent gene expression was significantly lower than that dependent on the mRNA<sup>Cap</sup>, and required multi-copy transduction to co-express the downstream gene in a sizable fraction of transduced cells. In addition, IRES's decreased expression of the upstream gene in the transcript, and displayed significant cell type-dependent variation in activity. Similar limitations have been reported when incorporating IRES's into other types of gene transfer vectors<sup>14,28-32</sup>. Thus, selection for downstream gene expression is likely to be required when using IRES to ensure co-expression in all target cells. Although selection protocols are compatible with some *ex vivo* gene transfer and therapy applications, they may adversely affect the biological properties of gene-corrected cells, in particular when selectable marker expression is inefficient. In fact, prolonged *ex vivo* culture and a limited size or clonal composition of the transduced cell population may reduce engraftment, long-term survival and tissue repopulation after transplantation<sup>33</sup>. Even more important, the inefficiency of IRES-dependent expression prevents most application of bicistronic vectors to direct *in vivo* gene transfer. Thus, authors explored novel strategies to take full advantage of gene transfer systems, such as LV, that allow efficient *ex vivo* transduction and direct *in vivo* administration<sup>34</sup>.

**[0060]** They have developed a new promoter design based on the juxtaposition of core promoter elements upstream, and in opposite orientation, to an efficient promoter. The bi-directional assembly drove divergent transcription, indicating that upstream enhancer/promoter elements within the efficient promoter were capable of promoting transcription in an orientation-independent manner and from both sides simultaneously. Upon incorporation of these promoters into LV, they reached efficient dual-gene transfer and coordinate expression in continuous cell lines and primary cells *ex vivo*. Because both transgenes were expressed in the vast majority of transduced cells, they did not need to select cells to ensure transgene co-expression. Upon direct injection of bi-directional LV into the CNS, the authors showed coordinate expression of two transgenes in neural cells *in vivo*. In addition, bi-directional LV allowed robust dual transgenesis, leading to pan-cellular expression of both transgenes in all tissues examined. All these results could not be reached until now using currently available technologies.

**[0061]** By monitoring transduced cells carrying a single vector copy, authors proved that divergent transcription occurred from a single bi-directional promoter, that expression of both transgenes was functionally linked and coordinately regulated, and that bi-directional promoters were consistently active in all types of target cells tested, without being silenced or randomly fixed in one direction of transcription, even after cellular differentiation. Although they did not map how close the two opposite core promoters must be for operational linkage, they may expect that close juxtaposition of the fused minimal core promoter to some of the upstream elements in the efficient promoter, as observed in natural promoters between core and upstream elements, may be required. Both the PGK and UBI-C promoters tested in this work drove divergent transcription when fused to a minimal core promoter in the opposite orientation. Intriguingly, both of these promoters were shown to be intrinsically capable of promoting divergent transcription, although to lower efficiency on the upstream than the downstream side, when incorporated into the bi-directional expression cassette that they developed. This surprising observation may indicate a specific feature of a class of ubiquitously-expressed housekeeping promoters, possibly related to their content of CpG islands (see below and<sup>35-37</sup>). However, they should not forget that both the promoter placement between two efficient expression cassettes endowed with post-transcriptional regulatory elements enhancing translation, and LV-mediated integration, which has been shown to preferentially target transcribed genes in the chromatin, may contribute to unravel latent transcriptional activity. Although the intrinsic bi-directional activity of the housekeeping promoters tested may not be efficient enough for exploitation *per se*, without the upstream assembly of core promoter elements described in this work, it provides the basis for the coordinate regulation of dual-gene ex-

pression reached by our new vectors. On the other hand, the propensity of these promoters to drive divergent transcription should be kept in mind when engineering vectors and analyzing transduced cells or tissues<sup>38</sup>, and may provide a possible mechanism for the frequently observed interference between nearby promoters in the same vector construct<sup>10,39</sup>. It is possible that the bi-directional design described here may be successfully applied to tissue-specific promoters to obtain coordinated expression of two transgenes in specific tissues. In addition, by combining bi-directional promoters with bicistronic transcripts one could express more than two transgenes within the same cell, although with the limitations described above for IRES-dependent vectors.

**[0062]** Inducible bi-directional promoters were originally developed in Tet-regulated expression systems, by duplicating a minimal promoter on both sides of a series of Tet operator repeats, to obtain exogenously regulated expression of two transgenes<sup>36, 40,41</sup>. This design was recently applied to other systems that also combine prokaryotic enhancer elements with chimeric trans-activators to regulate gene expression<sup>42</sup>. Although these inducible expression systems represent powerful tools for gene-function studies, they are dependent on co-expression and functional activity of protein trans-activators, and pose several challenges when applied to vector-based delivery and *in vivo* applications. A constitutive bi-directional promoter was recently tested for exogenous gene expression in plant biotechnology<sup>43</sup>. Our results provide the first description of synthetic bi-directional promoters that exploit the endogenous transcriptional machinery available to most animal cell types to drive robust and constitutive expression of two divergent transcripts. In nature, few instances of bi-directional promoters had been documented until recently. Intriguingly, a recent survey of the human genome indicated an abundance of divergently transcribed gene pairs, whose transcription start sites are separated by less than 1 kb<sup>44,45</sup>. It is likely that many of the promoter elements found between these gene pairs can initiate transcription in both directions, and contain shared elements that regulate both genes<sup>46</sup>. Thus, the synthetic bi-directional promoters that they have developed may mimic a well-represented and evolutionary conserved feature of eukaryotic transcription, providing a structural basis for their robust performance. The new lentiviral vectors built around these bi-directional promoters will likely advance the reach and the safety of gene therapy, the power of gene-function and target validation studies, and the applications of animal transgenesis. If adapted for the expression of short interfering RNA, they may also enable coordinate knock-down of multiple genes.

## REFERENCES

### [0063]

1. Kay, M.A., Glorioso, J.C. & Naldini, L. *Nat Med* 7, 33-40 (2001).
2. Neff, T. et al. *J Clin Invest* 112, 1581-1588 (2003).
3. Bordignon, C. & Roncarolo, M.G.. *Nat. Immunol.* 3, 318-321 (2002).
4. Sadelain, M.. *J Gene Med* 4, 113-121 (2002).
5. Bonini, C. et al. *Science* 276, 1719-1724 (1997).
6. Hacein-Bey-Abina, S. et al.. *Science* 302, 415-419 (2003).
7. Burton, E.A., Glorioso, J.C. & Fink, D.J *Gene Ther* 10, 1721-1727 (2003).
8. Sadelain, M., Riviere, I. & Brentjens, R.. *Nat Rev Cancer* 3, 35-45 (2003).
9. Miller, A.D. in *Retroviruses*. (eds. J. Coffin, S.H. Hughes & H.E. Varmus) 437-474 (Cold Spring Harbor Laboratory Press, Plainview; 2000).
10. Emerman, M. & Temin, H.M. *Mol Cell Biol* 6, 792-800 (1986).
11. Zhu, Y., et al.. *Mol.Ther.* 4,375-382 (2001).
12. Klump, H. et al. *Gene Ther.* 8, 811-817 (2001).
13. Furler, S., et al.. *Gene Ther* 8, 864-873 (2001).
14. Martinez-Salas, E.. *Curr.Opin.Biotechnol.* 10, 458-464 (1999).
15. Follenzi, A., et al.. *Nat Genet* 25, 217-222 (2000).
16. Ghattas, I.R., Sanes, J.R. & Majors, J.E.. *Mol.Cell Biol.* 11, 5848-5859 (1991).
17. Qiao, J., et al.. *Hum Gene Ther* 13, 881-887 (2002).
18. Oumard, A., et al.. 20,2755-2759 (2000).
19. Lois, C., et al.. *Science* 295, 868-872 (2002).
20. Baron, U. & Bujard, H.. *Methods Enzymol.* 327, 401-421 (2000).
21. Bray, M. et al. *Proc Natl Acad Sci USA* 91, 1256-1260 (1994).
22. Zufferey, R., et al.. *J. Virol.* 73, 2886-2892 (1999).
23. Ailles, L. et al.. *Mol Ther* 6, 615-626 (2002).
24. Cavallieri, S. et al.. *Blood* 102, 497-505 (2003).
25. Naldini, L., et al. *Proc Natl Acad Sci U SA* 93, 11382-11388 (1996).
26. Baekelandt, V. et al. *Hum Gene Ther* 13, 841-853 (2002).
27. Deglon, N. et al.. *Hum. Gene Ther.* 11, 179-190 (2000).

28. Sokolic, R.A. et al. Blood 87, 42-50 (1996).
29. Wong, E.T., Ngoi, S.M. & Lee, C.G. Gene Ther 9,337-344 (2002).
30. Kozak, M., Gene 318, 1-23 (2003).
31. Mizuguchi, H., et al., Mol Ther1, 376-382 (2000).
- 5 32. Hennecke, M. et al., Nucleic Acids Res 29, 3327-3334 (2001).
33. Mazurier, F., et al. Blood 103, 545-552 (2004).
34. Vigna, E. & Naldini, L., J Gene Med 2, 308-316 (2000).
35. Gardiner-Garden, M. & Frommer, M., J. Mol Biol 196, 261-282 (1987).
- 10 36. Lavia, P., Macleod, D. & Bird, A., EMBO J6, 2773-2779 (1987).
37. Johnson, P. & Friedmann, T., Gene 88, 207-213 (1990).
38. Scacheri, P.C. et al. Genesis 30, 259-263 (2001).
39. Vigna, E. et al., Mol Ther 5, 252-261 (2002).
40. Baron, U., et al., Nucleic.Acids.Res. 23, 3605-3606 (1995).
41. Unsinger, J., et al., Mol Ther 4,484-489 (2001).
- 15 42. Fux, C. et al., J Gene Med 5, 1067-1079 (2003).
43. Xie, M., He, Y. & Gan, SNat Biotechnol 19, 677-679 (2001).
44. Trinklein, N.D. et al., Genonze Res 14, 62-66 (2004).
45. Takai, D. & Jones, P.A. Mol Biol Evol 21, 463-467 (2004).
46. Adachi, N. & Lieber, M.R. Cell 109, 807-809 (2002).
- 20 47. Farson, D. et al. Hum Gene Ther 12, 981-997 (2001).
48. De Palma, M., et al., Nat Med 9, 789-795 (2003).
49. Follenzi, A., et al. Hum Gene Ther 13, 243-260 (2002).

SEQUENCE LISTING

[0064]

<110> FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

<120> LENTIVIRAL VECTORS CARRYING SYNTHETIC BI-DIRECTIONAL PROMOTERS AND USES THEREOF

<130> 81240PCT

<140> PCT/IT2004/000227

<141> 2004-04-21

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> primer

<220>

<221> misc\_feature

<222> (1)..(20)

<223> LV forward primer

<400> 1

tgaaagcgaa agggaaacca 20

<210> 2

<211> 15

<212> DNA

<213> Artificial Sequence

<220>  
 <223> primer  
 5 <220>  
 <221> misc\_feature  
 <222> (1)..(15)  
 <223> LV reverse primer

10 <400> 2  
 ccgtgcgcgc tcag 15

<210> 3  
 <211> 18  
 15 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> probe  
 20 <220>  
 <221> misc\_feature  
 <222> (1)..(18)  
 <223>

25 <220>  
 <221> misc\_feature  
 <222> (1)..(18)  
 <223> LV probe

30 <400> 3  
 ctctctcgac gcaggact 18

<210> 4  
 <211> 9613  
 35 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> plasmid  
 40 <220>  
 <221> misc\_feature  
 <222> (1)..(9613)  
 <223> plasmid containing the lentiviral vector construct RRL-MA1-lucif/ GFP

45 <400> 4

50

55

EP 1 616 012 B1

	caggtggcac ttttcgggga aatgtgcgcg gaacccttat ttgtttatctt ttctaaatac	60
	attcaaatac gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa	120
5	aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgcgggcat	180
	tttgccttcc tgtttttgct caccagaaa cgctggtgaa agtaaaagat gctgaagatc	240
	agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga	300
10	gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagtctg ctatgtggcg	360
	cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc	420
	agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcattgacag	480
	taagagaatt atgcagtgc gccataacca tgagtataa cactgcggcc aacttacttc	540
15	tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg	600
	taactcgcct tgatcggttg gaaccggagc tgaatgaagc catacacaac gacgagcgtg	660
	acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaactac	720
20	ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac	780
	cacttctgcg ctccggcctt ccggctgggt ggtttattgc tgataaatct ggagccggtg	840
	agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaagccc tcccgtatcg	900
25	tagttatcta cagcagggg agtcagggaa ctatggatga acgaaataga cagatcgctg	960
	agataggtgc ctactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac	1020
	tttagattga tttaaaactt ctttttaat ttaaaaggat ctaggatgaag atcctttttg	1080
30	ataatctcat gacaaaaac ccttaacgtg agttttcgtt ccactgagcg tcagaccccg	1140
	tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaac tgctgcttgc	1200
	aaacaaaaaa accaccgcta ccagcgggtg tttgtttgcc ggatcaagag ctaccaactc	1260
35	tttttccgaa ggtaactggc ttcagcagag cgcagatacc aaatactgtc cttctagtgt	1320
	agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac ctcgctctgc	1380
	taatcctggt accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact	1440
	caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac	1500
40	agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag	1560
	aaagcgccac gcttcccga gggagaaaagg cggacaggta tccggtgaagc ggcagggtcg	1620

45

50

55

EP 1 616 012 B1

	gaacaggaga ggcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtcctg	1680
	tcgggtttcg ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga	1740
5	gcctatggaa aaacgccagc aacgcggcct ttttacgggt cctggccttt tgctggcctt	1800
	ttgtcacat gttctttcct gcgttatccc ctgattctgt ggataaccgt attaccgcct	1860
	ttgagtgagc tgataccgct cgcgcagcc gaacgaccga gcgcagcgag tcagtgagcg	1920
10	aggaagcggg agagcgccca atacgcaaac cgctctccc gcgcggttg ccgattcatt	1980
	aatgcagctg gcacgacagg tttcccgaact ggaaagcggg cagtgcgcgc aacgcaatta	2040
	atgtgagtta gctcactcat taggcacccc aggctttaca ctttatgctt ccggctcgta	2100
	tggtgtgtg aattgtgagc ggataacaat ttcacacagg aaacagctat gacctgatt	2160
15	acgccaagcg cgcaattaac cctcactaaa gggaacaaaa gctggagctg caagcttaat	2220
	gtagtcttat gcaatactct tgtagtcttg caacatggta acgatgagtt agcaacatgc	2280
	cttacaagga gagaaaaagc accgtgcatg ccgattggtg gaagtaagggt ggtacgatcg	2340
20	tgccctatta ggaaggcaac agacgggtct gacatggatt ggacgaacca ctgaattgcc	2400
	gcattgcaga gatattgtat ttaagtgcct agctcgatac aataaacggg tctctctggt	2460
	tagaccagat ctgagcctgg gagctctctg gctaactagg gaaccactg cttagcctc	2520
25	aataaagctt gccttgagt cttcaagtag tgtgtgccc tctgtgtgt gactctggtg	2580
	actagagatc cctcagaccc ttttagtcag tgtggaaaat ctctagcagt ggcgcccgaa	2640
	cagggacctg aaagcgaaag ggaaaccaga gctctctga cgcaggactc ggcttgctga	2700
30	agcgcgcacg gcaagaggcg aggggcggcg actggtgagt acgcaaaaa tttgactag	2760
	cggaggctag aaggagagag atgggtgcga gagcgtcagt attaagcggg ggagaattag	2820
	atcgcgatgg gaaaaaatc gggttaaggcc agggggaaag aaaaaatata aattaaaaca	2880
	tatagtatgg gcaagcaggg agctagaacg attcgcagtt aatcctggcc tgtagaagc	2940
35	atcagaaggc tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga	3000
	agaacttaga tcattatata atacagtagc aaccctctat tgtgtgcac aaaggataga	3060
	gataaaagac accaaggaag ctttagacaa gatagaggaa gagcaaaaca aaagtaagac	3120
40	caccgcacag caagcgccg ctgatcttca gacctggagg aggagatatg agggacaatt	3180
	ggagaagtga attatataaa tataaagtag taaaaattga accattagga gtagcaccca	3240
	ccaaggcaaa gagaagagtg gtgcagagag aaaaaagagc agtgggaata ggagcttgt	3300
45	tccttgggtt cttgggagca gcaggaagca ctatgggcgc agcctcaatg acgtgacgg	3360
	tacaggccag acaattattg tctggtatag tgcagcagca gaacaattg ctgagggcta	3420
	ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag ctccaggcaa	3480
50	gaatcctggc tgtggaaaga tacctaaagg atcaacagct cctggggatt tggggttgct	3540
	ctggaaaact catctgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc	3600
	tggaacagat ttggaatcac acgacctgga tggagtggga cagagaaatt aacaattaca	3660

55

	caagcttaat acactcctta attgaagaat cgcaaaacca gcaagaaaag aatgaacaag	3720
	aattattgga attagataaa tgggcaagtt tgtggaattg gttaacata acaaattggc	3780
5	tgtggtatat aaaattattc ataatgatag taggaggctt ggtaggttta agaatagttt	3840
	ttgctgtact ttctatagtg aatagagtta ggcagggata ttcaccatta tcgtttcaga	3900
	cccacctccc aaccccagg ggacccgaca ggcccgaagg aatagaagaa gaagggtggag	3960
10	agagagacag agacagatcc attcgattag tgaacggatc tcgacggat cggttaactt	4020
	ttaaagaaa aggggggatt ggggggtaca gtgcagggga aagaatagta gacataatag	4080
	caacagacat acaaactaaa gaattacaaa aacaaattac aaaaattcaa aattttatcg	4140
15	atcacgagac tagcctcgag agatctgatc ataatcagcc ataccacatt tgtagaggtt	4200
	ttacttgctt taaaaaacct cccacacctc cccctgaacc tgaaacataa aatgaatgca	4260
	attgttgttg ttaacttggt tattgcagct tataatggtt acaataagg caatagcatc	4320
	acaaatttca caaataaggc atttttttca ctgcattcta gttttggttt gtccaaactc	4380
20	atcaatgtat cttatcatgt ctggatctca aatccctcgg aagctgcgcc tgtcttaggt	4440
	tggagtgata catttttatt actttttacc gtctttggat taggcagtag ctctgacggc	4500
	cctctgtct taggttagtg aaaaatgtca ctctcttacc cgtcattggc tgtccagctt	4560
25	agctcgcagg ggagggtggtc tggatcctct agaattacac ggcgatcttt ccgcccttct	4620
	tggcctttat gaggatctct ctgatttttc ttgcgtcgag ttttcggta agaccttctg	4680
	gtacttcgtc cacaacaca actcctccgc gcaactttt cgcggttggt acttgactgg	4740
30	ccacgtaatc cacgatctct ttttcgta tcgtctttcc gtgtccaaa acaacaacgg	4800
	cggcgggaag ttcaccggcg tcacgtcgg gaagacctgc gacacctgc tcgaagatgt	4860
	tggggtgttg gagcaagatg gattccaatt cagcgggagc cacctgatag cttttgtact	4920
35	taatcagaga cttcaggcgg tcaacgatga agaagtgttc gtcttcgtcc cagtaagcta	4980
	tgtctccaga atgtagccat ccattcctgt caatcaaggc gttggtcgct tccggattgt	5040
	ttacataacc ggacataatc ataggacctc tcacacacag ttcgcctctt tgattaacgc	5100
40	ccagcgtttt cccggtatcc agatccacaa ccttcgcttc aaaaaatgga acaactttac	5160
	cgaccgcgcc cggtttatca tccccctcgg gtgtaatcag aatagctgat gtagtctcag	5220
	tgagcccata tccttgccctg atacctggca gatggaacct cttggcaacc gcttccccga	5280
	cttccttaga gaggggagcg ccaccagaag caatttcgtg taaattagat aaatcgattt	5340
45	tgtcaatcag agtgcttttg gcgaagaagg agaataggtt tggcaccagc agcgcacttt	5400
	gaatcttgta atcctgaagg ctcttcagaa acagctcttc ttcaaattcta tacattaaga	5460
	cgactcgaat tccacatatc aaatatccga gtgtagtaaa cattccaaaa ccgtgatgga	5520
50	atggaacaac acttaaaatc gcagtatccg gaatgatttg attgccaaaa ataggatctc	5580
	tggcatgcga gaatctcacg caggcagttc tatgaggcag agcgacacct ttaggcagac	5640
	cagtagatcc agaggagtgc atgatcagtg caattgtctt gtccctatcg aaggactctg	5700
55		

	gcacaaaatc gtattcatta aaaccgggag gtagatgaga tgtgacgaac gtgtacatcg	5760
	actgaaatcc ctggtaatcc gttttagaat ccatgataat aattttttgg atgattggga	5820
5	gctttttttg cacgttcaaa attttttgca accccttttt ggaaacgaac accacggtag	5880
	gctgcgaaat gcccatactg ttgagcaatt cacgttcatt ataaatgtcg ttcgcgggcg	5940
	caactgcaac tccgataaat aacgcgcccc acaccggcat aaagaattga agagagtttt	6000
10	cactgcatac gacgattctg tgatttgat tcagcccata tcgtttcata gcttctgcca	6060
	accgaacgga cttttcgaag tactcagcgt aagtgatgtc cacctcgata tgtgcatctg	6120
	taaaagcaat tgttccagga accagggcgt atctcttcat agccttatgc agttgctctc	6180
15	cagcggttcc atcttccagc ggatagaatg gcgccgggcc tttctttatg tttttggcgt	6240
	cttccatggg gaattccgcg gaggctggat cggtcccggg gtcttctatg gaggtcaaaa	6300
	cagcgtggat ggcgtctcca ggcgatctga cggttcacta aacgagctct gcttatatag	6360
	gcctcccacc gtacacgcct accctcgaga agcttgatat cgaattccca cggggttggg	6420
20	gttgccctt ttccaaggca gccctgggtt tgcgcaggga cgcggctgct ctgggcgtgg	6480
	ttccgggaaa cgcagcggcg ccgaccctgg gtctcgcaca ttcttcacgt ccgttcgcag	6540
	cgtcacccgg atcttcgcg ctacccttgg gggcccccgc gcgacgcttc ctgtccgcc	6600
25	cctaagtcgg gaaggttcct tgcggttcgc ggcgtgccgg acgtgacaaa cggaagccgc	6660
	acgtctcact agtaccctcg cagacggaca gcgccaggga gcaatggcag cgcgccgacc	6720
	gcgatgggct gtggccaata gcgctgtctc agcggggcgc gccgagagca gcggccggga	6780
30	aggggcgggt cgggaggcgg ggtgtggggc ggtagtgtgg gccctgttcc tgcccgcgcg	6840
	gtgttccgca ttctgcaagc ctccggagcg cacgtcggca gtcggctccc tcgttgaccg	6900
	aatcaccgac ctctctcccc agggggatcc accggtcgcc accatggtga gcaagggcga	6960
35	ggagctgttc accggggtgg tgcccatcct ggtcgagctg gacggcgacg taaacggcca	7020
	caagttcagc gtgtccggcg agggcgaggg cgatgccacc tacggcaagc tgacctgaa	7080
	gttcactctg accaccggca agctgcccgt gccctggccc accctcgtga ccacctgac	7140
40	ctacggcgtg cagtgttca gccgctacct cgaccacatg aagcagcacg acttcttcaa	7200
	gtccgccatg cccgaaggct acgtccagga gcgcaccatc ttcttcaagg acgacggcaa	7260
	ctacaagacc cgcgccgagg tgaagttcga ggcgcacacc ctggtgaacc gcatcgagct	7320
	gaagggcatc gacttcaagg aggacggcaa catcctgggg cacaagctgg agtacaacta	7380
45	caacagccac aacgtctata tcatggccga caagcagaag aacggcatca aggtgaactt	7440
	caagatccgc cacaacatcg aggacggcag cgtgcagctc gccgaccact accagcagaa	7500
	cacccccatc ggcgacggcc ccgtgtgtgt gcccgacaac cactacctga gcaccagtc	7560
50	cgccttgagc aaagacccca acgagaagcg cgatcacatg gtcctgctgg agttcgtgac	7620
	cgcgcgggg atcactctcg gcatggacga gctgtacaag taaagcggcc gcgtcgacaa	7680
	tcaacctctg gattacaaaa ttgtgaaag attgactggg attcttaact atgttgctcc	7740
55		

	ttttacgcta tgtggatacg ctgctttaat gcctttgtat catgctattg cttcccgtat	7800
	ggcttttcatt ttctcctcct tgtataaatc ctggttgctg tctctttatg aggagtgtg	7860
5	gcccgttgtc aggcaacgtg gcgtggtgtg cactgtgttt gctgacgcaa cccccactgg	7920
	ttggggcatt gccaccacct gtcagctcct ttccgggact ttgctttcc cctccctat	7980
	tgccacggcg gaactcatcg ccgcctgcct tgcccgtgc tggacagggg ctgggtgtt	8040
10	gggcactgac aattccgtgg tgttgtcggg gaagctgacg tcctttccat ggctgctcg	8100
	ctgtgttgcc acctggattc tgcgcgggac gtccttctgc tacgtccctt cggccctcaa	8160
	tccagcggac cttccttccc gcggcctgct gccggctctg cggcctcttc cgcgtcttcg	8220
15	ccttcgccct cagacgagtc ggatctccct ttgggcccgc tccccgcctg gaattcgagc	8280
	tcggtacctt taagaccaat gacttacaag gcagctgtag atcttagcca ctttttaaaa	8340
	gaaaaggggg gactggaagg gctaattcac tcccaacgaa gacaagatct gctttttgct	8400
20	tgtactgggt ctctctggtt agaccagatc tgagcctggg agctctctg ctaactaggg	8460
	aaccactgc ttaagcctca ataaagcttg ccttgagtgc ttcaagtagt gtgtgccgt	8520
	ctgttgtgtg actctggtaa ctagagatcc ctacagacct ttagtcagt gtggaaaatc	8580
	tctagcagta gtagttcatg tcatcttatt attcagtatt tataacttgc aaagaaatga	8640
25	atatcagaga gtgagaggaa cttgtttatt gcagcttata atggttaca ataaagcaat	8700
	agcatcacia atttcacaa taaagcattt ttttactgc attctagtgtg tggtttgtcc	8760
	aaactcatca atgtatctta tcatgtctgg ctctagctat cccgcccta actccgcca	8820
30	gttccgcca ttctccgcc catggctgac taatttttt tatttatgca gaggccgagg	8880
	ccgcctcggc ctctgagcta ttccagaagt agtgaggagg cttttttgga ggcctaggct	8940
	tttgctcga gacgtaccca attcgccta tagtgagtcg tattacgcgc gtcactggc	9000
35	cgctgtttta caacgtcgtg actgggaaaa ccctggcgtt acccaactta atcgccttg	9060
	agcacatccc ctttccgcca gctggcgtaa tagcgaagag gcccgaccg atcgccttc	9120
	ccaacagttg cgcagcctga atggcgaatg gcgcgacgc cctgtagcg gcgcattaag	9180
40	cgcggcgggt gtggtgggta cgcgcagcgt gaccgctaca cttgccagcg ccctagcgc	9240
	cgctccttcc gctttcttcc cttcctttct cgccacgttc gccggcttcc cccgtcaagc	9300
	tctaaatcgg gggctccctt tagggttccg atttagtgct ttacggcacc tcgaccccaa	9360
45	aaaacttgat taggggtgat gttcacgtag tgggccatcg ccctgataga cggtttttcg	9420
	ccctttgacg ttggagtcca cgttctttta tagtggactc ttgttccaaa ctggaacaac	9480
	actcaaccct atctcggctt attcttttga ttataaggg attttgccga tttcggccta	9540
50	ttggttaaaa atgagctga tttaacaaaa atttaacgcg aattttaaca aaatattaac	9600
	gtttacaatt tcc	9613

&lt;210&gt; 5

&lt;211&gt; 9380

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(9380)

5 &lt;223&gt;

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(9380)

10 &lt;223&gt; plasmid containing the lentiviral vector construct CCL-MA1-GFP/de ItaLNGFR

&lt;400&gt; 5

15 caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt ttctaaatac 60  
 attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa 120  
 aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgcgggcat 180  
 ttgccccttc tgtttttgct caccagaaa cgctggtgaa agtaaaagat gctgaagatc 240  
 20 agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga 300  
 gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg 360  
 cgggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc 420  
 25 agaatgactt gggtgagtac tcaccagtca cagaaaagca tcttacggat ggcatgacag 480  
 taagagaatt atgcagtgtc gccataacca tgagtataaa cactgcggcc aacttacttc 540  
 tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg 600  
 30 taactcgcct tgatcgttgg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg 660  
 acaccacgat gcctgtagca atggcaacaa cgctgcgcaa actattaact ggcgaactac 720  
 ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac 780  
 35 cacttctgcg ctccggccct ccggctggct ggtttattgc tgataaatct ggagccgggtg 840  
 agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggttaagccc tcccgtatcg 900  
 tagttatcta cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg 960  
 40 agatagggtgc ctactgatt aagcattggg aactgtcaga ccaagtttac tcatatatac 1020

45

50

55

5      ttttagattga tttaaaaactt catttttaat ttaaaaaggat ctaggtgaag atcctttttg 1080  
 ataatctcat gaccaaaatc ccttaacgtg agtttttcgtt ccactgagcg tcagaccccg 1140  
 tagaaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc 1200  
 aaacaaaaaa accaccgcta ccagcgggtg tttgtttgcc ggatcaagag ctaccaactc 1260  
 tttttccgaa ggtaactggc ttcagcagag cgcagatacc aaatactgtc cttctagtgt 1320  
 10      agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac ctcgctctgc 1380  
 taatcctgtt accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact 1440  
 caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac 1500  
 agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag 1560  
 15      aaagcggcac gcttcccgaa gggagaaagg cggacaggta tccggttaagc ggcagggtcg 1620  
 gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtcctg 1680  
 tcgggtttcg ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga 1740  
 20      gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt tgctggcctt 1800  
 ttgctcacat gttctttcct gcgttatccc ctgattctgt ggataaccgt attaccgctt 1860  
 ttgagtgagc tgataccgct cgcgcagcc gaacgaccga gcgcagcgag tcagtgagcg 1920  
 25      aggaagcgga agagcgcca atacgcaaac cgcctctccc gcgcggttg ccgattcatt 1980  
 aatgcagctg gcacgacagg tttcccgact ggaaagcggg cagtgagcgc aacgcaatta 2040  
 atgtgagtta gctcactcat taggcacccc aggccttaca ctttatgctt ccggctcgta 2100  
 30      tgttgtgtg aattgtgagc ggataacaat ttcacacagg aaacagctat gaccatgatt 2160  
 acgccaagcg cgcaattaac cctcactaaa gggacaacaa gctggagctg caagcttggc 2220  
 cattgcatac gttgtatcca tatcataata tgtacattta tattggctca tgtccaacat 2280  
 35      taccgccatg ttgacattga ttattgacta gttattaata gtaatcaatt acgggggtcat 2340  
 tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaatt ggcccgcctg 2400  
 gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt cccatagtaa 2460  
 cgccaatagg gactttccat tgacgtcaat ggggtggagta tttacggtaa actgcccact 2520  
 40      tggcagtaca tcaagtgtat catatgccaa gtacgcccc tattgacgtc aatgacggta 2580  
 aatggcccg cttggcattat gcccagtaca tgaccttatg ggactttcct acttggcagt 2640  
 acatctacgt attagtcac gctattacca tgggtgatgc gttttggcag tacatcaatg 2700  
 45      ggcgtggata gcggtttgac tcacggggat ttccaagtct ccacccatt gacgtcaatg 2760  
 ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactccgccc 2820  
 cattgacgca aatgggcggg aggcgtgtac ggtgggaggt ctatataagc agagctcggt 2880  
 50      tagtgaaccg ggggtctctt ggttagacca gatctgagcc tgggagctct ctggctaact 2940  
 agggaaacca ctgcttaagc ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc 3000  
 ccgtctgttg tgtgactctg gtaactagag atccctcaga cccttttagt cagtgtggaa 3060

55

	aatctctagc agtggcgccc gaacagggac ctgaaagcga aagggaaacc agagctctct	3120
	cgacgcagga ctcggcttgc tgaagcgcgc acggcaagag gcgaggggcg gcgactggtg	3180
5	agtacgcca aatttttgac tagcggaggc tagaaggaga gagatgggtg cgagagcgtc	3240
	agtattaagc gggggagaat tagatcgcga tgggaaaaaa ttcggttaag gccaggggga	3300
	aagaaaaat ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca	3360
10	gttaatcctg gcctgttaga aacatcagaa ggctgtagac aaatactggg acagctacaa	3420
	ccatcccttc agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc	3480
	tattgtgtgc atcaaaggat agagataaaa gacaccaagg aagctttaga caagatagag	3540
	gaagagcaaa acaaaagtaa gaccaccgca cagcaagcgg ccgctgatct tcagacctgg	3600
15	aggaggagat atgagggaca attggagaag tgaattatat aaatataaag tagtaaaaat	3660
	tgaaccatta ggagtagcac ccaccaaggc aaagagaaga gtggtgcaga gaaaaaaag	3720
	agcagtggga ataggagctt tgttccttgg gttcttggga gcagcaggaa gcactatggg	3780
20	cgacgctca atgacgctga cggtagcggc cagacaatta ttgtctggta tagtgcagca	3840
	gcagaacaat ttgctgaggg ctattgaggc gcaacagcat ctgttgcaac tcacagtctg	3900
	gggcatcaag cagctccagg caagaatcct ggctgtggaa agatacctaa aggatcaaca	3960
25	gctcctgggg atttgggggt gctctggaaa actcatttgc accactgctg tgccttggaa	4020
	tgctagtgg agtaataaat ctctggaaca gattggaatc acacgacctg gatggagtgg	4080
	gacagagaaa ttaacaatta cacaagctta atacactcct taattgaaga atcgcaaaac	4140
30	cagcaagaaa agaataaaca agaattattg gaattagata aatgggcaag tttgtggaat	4200
	tggtttaaca taacaattg gctgtggtat ataaaattat tcataatgat agtaggaggc	4260
	ttggtaggtt taagaatagt ttttgcgtga ctttctatag tgaatagagt taggcaggga	4320
	tattcaccat tatcgtttca gaccacctc ccaaccccga ggggacctga caggcccga	4380
35	ggaatagaag aagaagggtg agagagagac agagacagat ccattcgatt agtgaacgga	4440
	tctcgacggt atcggttaac ttttaaaaga aaagggggga ttggggggta cagtgcaggg	4500
	gaaagaatag tagacataat agcaacagac atacaaacta aagaattaca aaaacaaatt	4560
40	acaaaaattc aaaattttat cgatcacgag actagcctcg agagatctga tcataatcag	4620
	ccataccaca tttgtagagg ttttacttgc tttaaaaaac ctcccacacc tccccctgaa	4680
	cctgaaacat aaaatgaatg caattgttgt tgtaacttg tttattgcag cttataatgg	4740
45	ttacaaataa ggcaatagca tcacaaattt cacaaataag gcattttttt cactgcattc	4800
	tagttttggt ttgtccaaac tcatcaatgt atcttatcat gtctggatct caaatccctc	4860
	ggaagctgcg cctgtcttag gttggagtga tacattttta tcacttttac ccgtctttgg	4920
50	attaggcagt agctctgacg gccctcctgt cttagggttag tgaaaaatgt cactctctta	4980
	cccgtcattg gctgtccagc ttagctcgca ggggagggtg tctggatccg agctcgaatt	5040
	ggccgcttta cttgtacagc tcgtccatgc cgagagtgat cccggcgcg gtcacgaact	5100
55		

## EP 1 616 012 B1

ccagcaggac catgtgatcg cgcttctcgt tgggggtcctt gctcagggcg gactgggtgc 5160  
 tcaggtagtg gttgtcgggc agcagcacgg ggccgtcgcc gatgggggtg ttctgctggt 5220  
 5 agtggtcggc gagctgcacg ctgccgtcct cgatgttggt gcggtatctg aagttcacct 5280  
 tgatgccgtt cttctgcttg tcggccatga tatagacgtt gtggctgttg tagttgtact 5340  
 ccagcttggtg ccccaggatg ttgccgtcct ccttgaagtc gatgcccttc agctcgatgc 5400  
 10 ggttcaccag ggtgtcggcc tcgaacttca cctcggcgcg ggtctttag tagtccgtcgt 5460  
 ccttgaagaa gatgggtcgc tcctggacgt agccttcggg catggcggac ttgaagaagt 5520  
 cgtgctgctt catgtggtcg gggtagcggc tgaagcactg cagcccgtag gtcaggggtg 5580  
 tcacgaggggt gggccagggc acgggcagct tgccgggtgt gcagatgaac ttcaggggtca 5640  
 15 gcttgccgta ggtggcatcg ccctcgccct cgccggacac gctgaacttg tggccgttta 5700  
 cgctcgccgtc cagctcgacc aggatgggca ccaccccggt gaacagctcc tcgcccttgc 5760  
 tcaccatggt gaattccgag gaggctggat cgggtccggt gtcttctatg gaggtcaaaa 5820  
 20 cagcgtggat ggcgctctca ggcgatctga cggttcacta aacgagctct gcttatatag 5880  
 gcctccacc gtacacgctt accctcgaga agcttgatat cgaattcca cggggttggtg 5940  
 gttgcgcctt ttccaaggca gccctgggtt tgcgcaggga cgcggtgct ctgggcgtgg 6000  
 25 ttccgggaaa cgcagcggcg ccgacctggt gtctcgaca ttcttcacgt ccgttcgcag 6060  
 cgtcaccggg atcttcggcg ctacccttgt gggcccccg gcgacgctt ctgctccgcc 6120  
 cctaagtcgg gaaggttctt tgcggttcgc ggcgtgccgg acgtgacaaa cggagccgc 6180  
 acgtctcact agtaccctcg cagacggaca gcgccaggga gcaatggcag cgcgccgacc 6240  
 30 gcgatgggct gtggccaata gcggtgctc agcggggcg gccgagagca gcggccggga 6300  
 agggggcgtg cgggagggcg ggtgtggggc ggtagtgtg gccctgttcc tgcccgcgcg 6360  
 gtgttcgcga ttctgcaagc ctccggagcg cagctcgga gtcggctccc tcgttgaccg 6420  
 35 aatcacgcac ctcttcccc agggggatcc cccgggtgc aggaattcgg gccgcggcca 6480  
 gctccggcgg gcaggggggg cgctggagcg cagcgcagcg cagccccatc agtccgaaa 6540  
 gcggaccgag ctggaagtcg agcgtgccc cgggagggcg gcgatggggg caggtgccac 6600  
 40 cggccgcgcc atggacgggc cgcgcctgct gctgttgctg cttctggggg tgtcccttg 6660  
 aggtgccaag gaggcagtc ccacaggcct gtacacacac agcggtagt gctgcaaagc 6720  
 ctgcaacctg ggcgaggggtg tggcccagcc ttgtggagcc aaccagaccg tgtgtgagcc 6780  
 45 ctgcctggac agcgtgacgt tctccgacgt ggtgagcgc accgagccgt gcaagccgtg 6840  
 caccgagtgc gtggggctcc agagcatgct ggcgcctgct gtggagggcg acgacgccgt 6900  
 gtgccgtgc gcctacggct actaccagga tgagacgact gggcgtgctg aggcgtgccg 6960  
 50 cgtgtgctgag gcgggctcgg gcctcgtgtt ctcctgccag gacaagcaga acaccgtgtg 7020  
 cgaggagtgc cccgacggca cgtattccga cgaggccaac cagtggtgacc cgtgcctgcc 7080  
 ctgcaccgtg tgcgaggaca ccgagcgcca gctccgcgag tgcacacgt gggccgacgc 7140

55

EP 1 616 012 B1

cgagtgcgag gagatcccctg gccgttgat tacacggtcc acacccccag agggctcgga 7200  
cagcacagcc cccagcacc aggagcctga ggcacctcca gaacaagacc tcatagccag 7260  
5 caggttgga ggtgtggtga ccacagtgt ggcagctcc cagcccgtg tgacccgagg 7320  
caccaccgac aacctcatcc ctgtctattg ctccatcctg gctgctgtg ttgtgggcct 7380  
tgtggcctac atagccttca agaggtggaa cagggggatc ctctagagtc gagtctagag 7440  
10 tcgacaatca acctctggat tacaattt gtgaaagatt gactggtatt cttactatg 7500  
ttgtccttt tacgtatgt ggatacgtg ctttaatgcc ttgtatcat gctattgctt 7560  
cccgatggc ttctatttc tcctcctgt ataatcctg gttgctgtc tttatgagg 7620  
agttgtggc cgtgtcagg caacgtggc tgggtgcac tgtgttgc gacgcaacc 7680  
15 ccactggtg gggcattgcc accacctgtc agctccttc cgggacttc gctttcccc 7740  
tcctattgc cagggcgaa ctcatcgcc cctgcctgc ccgtgctg acaggggctc 7800  
ggctgttgg cactgacaat tccgtggtg tgcggggaa gctgacgtc ttccatggc 7860  
20 tgctgcctg tgttgccacc tggattctg gcgggacgtc ctctgctac gtccctcgg 7920  
ccctcaatc agcggacctt cttcccgcg gcctgctgc ggctctcgg cctctccgc 7980  
gtcttcgct tcgccctcag acgagtcgga tctcccttg ggccgctcc ccgctggaa 8040  
25 ttcgagctc gtaccttaa gaccaatgac ttacaaggca gctgtagatc ttagccactt 8100  
tttaaagaa aaggggggac tggagggtc aattcactc caacgaagac aagatctgt 8160  
tttgttgt actgggtct tctggttaga ccagatctga gcctgggagc tctctggcta 8220  
30 actagggaa ccactgctta agcctcaata aagcttgct tgaagtctc aagtagtgt 8280  
tgcccgctg ttgtgtgact ctggtacta gagatccctc agacccttt agtcagtgtg 8340  
gaaaatcct agcagtagta gttcatgtc tctattatt cagtattat aacttgcaa 8400  
gaaatgaata tcagagagt agaggactt gtttattgca gcttataatg gttacaaata 8460  
35 aagcaatagc atcacaatt tcacaaata agcattttt tcaactgcatt ctagttgtg 8520  
tttgtccaa ctcatcaatg tatcttatc tgtctggctc tagctatccc gccctaact 8580  
ccgcccagtt ccgcccatt tccgcccct ggctgactaa tttttttat ttatgcagag 8640  
40 gccgaggcg cctcgccctc tgagctattc cagaagtagt gaggaggctt ttttgaggc 8700  
ctaggctttt gcgtcgagac gtacccaatt cgccctatag tgagtcgtat tacgcgcgt 8760  
cactggccgt cgttttaca cgtcgtgact gggaaaacc tggcgttacc caacttaac 8820  
45 gccttgagc acatccccct ttcgccagc ggcgtaata ggaagaggc cgcaccgatc 8880  
gcccttcca acagttgcgc agcctgaatg gcgaatggc cgacgcgcc ttagcggcg 8940  
cattaagcg gccgggtgt gtggttacg gcagcgtgac cgctacact gccagcgcc 9000  
tagcgccgc tctttcgt tcttccctt ctttctcgc caggttcgc ggctttccc 9060  
50 gtcaagctc aaatcgggg ctcccttag ggttccgatt tagtgctta cggcacctc 9120  
accccaaaa acttgattg ggtgatggt cagtagtgg gccatcgccc tgatagacg 9180

55

EP 1 616 012 B1

5

10

15

20

30

55

	ttactctagc	ttcccggcaa	caattaatag	actggatgga	ggcggataaa	gttgcaggac	780
	cacttctgcg	ctcggccctt	ccggctggct	ggtttattgc	tgataaatct	ggagccgggtg	840
5	agcgtgggtc	tcgcggtatc	attgcagcac	tggggccaga	tggttaagccc	tcccgtatcg	900
	tagttatcta	cacgacgggg	agtcaggcaa	ctatggatga	acgaaataga	cagatcgctg	960
	agataggtgc	ctcactgatt	aagcattggt	aactgtcaga	ccaagtttac	tcatatatac	1020
10	tttagattga	tttaaaactt	catttttaat	ttaaaaggat	ctaggtgaag	atcctttttg	1080
	ataatctcat	gacccaaaatc	ccttaacgtg	agttttcgtt	ccactgagcg	tcagacccccg	1140
	tagaaaagat	caaaggatct	tcttgagatc	ctttttttct	gcgcgtaatc	tgctgcttgc	1200
15	aaacaaaaaa	accaccgcta	ccagcgggtg	tttgtttgcc	ggatcaagag	ctaccaactc	1260
	tttttccgaa	ggtaactggc	ttcagcagag	cgcagatacc	aaatactgtc	cttctagtgt	1320
	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	gcctacatac	ctcgcctctgc	1380
	taatcctgtt	accagtggct	gctgccagtg	gcgataagtc	gtgtcttacc	gggttggact	1440
20	caagacgata	gttaccggat	aaggcgcagc	ggtcgggctg	aacgggggggt	tcgtgcacac	1500
	agcccagctt	ggagcgaacg	acctacaccg	aactgagata	cctacagcgt	gagctatgag	1560
	aaagcgccac	gcttcccga	gggagaaaag	cggacaggta	tccggtaagc	ggcagggtcg	1620
25	gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	ctggtatctt	tatagtcttg	1680
	tcgggtttcg	ccacctctga	cttgagcgtc	gatttttgtg	atgctcgtca	ggggggcgga	1740
	gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	cctggccttt	tgctggcctt	1800
30	ttgctcacat	gttcttttct	gcgttatccc	ctgattctgt	ggataaccgt	attaccgcct	1860
	ttgagtgagc	tgataccgct	cgccgcagcc	gaacgaccga	gcgcagcgag	tcagtgagcg	1920
	aggaagcgga	agagcgccca	atacgcaaac	cgctctctcc	cgcgcggttg	ccgattcatt	1980
35	aatgcagctg	gcacgacagg	tttcccga	ggaaagcggg	cagtgagcgc	aacgcaatta	2040
	atgtgagtta	gtcactcat	taggcacccc	aggctttaca	ctttatgctt	ccggctcgta	2100
	tgttgtgtgg	aattgtgagc	ggataacaat	ttcacacagg	aaacagctat	gacctgatt	2160
	acgccaaagc	cgcaattaac	cctcactaaa	gggaacaaaa	gctggagctg	caagcttaat	2220
40	gtagtcttat	gcaatactct	tgtagtcttg	caacatggta	acgatgagtt	agcaacatgc	2280
	cttacaagga	gagaaaaagc	accgtgcatg	ccgattggtg	gaagtaagggt	ggtacgatcg	2340
	tgctttatta	ggaaggcaac	agacgggtct	gacatggatt	ggacgaacca	ctgaattgcc	2400
45	gcattgcaga	gatattgtat	ttaagtgcct	agctcgatac	aataaacggg	tctctctggt	2460
	tagaccagat	ctgagcctgg	gagctctctg	gctaactagg	gaaccactg	cttaagcctc	2520
	aataaagctt	gccttgagtg	cttcaagtag	tgtgtgcccc	tctgttgtgt	gactctggtg	2580
50	actagagatc	cctcagaccc	ttttagttag	tgtggaaaat	ctctagcagt	ggcgcccgaa	2640
	cagggacctg	aaagcgaaag	ggaaaccaga	gtctctctga	cgcaggactc	ggcttgctga	2700
	agcgcgcacg	gcaagaggcg	aggggcggcg	actggtgagt	acgccaaaaa	ttttgactag	2760
55							

	cggaggctag aaggagagag atgggtgcga gagcgtcagt attaagcggg ggagaattag	2820
	atcgcgatgg gaaaaaattc ggttaaggcc agggggaaag aaaaaatata aattaaaaca	2880
5	tatagtatgg gcaagcaggg agctagaacg attcgcagtt aatcctggcc tgtagaaac	2940
	atcagaaggc tgtagacaaa tactgggaca gctacaacca tcccttcaga caggatcaga	3000
	agaacttaga tcattatata atacagtagc aaccctctat tgtgtgcatc aaaggataga	3060
10	gataaaagac accaaggaag ctttagacaa gatagaggaa gagcaaaaca aaagtaagac	3120
	caccgcacag caagcggccg ctgatcttca gacctggagg aggagatatg agggacaatt	3180
	ggagaagtga attatataaa tataaagtag taaaattga accattagga gtagcaccca	3240
15	ccaaggcaaa gagaagagtg gtgcagagag aaaaagagc agtgggaata ggagctttgt	3300
	tccttgggtt cttgggagca gcaggaagca ctatgggcgc agcctcaatg acgctgacgg	3360
	tacaggccag acaattattg tctggtatag tgcagcagca gaacaatttg ctgagggcta	3420
	ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag ctccaggcaa	3480
20	gaatcctggc tegtggaaaga tacctaaagg atcaacagct cctggggatt tggggttgct	3540
	ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt aataaatctc	3600
	tggaaacagat tggaatcaca cgacctggat ggagtgggac agagaaatta acaattacac	3660
25	aagcttaata cactccttaa ttgaagaatc gcaaaaccag caagaaaaga atgaacaaga	3720
	attattggaa ttagataaat gggcaagttt gtggaattgg ttaacataa caaattggct	3780
	gtggtatata aaattattca taatgatagt aggaggcttg gtaggtttaa gaatagtttt	3840
30	tgctgtactt tctatagtga atagagttag gcagggatat tcaccattat cgtttcagac	3900
	ccacctccca accccgaggg gacccgacag gcccgaaagg atagaagaag aaggtggaga	3960
	gagagacaga gacagatcca ttcgattagt gaacggatct cgacggatc ggtaacttt	4020
35	taaaagaaaa ggggggattg ggggggtacag tgcaggggaa agaatagtag acataatagc	4080
	aacagacata caaactaaag aattacaaaa acaaattaca aaaattcaaa attttatcga	4140
	tcacgagact agcctcgaga gatctgatca taatcagcca taccacattt gtagaggttt	4200
	tacttgcttt aaaaaacctc ccacacctcc ccctgaacct gaaacataaa atgaatgcaa	4260
40	ttgttggttg taacttggtt attgcagctt ataattggtt caaataaggc aatagcatca	4320
	caaatttcac aaataaggca tttttttcac tgcattctag ttttggtttg tccaaactca	4380
	tcaatgtatc ttatcatgtc tggatctcaa atccctcgga agctgcgcct gtcttaggtt	4440
45	ggagtgtac atttttatca cttttaccg tctttggatt aggcagtagc tctgacggcc	4500
	ctcctgtctt aggttagtga aaaatgtcac tctcttaccg gtcattggct gtccagctta	4560
	gctcgcaggg gaggtggtct ggatccctgg atatcaagaa ttcgtcctcg agctcagatc	4620
50	ctctagaatt acacggcgat ctttccgccc ttcttggcct ttatgaggat ctctctgatt	4680
	tttcttgctg cgagttttcc ggtaagacct ttcggtactt cgccacaaa cacaactcct	4740
	ccgcgcaact ttttcgcggt tgttacttga ctggccacgt aatccacgat ctctttttcc	4800
55		

	gtcatcgtct ttcggtgctc caaaacaaca acggcgggcg gaagttcacc ggcgtcatcg	4860
	tcgggaagac ctgcgacacc tgcgtcgaag atgttggggt gttggagcaa gatggattcc	4920
5	aattcagcgg gagccacctg atagcctttg tacttaatca gagacttcag gcggtcaacg	4980
	atgaagaagt gttcgtcttc gtcccagtaa gctatgtctc cagaatgtag ccatccatcc	5040
	ttgtcaatca aggcgttggg cgttcccgga ttgtttacat aaccggacat aatcatagga	5100
10	cctctcacac acagttcgcc tctttgatta acgcccagcg ttttccgggt atccagatcc	5160
	acaaccttcg cttcaaaaaa tggaacaact ttaccgaccg cgcccggttt atcatcccc	5220
	tcgggtgtaa tcagaatagc tgatgtagtc tcagttagcc catatccttg cctgatacct	5280
15	ggcagatgga acctcttggc aaccgcttcc ccgacttcct tagagagggg agcgccacca	5340
	gaagcaatct cgtgtaaatt agataaatcg tatttgtcaa tcagagtgtt tttggcgaag	5400
	aaggagaata gggttggcac cagcagcgca ctttgaatct tgtaatcctg aaggctcctc	5460
	agaaacagct cttcttcaaa tctatacatt aagacgactc gaaatccaca tatcaaatat	5520
20	ccgagtgtag taaacattcc aaaaccgtga tggaatggaa caacacttaa aatcgagta	5580
	tccggaatga tttgattgcc aaaaatagga tctctggcat gcgagaatct cacgcaggca	5640
	gttctatgag gcagagcgac acctttaggc agaccagtag atccagagga gttcatgatc	5700
25	agtgaattg tctgtccct atcgaaggac tctggcaca aatcgtattc attaaaaccg	5760
	ggaggtagat gagatgtgac gaacgtgtac atcgactgaa atccctggta atccgtttta	5820
	gaatccatga taataatctt ttggatgatt gggagctttt ttgcacgtt caaaatctt	5880
30	tgcaaccctt ttttggaaac gaacaccagc gtaggctgag aaatgcccat actgttgagc	5940
	aattcacgtt cattataaat gtcgttcgag ggcgcaactg caactccgat aaataacgcg	6000
	cccaacaccg gcataaagaa ttgaagagag ttttactgac atacgacgat tctgtgattt	6060
35	gtattcagcc catatcgttt catagcttct gccaaaccgaa cggacatttc gaagtactca	6120
	gcgtaagtga tgtccacctc gatatgtgca tctgtaaaag caattgttcc aggaaccagg	6180
	gcgtatctct tcatagcctt atgcagttgc tctccagcgg ttccatcttc cagcggatag	6240
	aatggcgccg ggcctttctt tatgtttttg gcgtcttcca tgggtgaattc cgatccccct	6300
40	ggggagagag gtcggtgatt cggtcaacga gggagccgac tgccgacgtg cgctccggag	6360
	gcttgacgaa tgcggaacac cgcgcgggca ggaacagggc ccacactacc gccccacacc	6420
	ccgcctccc caccgcccct tcccggccgc tgctctcggc gcgccccgt gagcagccgc	6480
45	tattggccac agcccatcgc ggtcggcgcg ctgccattgc tccctggcgc tgtccgtctg	6540
	cgaggggtact agtgagacgt gcggcttccg tttgtcacgt ccggcacgcc gcgaaccgca	6600
	aggaaccttc ccgacttagg ggcggagcag gaagcgtcgc cggggggccc acaagggtag	6660
50	cggcgaagat ccgggtgacg ctgcgaacgg acgtgaagaa tgtgcgagac ccagggtcgg	6720
	cgccgctgag tttcccggaa ccacgcccag agcagccgag tccctgcgca aaccagggc	6780
	tgcccttgaa aaggcgcaac cccaaccccg tgggaattcg atatcaagct tgcctatgtt	6840
55		

cttttggaat ctatccaagt cttatgtaaa tgcttatgta aaccataata taaaagagtg 6900  
 ctgatttttt gagtaaaactt gcaacagttcc taacattctt ctctcgtgtg tttgtgtctg 6960  
 5 ttcgccatcc cgtctccgct cgtcacttat ctttcacttt tcagaggggc ccccccagaga 7020  
 tcccgggtcac cctcaggtcg ggtcgacaac catggtgagc aagggcgagg agctgttcac 7080  
 cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt 7140  
 10 gtccggcgag ggcgagggcg atgccaccta cggcaagctg accctgaagt tcattctgcac 7200  
 caccggcaag ctgcccgtgc cctggccac cctcgtgacc accctgacct acggcgtgca 7260  
 gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc 7320  
 cgaaggctac gtccaggagc gcaccatctt ctcaaggac gacggcaact acaagacccg 7380  
 15 cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga 7440  
 cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa 7500  
 cgtctatatc atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca 7560  
 20 caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca ccccatcgg 7620  
 cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtcgg ccctgagcaa 7680  
 agaccccaac gagaagcgcg atcacatggt cctgctggag ttcgtgaccg ccgccgggat 7740  
 25 cactctcggc atggacgagc tgtacaagta aagcggcctc gacaatcaac ctctggatta 7800  
 caaaatttgt gaaagattga ctggtattct taactatgtt gctcctttta cgctatgttg 7860  
 atacgctgct ttaatgcctt tgtatcatgc tattgcttcc cgtatggctt tcattttctc 7920  
 30 ctcttctgat aaatcctggt tgcgtctctt ttatgaggag ttgtggcccg ttgtcaggca 7980  
 acgtggcgtg gtgtgactg tgtttgtgta cgcaaccccc actggttggg gcattgccac 8040  
 cacctgtcag ctcttttccg ggactttcgc ttccccctc cctattgcca cggcggaact 8100  
 catcgccgcc tgccttgccc gctgctggac aggggctcgg ctgttgggca ctgacaattc 8160  
 35 cgtggtgttg tcggggaagc tgacgtcctt tccatggctg ctgcctgtg ttgccacctg 8220  
 gattctgcgc gggagctcct tctgtacgt ccttcgggc ctcaatccag cggaccttc 8280  
 ttcccgcggc ctgctgccgg ctctgcggcc tcttcgcgt cttcgccctc gccctcagac 8340  
 40 gagtcggatc tccctttggg ccgcctcccc gcctggaatt cgagctcggg acctttaaga 8400  
 ccaatgactt acaaggcagc tgtagatctt agccactttt taaaagaaaa ggggggactg 8460  
 gaagggctaa ttcactccca acgaagacaa gatctgcttt ttgcttgtag tgggtctctc 8520  
 45 tggttagacc agatctgagc ctgggagctc tctggctaac tagggaaccc actgcttaag 8580  
 cctcaataaa gcttgccctg agtgcttcaa gtagtgtgtg cccgtctgtt gtgtgactct 8640  
 ggttaactaga gatccctcag acccttttag tcagtgtgga aaatctctag cagtagtagt 8700  
 50 tcattgtcatc ttattattca gtatttataa cttgcaaaga aatgaatata agagagttag 8760  
 aggaacttgt ttattgcagc ttataatggt tacaataaaa gcaatagcat cacaatttc 8820  
 acaataaag catttttttc actgcattct agttgtggtt tgtccaaact catcaatgta 8880

55

EP 1 616 012 B1

5 tcttatcatg tctggctcta gctatcccg cctaactcc gccagttcc gccattctc 8940  
 cgcccatgg ctgactaatt tttttatatt atgcagaggc cgaggccgcc tcggcctctg 9000  
 agctattcca gaagtagtga ggaggctttt ttggaggcct aggcttttgc gtcgagacgt 9060  
 acccaattcg ccctatagtg agtcgtatta cgcgcgtca ctggccgtcg ttttacaacg 9120  
 tcgtgactgg gaaaaccctg gcgttaccga acttaatcgc cttgcagcac atcccccttt 9180  
 10 cgccagctgg cgtaatagcg aagaggcccg caccgatcgc ctttcccaac agttgcgcag 9240  
 cctgaatggc gaatggcgcg acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt 9300  
 ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta gcgcccgtc ctttcgcttt 9360  
 cttcccttcc tttctcgcca cgttcgccgg ctttccccgt caagctctaa atcggggggt 9420  
 15 ccccttaggg ttccgattta gtgctttacg gcacctcgac cccaaaaaac ttgattaggg 9480  
 tgatgggtca cgtagtgggc catcgccctg atagacggtt tttcgccctt tgacgttggg 9540  
 gtccacgttc tttaatagtg gactcttggt ccaaactgga acaacactca accctatctc 9600  
 20 ggtctattct ttgatttat aagggatttt gccgatttcg gcctattggt taaaaaatga 9660  
 gctgatttaa caaaaattta acgcgaattt taacaaaata ttaacgttta caatttcc 9718

25 <210> 7  
 <211> 9490  
 <212> DNA  
 <213> Artificial Sequence

30 <220>  
 <223> plasmid  
 <220>  
 <221> misc\_feature  
 <222> (1)..(9490)  
 <223>

35 <220>  
 <221> misc\_feature  
 <222> (1)..(9490)  
 <223> plasmid containing the lentiviral vector construct CCL-MA3-GFP/de ItaLNGFR

40 <400> 7  
 caggtggcac ttctgggga aatgtgcgcg gaaccctat ttgttatt ttctaaatac 60

45

50

55

	attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa	120
	aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgcggcac	180
5	tttgccttcc tgtttttgct caccagaaa cgctggtgaa agtaaaagat gctgaagatc	240
	agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggtaag atccttgaga	300
	gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg	360
10	cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc	420
	agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcatgacag	480
	taagagaatt atgcagtgtc gccataacca tgagtataa cactgcggcc aacttacttc	540
15	tgacaacgat cggaggaccg aaggagctaa ccgctttttt gcacaacatg ggggatcatg	600
	taactcgcct tgatcggttg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg	660
	acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaaactac	720
20	ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac	780
	cacttctgcg ctgcggccct ccggctggct ggtttattgc tgataaatct ggagccggtg	840
	agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggtaaagccc tcccgtatcg	900
	tagttatcta cagcagggg agtcaggcaa ctatggatga acgaaataga cagatcgctg	960
25	agataggtgc ctactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac	1020
	tttagattga tttaaaactt cttttttaat ttaaaaggat ctaggatgaag atcctttttg	1080
	ataatctcat gaccaaaac ccttaacgtg agttttcgtt cactgagcg tcagaccccg	1140
30	tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc	1200
	aaacaaaaaa accaccgcta ccagcgggtg tttgtttgcc ggatcaagag ctaccaactc	1260
	tttttcgaa ggttaactggc ttacgcagag cgcagatacc aaatactgtc cttctagtgt	1320
35	agccgtagt ttaggccacc ttcaagaact ctgtagcacc gcttacatac ctgcctctgc	1380
	taatcctgt accagtggct gctgccagt gcgataagtc gtgtcttacc gggttggact	1440
	caagacgata gttaccggat aaggcgcagc ggtcgggctg aacgggggggt tcgtgcacac	1500
40	agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag	1560
	aaagcgccac gcttcccga gggagaaagg cggacaggta tccggtaagc ggcaggggtc	1620
	gaacaggaga gcgcacgagg gagcttcag ggggaaacgc ctggtatctt tatagtcctg	1680
45	tcgggtttcg ccacctctga cttgagcgtc gatttttgtg atgctcgtca ggggggcgga	1740
	gcctatggaa aaacgccagc aacgcggcct ttttacgggt cctggccttt tgctggcctt	1800
	ttgtcacat gttctttcct gcgttatccc ctgattctgt ggataaccgt attaccgcct	1860
	ttgagtgagc tgataccgct cgcgcagcc gaacgaccga gcgcagcgag tcagtgagcg	1920
50	aggaagcggg agagcgccca atacgaaac cgcctctccc cgcgcgttgg ccgattcatt	1980
	aatgcagctg gcacgacagg tttcccgact ggaaagcggg cagtgagcgc aacgcaatta	2040
55	atgtgagtta gctcactcat taggcacccc aggcctttaca ctttatgctt ccggctcgta	2100

	tgttgtgtgg aattgtgagc ggataacaat ttcacacagg aaacagctat gaccatgatt	2160
	acgccaagcg cgcaattaac cctcactaaa gggaacaaaa gctggagctg caagcttggc	2220
5	cattgcatac gttgtatcca tatcataata tgtacattta tattggctca tgtccaacat	2280
	taccgccatg ttgacattga ttattgacta gttattaata gtaatcaatt acggggctcat	2340
	tagttcatag cccatatatg gagttccgcy ttacataact tacggtaaatt ggcccgcctg	2400
10	gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt cccatagtaa	2460
	cgccaatagg gactttccat tgacgtcaat ggggtggagta ttacggtaa actgcccact	2520
	tggcagtaca tcaagtgtat catatgccaa gtacgcccc tattgacgtc aatgacggta	2580
15	aatggcccgc ctggcattat gcccagtaca tgaccttatg ggactttcct acttggcagt	2640
	acatctacgt attagtcacg gctattacca tgggtgatgcg gttttggcag tacatcaatg	2700
	ggcgtggata gcggtttgac tcacggggat ttccaagtct ccaccccatt gacgtcaatg	2760
20	ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactccgccc	2820
	cattgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc agagctcggt	2880
	tagtgaaccg gggctctctt ggttagacca gatctgagcc tgggagctct ctggctaact	2940
	agggaaacca ctgcttaagc ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc	3000
25	ccgtctgttg tgtgactctg gtaactagag atccctcaga cccttttagt cagtgtggaa	3060
	aatctctagc agtggcgccc gaacaggggac ctgaaagcga aagggaaacc agagctctct	3120
	cgacgcagga ctcggcttgc tgaagcgcg acggcaagag gcgaggggcy gcgactggtg	3180
30	agtacgcaa aaattttgac tagcggaggc tagaaggaga gagatgggtg cgagagcgctc	3240
	agtattaagc gggggagaat tagatcgcg tgggaaaaaa ttcggttaag gccaggggga	3300
	aagaaaaaat ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca	3360
35	gttaatcctg gcctgttaga aacatcagaa ggctgtagac aaatactggg acagctacaa	3420
	ccatcccttc agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc	3480
	tattgtgtgc atcaaaggat agagataaaa gacaccaagg aagctttaga caagatagag	3540
40	gaagagcaaa acaaaagtaa gaccaccgca cagcaagcgg ccgctgatct tcagacctgg	3600
	aggaggagat atgagggaca attggagaag tgaattatat aaatataaag tagtaaaaat	3660
	tgaaccatta ggagtagcac ccaccaaggc aaagagaaga gtggtgcaga gagaaaaaag	3720
	agcagtggga ataggagctt tgttcccttg gttcttggga gcagcaggaa gcactatggg	3780
45	cgcagcctca atgacgctga cggtagaggc cagacaatta ttgtctggta tagtgcagca	3840
	gcagaacaat ttgctgaggg ctattgaggc gcaacagcat ctgttgcaac tcacagtctg	3900
	gggcatcaag cagctccagg caagaatcct ggctgtggaa agatacctaa aggatcaaca	3960
50	gctcctgggg atttgggggt gctctggaaa actcatttgc accactgctg tgccttggaa	4020
	tgctagttag agtaataaat ctctggaaca gatttggaaat cacacgacct ggatggagtg	4080
55	ggacagagaa attaacaatt acacaagctt aatacactcc ttaattgaag aatcgcaaaa	4140

ccagcaagaa aagaatgaac aagaattatt ggaattagat aaatgggcaa gtttgtggaa 4200  
 ttggtttaac ataacaaatt ggctgtggta tataaaatta ttcataatga tagtaggagg 4260  
 5 cttggtaggt ttaagaatag tttttgctgt actttctata gtgaatagag ttaggcaggg 4320  
 atattcacca ttatcgtttc agaccacact cccaaccccg aggggacccg acaggcccg 4380  
 aggaatagaa gaagaagggt gagagagaga cagagacaga tccattcgat tagtgaacgg 4440  
 10 atctcgacgg tatcggttaa cttttaaag aaaagggggg attggggggg acagtgcagg 4500  
 ggaaagaata gtagacataa tagcaacaga catacaaaact aaagaattac aaaaacaaat 4560  
 taaaaaatt caaaatttta tcatcacga gactagcctc gaggagatct gatcataatc 4620  
 15 agccatacca cttttagtag ggttttactt gcttataaaa acctcccaca cctccccctg 4680  
 aacctgaaac ataaatgaa tgcaattgtt gttgttaact tgtttattgc agcttataat 4740  
 ggttacaat aaggcaatag catcacaaat ttcacaaata aggcattttt ttcactgcat 4800  
 tctagttttg gtttgtccaa actcatcaat gtatcttctc atgtctggat ctcaaatccc 4860  
 20 tcggaagctg cgcctgtctt aggttggagt gatacatttt tatcactttt acccgctttt 4920  
 ggattaggca gtagctctga cggccctcct gtcttaggtt agtgaaaaat gtcactctct 4980  
 taccgctcat tggctgtcca gcttagctcg caggggaggt ggtctggatc caccatgtct 5040  
 25 agagaatagg aacttcggaa taggaacttc gcggccgctt tacttgtaga gtcgtccat 5100  
 gccgagagt atcccgccg cggctcacga ctccagcagg accatgtgat cgcgcttctc 5160  
 gttggggtct ttgctcagg cggactgggt gctcaggtag tggttgtcgg gcagcagcac 5220  
 30 ggggccgctc ccgatggggg tgttctgctg gtagtggtcg gcgagctgca cgctgccgtc 5280  
 ctcgatgttg tggcgatct tgaagtac cttgatgccg ttcttctgct tgcggccat 5340  
 gatatagacg ttgtggtgtg ttagttgta ctccagcttg tgccccagga tgttgccgtc 5400  
 35 ctcttgaag tcatgccct tcagctcgat gcggttcacc aggtgtcgc cctcgaactt 5460  
 cactcggcg cgggtcttgt agttgccgtc gtccttgaag aagatgggtg gtcctggac 5520  
 gtagccttcg ggcattggcg acttgaagaa gtcgtgctgc ttcattgtgt cggggtagcg 5580  
 40 gctgaagcac tgcacgccgt aggtcagggt ggtcacgagg gtgggccagg gcacgggcag 5640  
 cttgccggtg gtgcagatga acttcagggt cagcttgccg taggtggcat cgcctcggc 5700  
 ctgcgggac acgctgaact tgtggccgtt tacgtcggc tccagctcga ccaggatggg 5760  
 caccaccccg gtgaacagct cctgcctt gctcaccatg gttgtcgacc cgacctgagg 5820  
 45 gtgaccggga tctgcggggg gacctctga aaagtgaagg ataagtgacg agcggagacg 5880  
 ggatggcgaa cagacacaaa cacacgagag aagaatgtta ggactgttgc aagtttactc 5940  
 aaaaaatcag cactctttta tattatggtt tacataagca ttacataag acttgatag 6000  
 50 attcaaaaag aacataggca agcttgatat cgaattccca cggggttggg gttgcgcctt 6060  
 ttcaaggca gccctgggtt tgcgaggga cgcggctgct ctggcggtg ttccgggaaa 6120  
 cgcagcggcg ccgacctg gtctgcaca ttcttcacgt ccgttcgag cgtcaccgg 6180

55

	atcttcgccc	ctacccttgt	gggccccccg	gcgacgcttc	ctgctccgcc	cctaagtcgg	6240
	gaagggttcct	tgcggttcgc	ggcgtgccgg	acgtgacaaa	cggaagccgc	acgtctcact	6300
5	agtaccctcg	cagacggaca	gcgccaggga	gcaatggcag	cgcgccgacc	gcgatgggct	6360
	gtggccaata	gcggctgctc	agcggggcgc	gccgagagca	gcggccggga	aggggcggtg	6420
	cgggaggcgg	ggtgtggggc	ggtagtgtgg	gccctgttcc	tgcccgcgcg	gtgttccgca	6480
10	ttctgcaagc	ctccggagcg	cacgtcggca	gtcggctccc	tcgttgaccg	aatcaccgac	6540
	ctctctcccc	agggggatcc	cccgggctgc	aggaattcgg	gccgcggcca	gctccggcgg	6600
	gcaggggggg	cgttgagcgc	cagcgcagcg	cagccccatc	agtcgcgaaa	gcggaccgag	6660
15	ctggaagtcg	agcgtgccg	cgggaggcgg	gcgatggggg	caggtgccac	cggccgcgcc	6720
	atggacgggc	cgcgcctgct	gctgttgctg	cttctggggg	tgtcccttgg	aggtgccaa	6780
	gaggcatgcc	ccacaggcct	gtacacacac	agcggtgagt	gctgcaaagc	ctgcaacctg	6840
	ggcgagggtg	tggcccagcc	ttgtggagcc	aaccagaccg	tgtgtgagcc	ctgcctggac	6900
20	agcgtgacgt	tctccgacgt	ggtgagcgcg	accgagccgt	gcaagccgtg	caccgagtgc	6960
	gtggggctcc	agagcatgtc	ggcgccgtgc	gtggaggccg	acgacgccgt	gtgccgctgc	7020
	gcctacggct	actaccagga	tgagacgact	gggcgctgcg	aggcgtgccg	cgtgtgcgag	7080
25	gcgggctcgg	gcctcgtgtt	ctcctgccag	gacaagcaga	acaccgtgtg	cgaggagtgc	7140
	cccgaaggca	cgtattccga	cgaggccaac	cacgtggacc	cgtgcctgcc	ctgcaccgtg	7200
	tgcgaggaca	ccgagcgcca	gctccgcgag	tgcacacgct	gggcccgcgc	cgagtgcgag	7260
30	gagatccctg	gccgttggat	tacacggctc	acacccccag	agggctcgga	cagcacagcc	7320
	cccagcaccc	aggagcctga	ggcacctcca	gaacaagacc	tcatagccag	cacggtggca	7380
	ggtgtggtga	ccacagtgat	gggcagctcc	cagcccgtgg	tgacccgagg	caccaccgac	7440
35	aacctcatcc	ctgtctattg	ctccatcctg	gctgctgtgg	ttgtgggcct	tgtggcctac	7500
	atagccttca	agaggtggaa	cagggggatc	ctctagagtc	gagtctagag	tcgacaatca	7560
	acctctggat	tacaaaattt	gtgaaagatt	gactgggtatt	cttaactatg	ttgtcctttt	7620
40	tacgctatgt	ggatacgctg	ctttaatgcc	tttgtatcat	gctattgctt	cccgtatggc	7680
	tttcattttc	tcctccttgt	ataaatcctg	gttgctgtct	ctttatgagg	agttgtggcc	7740
	cgttgtcagg	caacgtggcg	tggtgtgcac	tgtgtttgct	gacgcaaccc	ccactggttg	7800
	gggcattgcc	accacctgtc	agtccttttc	cgggactttc	gctttccccc	tcctatttgc	7860
45	cacggcggaa	ctcatcgccg	cctgccttgc	ccgctgctgg	acaggggctc	ggctgttggg	7920
	cactgacaat	tccgtggtgt	tgtcggggaa	gctgacgtcc	tttccatggc	tgctcgcttg	7980
	tgttgccacc	tggattctgc	gcgggacgtc	cttctgctac	gtcccttcgg	ccctcaatcc	8040
50	agcggacctt	ccttcccgcg	gcctgctgcc	ggctctgcgg	cctcttcgcg	gtcttcgect	8100
	tcgccctcag	acgagtcgga	tctccctttg	ggccgcctcc	ccgcctggaa	ttcgagctcg	8160
55	gtacctttaa	gaccaatgac	ttacaaggca	gctgtagatc	ttagccactt	tttaaaagaa	8220

aaggggggac tggaagggct aattcactcc caacgaagac aagatctgct ttttgcttgt 8280  
 actgggtctc tctggttaga ccagatctga gcctgggagc tctctggcta actagggAAC 8340  
 5 ccactgctta agcctcaata aagcttgccct tgagtgcctc aagtagtggtg tgcccgtctg 8400  
 ttgtgtgact ctggtaacta gagatccctc agaccctttt agtcagtgtg gaaaatctct 8460  
 agcagtagta gtcatgtca tcttattatt cagtatttat aacttgcaa gaaatgaata 8520  
 10 tcagagagtg agaggaactt gtttattgca gcttataatg gttacaaata aagcaatagc 8580  
 atcacaaatt tcacaaataa agcatttttt tcactgcatt ctagttgtgg tttgtccaaa 8640  
 ctcatcaatg tatcttatca tgtctggctc tagctatccc gcccttaact ccgccagtt 8700  
 15 ccgccattc tcgccccat ggctgactaa tttttttat ttatgcagag gccgaggccg 8760  
 cctcggcctc tgagctattc cagaagtagt gaggaggcct ttttgaggc ctaggctttt 8820  
 gcgtcgagac gtaccaatt cgccctatag tgagtcgtat tacgcgcgt cactggccgt 8880  
 cgttttaca cgtcgtgact gggaaaacc tggcgttacc caacttaac gccttgacgc 8940  
 20 acatccccc ttcgccagct ggcgtaatag cgaagaggcc cgcaccgat gcccttcca 9000  
 acagttgcgc agcctgaatg gcgaatggcg cgacgcgcc ttagcggcg cattaagcgc 9060  
 ggcggtgtg gtggttacgc gcagcgtgac cgctacact gccagcgccc tagcgccgc 9120  
 25 tcttttcgt tctttccctt cttttctgc cacgttcgcc ggctttccc gtcaagctct 9180  
 aaatcgggg ctccctttag ggtccgatt tagtgcttta cggcacctcg acccaaaaa 9240  
 acttgattag ggtgatggt cacgtagtgg gccatcgccc tgatagacgg tttttcgccc 9300  
 30 tttagcgtg gagtcacgt tctttaatag tggactcttg ttccaaactg gaacaacact 9360  
 caaccctatc tcggtctatt cttttgattt ataagggtt ttgccgattt cggcctattg 9420  
 gttaaaaaat gagctgattt aacaaaaatt taacgcgaat ttaacaaaa tattaacgtt 9480  
 35 tacaatttcc 9490

&lt;210&gt; 8

&lt;211&gt; 10086

&lt;212&gt; DNA

40 &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; plasmid

&lt;220&gt;

45 &lt;221&gt; misc\_feature

&lt;222&gt; (1)..(10086)

&lt;223&gt;

&lt;220&gt;

50 &lt;221&gt; misc\_feature

&lt;222&gt; (1)..(10086)

&lt;223&gt; plasmid containing the lentiviral vector construct CCL-MA4-GFP/de ItaNFR

&lt;400&gt; 8

55

	caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttatTT ttctaaatac	60
	attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa	120
5	aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt ttgcggcac	180
	tttgccttcc tgTTTTtgct cccccagaaa cgctggtgaa agtaaaagat gctgaagatc	240
	agttgggtgc acgagtgggt tacatcgaac tggatctcaa cagcggttaag atccttgaga	300
10	gttttcgccc cgaagaacgt tttccaatga tgagcacttt taaagttctg ctatgtggcg	360
	cggattatc ccgtattgac gccgggcaag agcaactcg tcgccgcata cactattctc	420
	agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat ggcattgacag	480
15	taagagaatt atgcagtgc gccataacca tgagtataa cactgcggcc aacttacttc	540
	tgacaacgat cggaggaccg aaggagctaa ccgctTTTT gcacaacatg ggggatcatg	600
	taactcgctt tgatcgttg gaaccggagc tgaatgaagc cataccaaac gacgagcgtg	660
	acaccacgat gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcgaaactac	720
20	ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa gttgcaggac	780
	cacttctgcg ctcgccctt ccggctggct ggtttattgc tgataaatct ggagccggtg	840
	agcgtgggtc tcgcggtatc attgcagcac tggggccaga tggttaagccc tcccgatcgc	900
25	tagttatcta cacgacgggg agtcaggcaa ctatggatga acgaaataga cagatcgctg	960
	agatagggtc ctactgatt aagcattgggt aactgtcaga ccaagtttac tcatatatac	1020
	tttagattga tttaaaactt catTTTTaat ttaaaaggat ctagggtgaag atcctTTTTg	1080
30	ataatctcat gacaaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg	1140
	tagaaaagat caaaggatct tcttgagatc cttttttct gcgcgtaatc tgctgcttgc	1200
	aaacaaaaaa accaccgcta ccagcgggtg tttgtttgcc ggatcaagag ctaccaactc	1260
35	tttttccgaa ggtaactggc ttcagcagag cgcagatacc aaatactgtc cttctagtgt	1320
	agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac ctgcctctgc	1380
	taatcctgtt accagtggct gctgccagt gcgataagtc gtgtcttacc gggttggact	1440
40	caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac	1500
	agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag	1560
	aaagcgccac gcttcccga gggagaaagg cggacaggta tccggtaagc ggcagggtcg	1620
45	gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtctctg	1680

50

55

	tcgggtttcg ccacctctga cttgagcgtc gatTTTTgtg atgctcgtca ggggggcgga	1740
	gcctatggaa aaacgccagc aacgcggcct ttttacgggt cctggccttt tgcTgcctt	1800
5	ttgtcacat gttctttcct gcgttatccc ctgattctgt ggataaccgt attaccgcct	1860
	ttgagtgagc tgataccgct cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg	1920
	aggaagcgga agagcgccca atacgcaaac cgctctccc cgcgcggttg ccgattcatt	1980
10	aatgcagctg gcacgacagg tttcccgaact ggaaagcggg cagtgagcgc aacgcaatta	2040
	atgtgagtta gctcactcat taggcacccc aggctttaca ctttatgctt ccggctcgta	2100
	tgTgtgtg aattgtgagc ggataacaat ttcacacagg aaacagctat gaccatgatt	2160
15	acgccaagcg cgcaattaac cttcactaaa gggaacaaaa gctggagctg caagcttggc	2220
	cattgcatac gttgtatcca tatcataata tgtacattta tattggctca tgtccaacat	2280
	taccgccatg ttgacattga ttattgacta gttattaata gtaatcaatt acggggtcac	2340
20	tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaatt ggcccgctg	2400
	gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt cccatagtaa	2460
	cgccaatagg gactttccat tgacgtcaat gggTggagta tttacggtaa actgcccact	2520
25	tggcagtaca tcaagtgtat catatgccaa gtacgcccc tattgacgtc aatgacggta	2580
	aatggcccgC ctggcattat gcccagtaca tgacctatg ggactttcct acttggcagt	2640
	acatctacgt attagtcac gctattacca tggTgatgcg gttttggcag tacatcaatg	2700
	ggcgtggata gcggtttgac tcacggggat ttccaagtct ccacccatt gacgtcaatg	2760
30	ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac aactccgccc	2820
	cattgacgca aatggggcgt aggcgtgtac ggtgggaggt ctatataagc agagctcggt	2880
	tagtgaaccg gggTctctct ggttagacca gatctgagcc tgggagctct ctggctaact	2940
35	agggaaacca ctgcttaagc ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc	3000
	ccgtctgttg tgtgactctg gtaactagag atccctcaga cccttttagt cagtgtggaa	3060
	aatctctagc agtggcgccc gaacagggac ctgaaagcga aagggaacc agagctctct	3120
40	cgacgcagga ctcggttgC tgaagcgcgc acggcaagag gcgagggcg gcgactggTg	3180
	agtacgcaa aaattttgac tagcggaggc tagaaggaga gagatgggtg cgagagcgtc	3240
	agtattaagc gggggagaat tagatcgCga tgggaaaaa ttcggttaag gccaggggga	3300
45	aagaaaaaat ataaattaaa acatatagta tgggcaagca gggagctaga acgattcgca	3360
	gttaatcctg gcctgttaga aacatcagaa ggctgtagac aaatactggg acagctacaa	3420
	ccatcccttc agacaggatc agaagaactt agatcattat ataatacagt agcaaccctc	3480
	tattgtgtgc atcaaaggat agagataaaa gacaccaagg aagctttaga caagatagag	3540
50	gaagagcaaa acaaaagtaa gaccaccgca cagcaagcg ccgctgatct tcagacctgg	3600
	aggaggagat atgagggaca attggagaag tgaattatat aaatataaag tagtaaaat	3660
55	tgaaccatta ggagtagcac ccaccaaggc aaagagaaga gtggtgcaga gaaaaaaag	3720

agcagtggga ataggagctt tgttccttgg gttcttggga gcagcaggaa gcactatggg 3780  
 cgcagcctca atgacgctga cggtagcaggc cagacaatta ttgtctggta tagtgacgca 3840  
 5 gcagaacaat ttgtcgaggg ctattgaggc gcaacagcat ctgttgcaac tcacagtctg 3900  
 gggcatcaag cagctccagg caagaatcct ggctgtggaa agatacctaa aggatcaaca 3960  
 gctcctgggg atttgggggt gctctggaaa actcatttgc accactgctg tgccttggaa 4020  
 10 tgctagttag agtaataaat ctctggaaca gattggaatc acacgacctg gatggagtgg 4080  
 gacagagaaa ttaacaatta cacaagctta atacactcct taattgaaga atcgcaaaac 4140  
 cagcaagaaa agaataaaca agaattattg gaattagata aatgggcaag tttgtggaat 4200  
 15 tgggttaaca taacaaattg gctgtggtat ataaaattat tcataatgat agtaggaggc 4260  
 ttggtagggt taagaatagt ttttgcgtga ctttctatag tgaatagagt taggcaggga 4320  
 tattcaccat tatcgtttca gaccacctc ccaacccga ggggacccga caggcccgaa 4380  
 ggaatagaag aagaaggtag agagagagac agagacagat ccattcgatt agtgaacgga 4440  
 20 tctcgacggt atcggttaac ttttaaaaga aaagggggga ttggggggta cagtgcaggg 4500  
 gaaagaatag tagacataat agcaacagac atacaaacta aagaattaca aaaacaatt 4560  
 acaaaaattc aaaattttat cgatcacgag actagcctcg agagatctga tcataatcag 4620  
 25 ccataccaca tttgtagagg ttttacttgc tttaaaaaac ctcccacacc tccccctgaa 4680  
 cctgaaacat aaaatgaatg caattgttgt tgttaacttg tttattgcag cttataatgg 4740  
 ttacaataaa ggcaatagca tcacaaattt cacaaataag gcattttttt cactgcattc 4800  
 30 tagttttggt ttgtccaaac tcatcaatgt atcttatcat gtctggatct caaatccctc 4860  
 ggaagctgag cctgtccttag gttggagtga tacattttta tcactttttac ccgtctttgg 4920  
 attaggcagt agctctgacg gccctcctgt cttagggttag tgaaaaatgt cactctctta 4980  
 35 cccgtcattg gctgtccagc ttagctcgca ggggaggtgg tctggatccg agctcgaaat 5040  
 ggccgcttta cttgtacagc tcgtccatgc cgagagtgat cccggcgggc gtcacgaact 5100  
 ccagcaggac catgtgatcg cgcttctcgt tggggctctt gtcagggcg gactgggtgc 5160  
 40 tcaggtagtg gttgtcgggc agcagcacgg ggccgtcgcc gatgggggtg ttctgctggt 5220  
 agtggctggc gagctgcacg ctgccgtcct cgatgttgtg gcggtcttg aagttcacct 5280  
 tgatgccgtt cttctgcttg tcggccatga tatagacgtt gtggctgttg tagttgtact 5340  
 ccagcttggt ccccaggatg ttgccgtcct ccttgaagtc gatgcccttc agctcgatgc 5400  
 45 ggttcaccag ggtgtcgccc tcgaacttca cctcggcgcg ggtctttag ttgccgtcgt 5460  
 ccttgaagaa gatggtgcgc tcctggacgt agccttcggg catggcggaac ttgaagaagt 5520  
 cgtgctgctt catgtggtcg gggtagcggc tgaagcactg cacgccgtag gtcagggtgg 5580  
 50 tcacgagggt gggccagggc acgggcagct tgccggtggt gcagatgaac ttcagggtca' 5640  
 gcttgccgta ggtggcatcg ccctcgccct cgccggacac gctgaacttg tggccgttta 5700  
 cgtcgccgtc cagctcgacc aggatgggca ccaccccggt gaacagctcc tcgcccttgc 5760

55

	tcaccatggt gaattccgcg gaggtggat cgggtcccgt gtcttctatg gaggtcaaaa	5820
	cagcgtggat ggcgtctcca ggcgatctga cggttcacta aacgagctct gcttatatag	5880
5	gcctcccacc gtacacgcct accctcgaga agcttgatta acccgtgtcg gctccagatc	5940
	tggcctccgc gccgggtttt ggcgcctccc gcgggcgccc ccttcctcac ggcgagcgct	6000
	gccacgtcag acgaagggcg cagcgagcgt cctgatcctt ccgcccggac gctcaggaca	6060
10	gcggcccgt gctcataaga ctggccctta gaacccagat atcagcagaa ggacatttta	6120
	ggacgggact tgggtgactc tagggcactg gttttctttc cagagagcgg aacaggcgag	6180
	gaaaagtagt cctttctcgg cgattctcgg gagggatctc cgtggggcgg tgaacgccga	6240
15	tgattatata aggacgcgcc ggggtgtggca cagctagttc cgtcgagcc gggatttggg	6300
	tcgcggttct tgtttgtgga tcgctgtgat cgtcacttgg tgagttgcgg gctgctgggc	6360
	tggccggggc tttcgtggcc gccgggccgc tcggtgggac ggaagcgtgt ggagagaccg	6420
20	ccaagggctg tagtctgggt ccgcgagcaa ggttgccctg aactgggggt tggggggagc	6480
	gcacaaaatg gcggtgttc ccgagcttg aatggaagac gcttctaagg cgggctgtga	6540
	ggtcgtttaa acaaggtggg gggcatggtg ggcggcaaga acccaaggtc ttgaggcctt	6600
	cgctaagtgc ggaaagctct tattcgggtg agatgggctg gggcaccatc tggggaccct	6660
25	gacgtgaagt ttgtcactga ctggagaact cgggtttgtc gtctggttgc gggggcggca	6720
	gttatgcggt gccgttgggc agtgcacccg tacctttggg agcgcgcgcc tcgtcgtgtc	6780
	gtgacgtcac ccgttctgtt ggcttataat gcagggtggg gccacctgcc ggtaggtgtg	6840
30	cggtaggctt ttctccgtcg caggacgcag ggttcgggcc tagggtaggc tctctgaat	6900
	cgacaggcgc cggacctctg gtgaggggag ggataagtga ggcgtcagtt tctttggtcg	6960
	gttttatgta cctatcttct taagtagctg aagctccggt tttgaactat gcgctcgggg	7020
35	ttggcgagtg tgtttgtga agtttttttag gcacctttt aaatgtaatc atttgggtca	7080
	atatgtaatt ttcagtgtta gactagtaaa ttgtccgcta aattctggcc gtttttggt	7140
	tttttggttag acgaagcttg ggctgcagga attcgggccg cgccagctc cggcgggcag	7200
40	ggggggcgct ggagcgcagc gcagcgcagc cccatcagtc cgcaaagcgg accgagctgg	7260
	aagtgcgagc ctgccgcggg aggcgggcga tgggggcagg tgccaccggc cgcgccatgg	7320
	acgggcccgc cctgtgctg ttgtctcttc tgggggtgtc ccttgagggt gccaaggagg	7380
	catgccccac aggcctgtac acacacagcg gtgagtgtc caaagcctgc aacctgggcg	7440
45	aggggtgtgg ccagccttgt ggagccaacc agaccgtgtg tgagccctgc ctggacagcg	7500
	tgacgttctc cgacgtggtg agcgcgaccg agccgtgcaa gccgtgcacc gagtgcgtgg	7560
	ggctccagag catgtcggcg ccgtgcgtgg aggccgacga cgccgtgtgc cgtgcgcct	7620
50	acggctacta ccaggatgag acgactgggc gctgcgaggg gtgcccgtg tgcgaggcgg	7680
	gctcgggcct cgtgttctcc tgccaggaca agcagaacac cgtgtgcgag gagtgcctcg	7740
	acggcacgta ttccgacgag gccaaaccag tggaccctg cctgccctgc accgtgtgcg	7800
55		

	aggacaccga gcgccagctc cgcgagtga cacgctgggc cgacgccgag tgcgaggaga	7860
	tccctggccg ttggattaca cgggccacac ccccagaggg ctccgacagc acagccccc	7920
5	gcacccagga gcctgaggca cctccagaac aagacctcat agccagcacg gtggcaggtg	7980
	tggtgaccac agtgatgggc agtccccagc ccgtgggtgac ccgaggcacc accgacaacc	8040
	tcatccctgt ctattgctcc atcctggctg ctgtggttgt gggccttgtg gcctacatag	8100
10	ccttcaagag gtggaacagg gggatcctct agagtcgagt cttagagtcga caatcaacct	8160
	ctggattaca aaatttgtga aagattgact ggtattctta actatgttgc tcctttttacg	8220
	ctatgtggat acgctgcttt aatgcctttg tatcatgcta ttgcttcccg tatggctttc	8280
15	atcttctcct ccttgataaa atcctgggtg ctgtctcttt atgaggagtt gtggcccggt	8340
	gtcaggcaac gtggcgtggt gtgactgtg tttgctgacg caacccccac tggttggggc	8400
	attgccacca cctgtcagct cctttccggg actttcgctt tccccctccc tattgccacg	8460
	gcggaactca tcgccgctg ccttgcccgc tgctggacag gggctcggct gttgggcact	8520
20	gacaattccg ttgtgttgtc ggggaagctg acgtcctttc catggctgct cgcctgtgtt	8580
	gccacctgga ttctgcgcgg gacgtccttc tgctacgtcc cttcggccct caatccagcg	8640
	gaccttcctt cccgcggcct gctgcggcct ctgcggccct tccgcgtct tcgccttcgc	8700
25	cctcagacga gtcggatctc cctttgggcc gcctccccgc ctggaattcg agctcggtag	8760
	ctttaagacc aatgacttac aaggcagctg tagatcttag ccacttttta aaagaaaagg	8820
	ggggactgga agggctaatt cactcccaac gaagacaaga tctgcttttt gcttgtagctg	8880
30	ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta gggaaccac	8940
	tgcttaagcc tcaataaagc ttgccttgag tgcttcaagt agtggtgacc cgtctgttgt	9000
	gtgactctgg taactagaga tccctcagac ccttttagtc agtggtgaaa atctctagca	9060
35	gtagtagttc atgtcatctt attattcagt atttataact tgcaaagaaa tgaatatcag	9120
	agagtgagag gaacttgttt attgcagctt ataatggtta caaataaagc aatagcatca	9180
	caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg tccaaactca	9240
40	tcaatgtatc ttatcatgtc tggctctagc tatccccccc ctaactccgc ccagttccgc	9300
	ccattctccg ccccatggct gactaatttt ttttatttat gcagaggccg aggccgcctc	9360
	ggcctctgag ctattccaga agtagtgagg aggtcttttt ggaggcctag gcttttgcgt	9420
45	cgagacgtac ccaattcgcc ctatagttag tcgtattacg cgcgctcact ggccgtcgtt	9480
	ttacaacgtc gtgactggga aaaccctggc gttacccaac ttaatcgctt tgcagcacat	9540
	ccccctttcg ccagctggcg taatagcgaa gagggccgca ccgatcgccc tcccaacag	9600
50	ttgcgcagcc tgaatggcg aatggcgcgac gcgccctgta gcggcgcat aagcgcggcg	9660
	ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca gcgccctagc gcccgctcct	9720
	ttcgttttct tcccttcctt tctcgcacg ttcgccggct tccccgtca agctctaaat	9780
55	cgggggctcc ctttaggggt ccgatttagt gctttacggc acctcgaccc caaaaaactt	9840

gattaggggtg atgggttcacg tagtgggcca tcgccctgat agacgggttt tcgccctttg 9900  
 acgttggagt ccacgttctt taatagtgga ctcttggtcc aaactggaac aacactcaac 9960  
 5 cctatctcgg tctattcttt tgatttataa gggattttgc cgatttcggc ctattggtta 10020  
 aaaaatgagc tgatttaaca aaaatttaac gcgaatttta aaaaatatt aacgtttaca 10080  
 atttcc 10086

# Claims

1. A bidirectional promoter for expression of at least two coding sequences in opposite direction in animal cells comprising 5' end to 3' end:

- a) a first minimal promoter sequence derived from cytomegalovirus (CMV) or mouse mammary tumor virus (MMTV) genomes;
- b) a promoter sequence derived from an animal gene comprising an enhancer region and a second minimal promoter sequence;

the two promoter sequences driving a coordinate transcription of said coding sequences in the opposite orientation.

2. The bidirectional promoter according to claim 1 wherein the full efficient promoter sequence derives from ubiquitously expressed genes comprising the phosphoglycerate kinase or the ubiquitin gene.

3. A bidirectional expression cassette essentially comprising the bidirectional promoter according to previous claims, convenient insertion sites positioned downstream to each promoter, and polyadenylation sites positioned downstream to each insertion site.

4. The bidirectional expression cassette according to claim 4 further comprising at least one post-transcriptional regulatory element positioned upstream to one or each polyadenylation site.

5. The bidirectional expression cassette according to claim 4 or 5 further comprising at least one internal ribosome entry site (IRES) sequence to express three or more genes.

6. An expression construct containing the bidirectional promoter according to claim 1 or 2.

7. An expression construct containing the bidirectional expression cassette according to claims 4-6.

8. A gene transfer expression vector containing the expression construct according to claims 7 or 8 further comprising lentiviral or retroviral sequences.

9. Use of the gene transfer expression vector according to claim 8 for the preparation of a delivery and expression system in animal cells.

10. Use of the gene transfer expression vector according to claim 9 wherein animal cells are tissue animal cells in vivo.

11. Use of the gene transfer expression vector according to claim 10 wherein tissue animal cells are comprising brain neurons.

12. An in vitro method for the coordinate expression of two exogeneous coding sequences into an animal cell comprising the following steps:

- a) cloning said coding sequences into the gene transfer expression vector according to claim 8, each coding sequence under the control of one of the two promoters of the bidirectional promoter;
- b) transforming animal cells by means of said vectors;

c) allowing the expression of the vector.

13. The in vitro method for the coordinate expression of two exogeneous coding sequences according to claim 12 wherein the animal cell is an human cell.

14. The in vitro method for the coordinate expression of two exogeneous coding sequences according to claim 13 wherein the human cell is a retransplantable human cell.

15. The in vitro method for the coordinate expression of two exogeneous coding sequences according to claim 14 wherein the retransplantable human cell is an hematopoietic cell.

16. Method for generating a transgenic non human organism comprising the step of transforming appropriate cells with an expression construct containing the bidirectional cassette according to claims 6 or 7.

17. Method for generating a transgenic non human organism comprising the step of transforming appropriate cells by means of the gene transfer expression vector according to claim 8.

#### Patentansprüche

1. Bidirektionaler Promotor für die Expression von mindestens zwei Kodierungssequenzen in entgegen gesetzter Richtung in Tierzellen, umfassend vom 5'-Ende zum 3'-Ende:

a) eine erste minimale Promotorsequenz, die aus dem Genom des Zytomegalievirus (ZMV) oder des Mausmammatumovirus (MMTV) stammt;

b) eine Promotorsequenz, die aus einem Tiergen stammt und die eine Verstärker (Enhancer)-Region und eine zweite minimale Promotorsequenz aufweist;

wobei die beiden Promotorsequenzen eine koordinierte Transkription der Kodierungssequenzen in entgegen gesetzter Richtung steuern.

2. Bidirektionaler Promotor nach Anspruch 1, wobei die voll effiziente Promotorsequenz aus ubiquitär exprimierten Genen stammt, welche das Phosphoglyceratkinasegen oder das Ubiquitinen umfassen.

3. Bidirektionale Expressionskassette, die im Wesentlichen den bidirektionalen Promotor nach den vorherigen Ansprüchen, stromabwärts (downstream) von jedem Promotor positionierte, geeignete Insertionsstellen und (downstream) von jeder Insertionsstelle positionierte Polyadenylierungsstellen aufweist.

4. Bidirektionale Expressionskassette nach Anspruch 4, die des Weiteren mindestens ein stromaufwärts (upstream) von einer oder jeder Polyadenylierungsstelle positioniertes posttranskriptionales regulatorisches Element aufweist.

5. Bidirektionale Expressionskassette nach Anspruch 4 oder 5, die des Weiteren mindestens eine interne Ribosomen-eintrittsstellen(IRES)-Sequenz aufweist, um mindestens drei Gene zu exprimieren.

6. Expressionskonstrukt, welches den bidirektionalen Promotor nach Anspruch 1 oder 2 enthält.

7. Expressionskonstrukt, welches die bidirektionale Expressionskassette nach Anspruch 4-6 enthält.

8. Gentransferexpressionsvektor, welcher das Expressionskonstrukt nach Anspruch 7 oder 8 enthält und des Weiteren lentivirale oder retrovirale Sequenzen aufweist.

9. Verwendung des Gentransferexpressionsvektors nach Anspruch 8 für die Herstellung eines Einführungs- und Expressionssystems in Tierzellen.

10. Verwendung des Gentransferexpressionsvektors nach Anspruch 9, wobei Tierzellen Tiergewebezellen in vivo sind.

11. Verwendung des Gentransferexpressionsvektors nach Anspruch 10, wobei Tiergewebezellen Gehirneuronen umfassen.

12. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen in eine Tierzelle, umfassend die folgenden Schritte:

- a) Klonieren der Kodierungssequenzen in den Gentransferexpressionsvektor nach Anspruch 8, wobei jede Kodierungssequenz unter der Kontrolle von einem der beiden Promotoren des bidirektionalen Promotors steht;
- b) Transformieren von Tierzellen mittels der Vektoren;
- c) Zulassen der Expression des Vektors.

13. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen nach Anspruch 12, wobei die Tierzelle eine menschliche Zelle ist.

14. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen nach Anspruch 13, wobei menschliche Zelle einer retransplantierbare menschliche Zelle ist.

15. In-vitro-Verfahren für die koordinierte Expression zweier exogener Kodierungssequenzen nach Anspruch 14, wobei die retransplantierbare menschliche Zelle eine hämatopoietische Zelle ist.

16. Verfahren zum Herstellen eines transgenen, nicht menschlichen Organismus, das den Schritt des Transformierens geeigneter Zellen mit einem Expressionskonstrukt, das die bidirektionale Kasette nach Anspruch 6 oder 7 enthält, umfasst.

17. Verfahren zum Herstellen eines transgenen, nicht menschlichen Organismus, das den Schritt des Transformierens geeigneter Zellen mittels des Gentransferexpressionsvektors nach Anspruch 8 umfasst.

## Revendications

1. Promoteur bidirectionnel pour l'expression d'au moins deux séquences codantes dans une direction opposée dans des cellules animales comprenant, de l'extrémité 5' à l'extrémité 3' :

- a) une première séquence promotrice minimale dérivée des génomes du cytomégalo virus (CMV) ou du virus de la tumeur mammaire murine (MMTV) ;
- b) une séquence promotrice dérivée d'un gène animal comprenant une région amplificatrice et une seconde région promotrice minimale ;

les deux séquences promotrices régissant une transcription coordonnée desdites séquences codantes dans l'orientation opposée.

2. Promoteur bidirectionnel selon la revendication 1, dans lequel la totalité de la séquence promotrice efficace dérive de gènes exprimés de manière ubiquitaire comprenant la phosphoglycérate kinase ou le gène de l'ubiquitine.

3. Cassette d'expression bidirectionnelle comprenant essentiellement le promoteur bidirectionnel selon les revendications précédentes, des sites d'insertion adaptés positionnés en aval de chaque promoteur, et des sites de polyadénylation en aval de chaque site d'insertion.

4. Cassette d'expression bidirectionnelle selon la revendication 4, comprenant en outre au moins un élément de régulation post-transcriptionnel positionné en amont de l'un des ou de chaque site(s) de polyadénylation.

5. Cassette d'expression bidirectionnelle selon la revendication 4 ou 5, comprenant en outre au moins une séquence IRES (site d'entrée interne du ribosome) pour exprimer trois gènes ou plus.

6. Construit d'expression contenant le promoteur bidirectionnel selon la revendication 1 ou 2.

7. Construit d'expression contenant la cassette d'expression bidirectionnelle selon les revendications 4 à 6.

8. Vecteur d'expression de transfert de gènes contenant le construit d'expression selon la revendication 7 ou 8, comprenant en outre des séquences lentivirales ou rétrovirales.

9. Utilisation d'un vecteur d'expression de transfert de gènes selon la revendication 8, pour la préparation d'un système de délivrance et d'expression dans les cellules animales.
- 5 10. Utilisation du vecteur d'expression de transfert de gènes selon la revendication 9, dans laquelle les cellules animales sont des cellules de tissu animal *in vivo*.
11. Utilisation d'un vecteur d'expression de transfert de gènes selon la revendication 10, dans laquelle les cellules de tissu animal comprennent des neurones cérébraux.
- 10 12. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes dans une cellule animale comprenant les étapes suivantes :
  - a) le clonage desdites séquences codantes dans le vecteur d'expression de transfert de gènes selon la revendication 8, chaque séquence codante sous le contrôle de l'un des deux promoteurs du promoteur bidirectionnel ;
  - 15 b) la transformation de cellules animales par les moyens desdits vecteurs ;
  - c) le fait de permettre l'expression du vecteur.
13. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes selon la revendication 12, dans lequel la cellule animale est une cellule humaine.
- 20 14. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes selon la revendication 13, dans lequel la cellule humaine est une cellule pouvant être retransplantée.
- 15 15. Procédé *in vitro* pour l'expression coordonnée de deux séquences codantes exogènes selon la revendication 14, dans lequel la cellule humaine pouvant être retransplantée est une cellule hématopoïétique.
16. Procédé de génération d'un organisme transgénique non humain comprenant l'étape consistant à transformer des cellules adaptées avec un construit d'expression contenant la cassette bidirectionnelle selon les revendications 6 ou 7.
- 30 17. Procédé de génération d'un organisme transgénique non humain comprenant l'étape consistant à transformer des cellules adaptées par les moyens du vecteur d'expression de transfert de gènes selon la revendication 8.




Figure 1




Figure 2




Figure 3





Figure 4



*Figure 5*




Figure 6




Fig 7a

Fig. 7b (1 of 3)

cagggtggcacttttcggggaaatgicgcgggaacccctatttgttttttctaatacattcaaatatgtatccgctcatgaga  
 caataaccctgataaatgcttcaataatattgaaaaagggaagagtatgagtattcaacatttcgctgcgcccttattcccttttt  
 gggcattttgcttccctgtttttgctcaccagaaacgctggtgaaagttaaaagatgctgaagatcagttgggtgcacgagt  
 gggttacatcgaactggatctcaacagcggtaagatccttgagagtttgcgcccgaaagacgttttccaatgatgagcacttt  
 taaagtctgtatgtggcgggtattatccgtattgacggcgggcaagagcaactcgggtgcgcgcatacacttattctcaga  
 atgacttgggtgagtactaccagtcacagaaaagcatcttaccggtgacatgacagtaagagaattatgcagtgtgccat  
 aaccatgagtataacactgcggccaacttactctgacaacgatcggaggaccggaaggagcctaaccgctttttgcacaac  
 atgggggatcatgtaactgccttgatcgttgggaaccggagctgaatgaagccataccacaacgacgagcgtgacaccac  
 gatgcctgtagcaatggcaacaacgcttgcgcaactattactggcgaactacttactctagcttccggcaacaataatag  
 actggatggaggcgggataaagtgcaggaccacttctgcctcggcccttccggctggctgtttattgctgataaatctgg  
 agccggtagcgtgggtctcgggtatcattgcagcactggggccagatggtaaagccctcccgatctagttatctacac  
 gacggggagtgcaactatggatgaacgaaatagacagatcgtgagataggtgcctcactgattaaagcatttggttaact  
 gtcagaccaagtgtactatatactttagattgatttaaaacttcttttaatttaaaaggatctagggtgaagatccttttgata  
 atctcatgaccaaaatcccttaacgtgagtttctgttccactgagcgtcagaccctgtgaaaagatcaaggatcttcttgag  
 atccttttttctgcgcgtaactgtgcttgcgcaaaaaaacaccgctaccagcgggtgtttgtttgctggatcaagagct  
 accaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtcttctagtgtagccgtagttaggcc  
 accacttcaagaactctgtagcaccgctacatactcgtctgctaactctgttaccagtggctgtgctgacgtggcgataag  
 tctgttcttaccgggttgactcaagacgatagttaccggataaggcgcagcggctgggtgaaaggggggtctgtgcac  
 acagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaagcggcacgcttccc  
 gaaggagaaaggcggacaggtatccggtaagcggcagggtcggaaacaggagagcgcacgaggggagcttccagggg  
 ggaaacgcttggatctttagtctgtcgggttccgacactctgactgagcgtcgtttttgtgatgctgtaggggggg  
 cggagcctatgaaaaacgccagcaacgcggcctttttacggttctggccttttctggtccttttgcacatgtcttctctg  
 cgttatccctgattctgttgataaccgtattaccgctttgagtgtgagctgataccgctcggcgagccgaacgaccgagcg  
 cagcgagtcagtgagcgaggaagcgggaagagcgcccaatagcaaacgctctcccgcggttggccgattcattaa  
 tgacgttggcacgacaggttcccactggaaagcgggagtgagcgcaacgcaattaatgtgagttagctcactcattag  
 gcaccccaggctttacatttatgttccggctcgtatgtgtgtggaattgtgagcggataacaatttcacacaggaaacagc  
 tatgaccatgattacgccaagcgcgaattaacccctactaaagggaacaaaagctggagctgcaagcttaattagttctta  
 tgcaatactctttagtcttgaacatggtaacgatgagtttagcaacatgccttacaaggagagaaaaagcaccgtgcatgc  
 cgatttgggtgaagtaaggtgtgacgatcgtgccttattaggaaggcaacagacgggtctgacatggattggacgaaccact  
 gaattgccgcatgtagagatattgtattagtgcttagctcagatacaataaacgggtctctctggttagaccagatctgagc  
 ctgggagctctctggtaactagggaaaccactgcttaagcctcaataaagcttgccttgagtgtctcaagtagtgtgtccc  
 gtctgtgtgtgactctggtaactagagatccctcagacccttttagttagtggaaaatctctagcagtggcgcccgaaac  
 gggacctgaaagcgaaagggaaccagagctctctcagcagcagactcggcttgcgtgaagcgcgacggcaagaggc  
 gagggggcgagcgtgtgagtagcccaaaatgtgactagcggaggttagaaggagagagatgggtgcgagagcgtc  
 agtattaaagcgggggagaattagtcgcgatgggaaaaaattcgttaaggccagggggaaagaaaaatataaattaaa  
 acatatagtatgggcaagcaggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaagcctgtagaca  
 aatactgggacagctacaaccatccctcagacaggatcagaagaacttagatcattatataatacagtagcaacccttatt  
 gtgtgcatcaaaaggatagagataaaagacaccaagggaagcttttagacaagatagaggaaagcaaaaacaaagtaagac  
 caccgcacagcaagcggcgctgatcttcagacctggaggaggagatagagggaacttggagaagtgaattatataaa  
 tataaagtagtaaaaattgaaccattaggagtagcaccaccaaaggcaagagaagagtggtgcagagagaaaaaagag  
 cagtgggaataaggagccttggcttgggttctggggagcagcagggaagcactatggggcgagcctcaatgacgtgacgg  
 tacaggccagacaattattgtctgtatagtcagcagcagacaatttgcgtgagggttattgaggcgcaacagcatctgtt  
 gcaactcacagctcgtgggcatcaagcagctccaggcaagaatcctggctgtggaagatacctaaggatcaacagctcc  
 tggggatttgggttgccttgaaaactcatttgcaccactgtgtgccttggaaatgctagtggagtaataatctctggaac  
 agatttggaaatcacacgacctggatggagtgaggacagagaaattacaattacacaagcttaatacactccttaattgaaga  
 atcgcaaaaccagcaagaaaggaatgaacaagaattattggaattagataaatgggcaagtttgggaattggttaacataa  
 caaattggctgtgtatataaaattatcataatgatagtaggagccttggttaggttaagaatgttttctgtacttctatagt  
 gaatagagttaggcaggatattaccattatcgttccagaccacccctcccaaccccgagggggacccgacagcccggaag

Fig. 7b (2of 3)

gaataagaagaagggtggagagagagacagagacagatccattcgattagtgaacggatcgcacgggtatcggttaact  
 tttaaaaaagaaaggggggattgggggtacagtgacggggaaagaatagtagacataataagcaacagacatacaaaacta  
 aagaaltacaaaaacaaattacaaaaattcaaaattttatcgatcacgagactagccctcgagagatcigatcataaicaagccat  
 accacattttagtaggggtttacttgcctttaaanaaacctcccacacccctccctgaacctgaacataaaatgaatgcaattgttg  
 ttgttaacttgtttattgcagcttataatggttacaataaggaatagcatcacaaattcacaataaggcattttttactgcga  
 ttctagttttgggttgcctaaactatcaatgtatcttatcatgtctggatctcaaatccctcggaagctgcgcctgtcttaggttgg  
 agtgatcacattttactacttttaccctgtcttggattaggcagtagctctgacggccctcctgtcttaggttagtgaanaatgtca  
 ctctctaccctgtacttggctgtcagcttagctgcaggggaggtgtgtggtatcctctagaattacacggcgatcttccgc  
 cctctgtggcctttatgaggatctctgtgattttctgtcgtcggatttccggtaagaccttccggtacttctgccacaacacaa  
 ctctccgcgcaacttttccggttgttacttgactggccacgtaatccacgatctcttttccgtcactgtcttccgtgctcca  
 aaacaacaacggcggtgggaaggttaccggcggtcactcgtcgggaagacctgcgacacctgcgtcgaagatgttgggt  
 gttggagcaagatggattccaattcagcgggagccacctgatagccttctactaatcagagacttcaggcgggtcaacgat  
 gaagaagtgttctgtcttctgccagtaagctatgtctccagaatgtagccatccatccttgcatacaaggcgttggctgctc  
 cggattgtttacataaccggacataatcataggacctctcacacacagttcgccttctgattaacggccagcgttttccggta  
 tccagatccacaaccttgcctcaaaaaatggaacaactttaccgaccgcgcccggttatcaccctcgggtgtaatcag  
 aatagctgatgtagctcagtgagcccatatccttgcctgataacctggcagatggaacctcttggcaaccgcttccccgactt  
 ccttagagagggggagcggccaccagaagcaatttctgttaaatgataaatcgtatttgcatacagagtgcttggcgaag  
 aaggagaatagggttggcaccagcagcgcacttgaatcttgaatcctgaaggctctcagaacagctcttctcaaatct  
 atacattaagacgactcgaatccacatafcaatafcccagtgtagtaaacatfcaaaaccggtatggaatggaacaaca  
 ctiaaaatcgagtatccggaatgatttattgcaaaaaataggatcttggcatgcgagaatctcagcaggcagttctatg  
 aggcagagcgcacaccttttaggcagaccagtagatccagagggtcatgatcagtgcaattgtcttgcctatcgaaggga  
 ctctggcacaanaatgtattcattaaaaccgggaggtagatgagatgtgacgaacgtgtacatcgactgaaatccctggtaa  
 tccgttttagaattcatgataaataatttttggatgattgggagcttttttgcacgttcaaaatttttgaaccccttttggaaacg  
 aacaccacggtaggtgcgaaatgccatactgttgagcaattcaggttcattataaatgtcgttcgaggcgcaactgcaa  
 ctccgataaataacgcgccaacaccggcataaagaattgaagagagtttactgcatacgacgattctgtgatttgaattca  
 gccatactggttcatagcttctgccaaaccgaacggacatttgaagtactcagcgtgaagtgaatgccacctcgatatgtcat  
 ctgtaaaagcaattgttcagggaaccaggggcgtatcttctatagccttatgcagttgtctccagcgggttccatctccagcg  
 gatagaatggcgccgggcttcttattgttttggcgtcttccatggtgaattccggagggttgatcgggtcccggtgtcttc  
 tatggaggtcacaacagcgtggatggcgtctccaggcgtatcagcgttcactaaacgagctctgcttatataaggcctccca  
 ccgtacacgcctaccctcgagaagcttgatatgaattccacggggttggggttgcgcctttccaaggcagccctgggtt  
 tgcgcaggagcgcggctgcttggcgtgtgttccgggaaacgcagcggcgccgaccttgggtctgcacattctacag  
 tccgttcgcagcgtcaccggatcttccgctacccttgtgggcccccgccgacgttctgtctccgcccctaaatcgg  
 gaaggttcttgcggttcgaggcgtgcccggacgtgacaacgggaagccgcacgtctcactagtaccctcgcagacggac  
 agcggcaggagcaatggcagcgcggcggacggcgatgggctgtggccaatagcggctgtcagcggggcgccgga  
 gagcagcggcggaaggggcggttggggaggggggggtgtggggcggtagtgtggccctgttcttgcggcgcg  
 tgttccgcatcttgaagcctccggagcgcacgtcggcagtggtctccctggtgacgaatcaccgacctctctcccag  
 ggggatccaccggctgccaccatggtgagcaaggggcgaggagctgttcaccgggggtggtgccatcctgtgtcagctg  
 gacggcgacgtaaacggccacaagttagcgtgtccggcgaggggcgaggcgatgccacctacggcaagctgacct  
 gaagttcaictgaccaccggcaagctgcccgtgccctggcccaccctgtgaccacctgacctacggcgtgagtgctt  
 cagccgtacccccgaccacatgaagcagcagacttcttaagttccgcatgccgaaggctacgtccaggagcgcacc  
 atcttctcaaggacgacggcaactacaagaccgcggcgagggtgaagttcgaggggcgacacctggtgaaccgcatcg  
 agctgaagggtcagtgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacg  
 tctatatcatggccgacaagcagaagaacggcatcaagggtgaacttcaagatccgccacaacatcgaggacggcagcgt  
 gcagctcggcgaccactaccagcagaacacccccatcgccgacggccccgtgctgctgcccagacaaccactacotgag  
 caccagtcggccctgagcaaaagaccccaacgagaagcgcgatcacatgtctctgtgaggttcgtgaccggcgccgg  
 gatcactctcggcatggacgagctgtacaagtaagcggcgccgtcgacaatcaacctctggattacaaaatttgaag  
 attgactgtgattcttaactatgttgccttttaccgtatgtggatagcgtctttaaagcctttgtatcatgctattgtctccgtat  
 ggcttctatttctcctctgtataaatcctggtgtgtctctttataggaggttggggcggtgtcaggcaacgtggcggtgt

Fig. 7b (3 of 3)

gtgcactgtgttgctgacgcaacccccactgggtggggcattgccaccacctgtcagctccttccgggacittcgctttccc  
 cctccctattgccacggcggaactcatcgccgctgacctgccgctgctggacaggggctcggctgttgggactgaca  
 attccgtgggtgttcggggaagctgacgtcctttccatggctgctcgcctgtgttgcacctggattctgcgcgggacgtcc  
 ttctgctacgtcccttcggccctcaatccagcggacctccttcccggccctgctgccggctctgcggcctctccgcgttt  
 cgccttcgccctcagacgagtcggatctcccttggggccgectccccgcctggaattcgagctcggtagctttaagaccaat  
 gactacaaggcagctgtagatcttagccactttttaaagaaaaggggggactggagggttaattcactccaacgaag  
 acaagatctgcttttctgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaaacc  
 actgcttaagcctcaataaagcttgccttgagtgttcaagtagtgtgtgcccgctgtgtgtgactctggttaactagagatcc  
 ctacagaccttttagtcagtgtggaatactctagcagtagtagtcatgtcatcttattattcagtatttataacttgcaagaaat  
 gaatatcagagagtgagagggaacttgtttattgcagcttataatggttacaataaagcaatagcatcacaaatttcacaaata  
 aagcattttttcactgcattctagtgtgtgttgcctaaactcatcaatgtatcttatcatgtctggctctagctatcccgccctaa  
 ctccgcccagttccgcccatctccgccccatggctgactaatttttttattatgcagaggccgaggccgctcggcctctg  
 agctattccagaagtagtgaggaggctttttggaggcctaggccttttgcgtcgagacgtacccaattcgccctatagtga  
 cgtattacgcgcgctcactggccgtctgtttacaacgtcgtgactgggaaaacctggcgttaccctaacttaacgccttga  
 gcacatcccccttccgacgtggcgtaatagcgaagaggcccgaccgatcgcccttcccaacagttgcgcagcctgaa  
 tggcgaaatggcgcgacgcgccctgtagcggcgcatgaagcgcggggtgtggtgtgtacgcgcagcgtgaccgctac  
 acttgcagcgccctagcgcccgctccttccgcttcttcccttcttctcgcacgttcgccggcttccccgtaagctcta  
 aatcgggggctccctttaggggtccgatttagtctttacggcacctcgacccccaaaaacttgattaggggtgatgggtcacgt  
 agtggggccatcgccctgatagacgggttttgcctttgacgttggagtcacgttcttaatagtgacitctgttccaaactg  
 gaacaacactcaacctatctcggctattctttgatttataagggaatttgcgaattcggcctattggttaaaaaatgagctga  
 ttaacaaaaatttaacgcgaatttaacaaaatattaacgtttacaatttc




Fig. 8a

Fig. 8b (1 of 3)

cagggtggcacttttcggggaaatgtgcgcggaacccctatttgttttttctaaatacatcaaatatgtatccgctcatgaga  
 caataaccctgataaatgcttcaataatattgaaaaaggaagatgatgagtattcaacattccgtgtcgccttattcccttttt  
 cgggcattttgccttctgttttctcaccagaaacgctggtgaaagttaaagatgctgaagatcagttgggtgcacgagt  
 ggggtacatcgaactggatctcaacagcggtaagatccttgagagtttgcggccgaagaacgttttccaatgatgagcacttt  
 taaagtctgtatgtgcgcggtattatcccgattgacgccgggcaagagcaactcggtcggcgatacactatctcaga  
 atgacttgggtgagtactaccagtcacagaaaagcaatcttaccggtgcatgacagtaagagaattatgcagtgtgccat  
 aacctgagtataacactcgggccaacttactctgacaacgaltcggaggaccgaaggagtaaccgctttttgcacaac  
 atgggggcatgataactgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccac  
 gatgcctgtagcaatggcaacaacgttgcgcaactattaactggcgaactacttactctagcttcccggcaacaattaatag  
 actggatggaggcgggataaagtgcaggaccacttctgcgctcggccctcgggctgggtgtttattgctgataaatctgg  
 agccggtgagcgtgggtctcgcgggtatcattgcagcactggggccagatggaagccctcccgatcgtatgtatctacac  
 gacggggagtcaggcaactatggatgaagaaatagacagatcgtgagataggtgcctcactgattaagcattggtaact  
 gtcagaccaagtttactataatatacttttagattgatttaaaacttattttaattaaaaggatctagggtgaagatccttttgata  
 atctcatgacaaaatcccttaacgtgagtttctgctcactgagcgtcagaccccgtagaaaagatcaaaaggatctcttgag  
 atccttttttctgcgcgtaactgtgctgcttgcacaaaaaaacaccgctaccagcgggtgtgttggcggatcaagagct  
 accaactcttttccgaaggaactggcttcagcagcgcgataccaaactgtccttctagtgtagccgtagttaggcc  
 accacttcaagaactctgtagcacgcctacatacctcgtctgtatctgttaccagtggtgctgctgccagtggcgataag  
 tctgtgttaccgggttgactcaagcagatagttaccggataagggcgagcgggtcgaacggggggtcgtgtcac  
 acagcccagcttgagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcggccacgcttccc  
 gaaggagaaagcgggacaggtatccgtaagcggcagggtcggaaacaggagagcgcacgaggggagcttcagggg  
 ggaacgccttggtatctttatagctctgctgggttccgaccttgacttgagcgtcgtttttgtgatgctcgtcagggggg  
 cggagcctatggaanaacgccagcaacgcggccttttaccggttctggtccttttgccttttgcctcacatgttcttctg  
 cgttatccctgattctgtgataaccgtattaccgctttagtgagctgataccgctcggcgagccgaacgaccgagcg  
 cagcgagtacgtgagcagggaagcgggaagagcgcccaatacgcgaacgcctctcccgcgggttgccgattcattaa  
 tgcagctggcagcagaggttcccgaactggaaagcgggcagtgagcgaacgcaattaatgtgagttgactcactattag  
 gcaccccagcgtttacattatgtcttccgctcgtatgttgtgtgaattgtgagcggataacaatttcacacaggaacagc  
 tatgacctgattacgccaagcgcgcaattaacctcactaaagggaacaaaagctggagctgcaagcttggccattgcat  
 acgttgtatccatacataatataatgtacatttataatggctcatgtccaacattaccgcatgttgacattgattattgactgttata  
 atagtaatacaattacgggtcattagttcatagccatataatggagtccggttacataactacggtaaatggcccgctgg  
 ctgaccgccaacgacccccgccattgacgtcaataatgacgtatgttccatagtaacgccaatagggaacttccattga  
 cgtcaatgggttgagatttaccgtaaaactgccacttggcagtaatacaagtgatcatatgccaagtacgccccctattga  
 cgtcaatgacggtaaatggcccgctggcattatgccagtaacattgaggacttctacttggcagtaacatctacgt  
 attagtcacgtattaccatggtgatgcggttttggcagtaacatgagcgtggtgatagcgggttgactcacggggatttcc  
 aagctcaccaccattgacgtcaatgggagtttgggttggcaccaaaatcaacgggacttccaaaatgtcgtacaacactccg  
 cccattgacgcaaatgggcggtagcgtgtacgggtgggaggtctatataagcagagctcgtttagtgaaccggggtctct  
 ctggttagaccagatctgagcctgggagctctctggttaactaggggaacccactgcttaagcctcaataaagcttgccttga  
 gtgcttcaagtagtgtgtgccgtctgtgtgtgactctgtaactagagatccctcagacccttttagtcagtggtggaaaatct  
 ctgacagtgccgcccgaacaggggacctgaaagcgaaagggaacagagctctctcgcagcaggactcggcttgcgtga  
 agcgcgcacggcgaagaggcgaggggcgccgactgtgtgagtagccaaaaattttagactagcggaggctagaaggaga  
 gagatgggtgcgagagcgtcagtttaagcgggggagaaattagatcgcgatgggaaaaaattcgttaaggccagggggg  
 aaagaaaaaataataaattaaaacatagtagtgggcaagcaggagctagaacgaltcgcagttatcctggcctgttagaa  
 acatcagaaggctgtagacaaatactgggacagctacaacctccctcagacaggaatcagaagaacttagatcattatata  
 atacagtagcaacccctctattgtgtcatcaaaaggatagagataaaagacacaaagggaagctttagacaagatagaggaa  
 agcaaaaacaaagtaagaccaccgcacagcaagcggcgtgatcttcagacctggaggaggagatagagggacaaat  
 tggagaagtgaattatataaataaagtagtaaaaattgaaccattaggagtagcaccaccagggcaagagagaagagt  
 gtgcagagagaaaaagagcagtgagggaataggagcttgttcttgggttcttgggagcagcagggaagcactatggcgcc  
 agcctcaatgacgctgacgggtacaggccagacaattattgtctgtatagtgacgagcagagaacaatttgcagggtctatt

**Fig. 8b (2 of 3)**

[illegible]

Fig. 8b (3 of 3)

ccgcctgccttgcgcgtgctggacaggggctcggctgttgggcactgacaaltccgtgggtgtcgggggaagctgacgt  
 cctttccatggctgctcgcctgtgttgcacctggattctgcgcgggacgtccttctgctacgtccctcggccctcaatccag  
 cggaccttccctcccgccgtgctgccggtctcggcctcttccgcgtctcgcctcggccctcagacgagtcggatctc  
 cctttggccgctcccgccgtggaaltcagctcgggtacctttaagaccaatgacttacaaggcagctgtagatcttagcca  
 cttttaaaagaaaaggggggactggaagggttaattcactcccaacgaagacaagatctgcttttctgtactgggtctct  
 ctggttagaccagatctgagcctgggagctctcgtgctaactagggaaaccactgcttaagcctcaataaagcttgcctga  
 gtgctcaagtagtgtgtgccgtctgtgtgactctggtaactagagatccctcagacccttttagtcagtggtgaaaatct  
 ctgacgtagtagttagtcatcttattatcagttattataacttgaagaaatgaatatcagagagttagagggaacttgttta  
 ttgacgttataatggttacaataaagcaatagcatcacaaattcacaaataaagcatttttctactgcattctagtgtggtt  
 gtccaaactcatcaatgtatcttatcatgtctggtcttagctatcccggccctaactccggccagttccggccatttccgccc  
 atggctgactaatttttttattatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggctttt  
 tggaggcctaggcttttgcgtcagacgtacccaattcggcctatagttagtctgattacgcgcgtcactggccgtcgttta  
 caacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatcccccttccgacgtggcgttaata  
 gcgaagaggcccgaccgatcggccttcccaacagttgcgcagcctgaatggcgaatggcgcgacgcgcctgtagcg  
 gcgcattaagcggcggggtgtgtgtgttacgcgcagcgtgaccgctacacttgcagcgccttagcggccgtccttcc  
 gcttcttcccttcttctcggcacgttgcggccttcccgctcaagctctaaatcgggggctcccttaggggtccgatttag  
 tgccttacggcacctcgaacccaaaaaacttgattagggtgatgtgttcacgtagtggccatcgcctgatagacgggtttc  
 gcccttgacgttggagtcacgttcttaatagtggactctgttccaaacttgaacaacactcaaccctatctcgggtatct  
 ttgatttataagggatttgcgatttggcctattgttaaaaaatgagctgatttaacaaaaatttaacgcgaatttaacaaa  
 atattaacggttacaatttc




Fig. 9a

Fig. 9b (1 of 3)

caggtggcacttttcgggaaatgtgcgcggaacccctatttgttttttctaatacattcaaatatgtatccgctcatgaga  
 caataaccctgataaatgttcaataatattgaaaagggaagatgatgattcaacatttccgtgcgccctattccctttt  
 gggcattttgccttctgtttttgtcaccagaaacgctggtgaaagttaaagatgctgaagatcagttgggtgcacgagt  
 ggggttacatcgaactggatctcaacagcggtaagatccttgagagtttgcgccgaagaaacgttttccaatgatgacacttt  
 taaagtctgtatgtggcgcgggtattatcccgtattgacgccgggcaagagcaactcggcgcgcatacactatttctcaga  
 atgacttgggtgagtactcaccagtcacagaaaagcatcttaccggatggcatgacagtaagagaattatgcagtgtgccat  
 aaccatgagtataactgcggccaacttacttctgacaacgatcggaggaccgaaggagtaaccgctttttgcacaac  
 atgggggatcatgttaactgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccac  
 gatgctgtagcaatggcaacaacgttgcgcaaaactattactggaactacttactctgacttcccggcaacaattaatag  
 actggatggagcgggataaagttgcaggaccacttctgcgcctggcccttccggctggtgtttattgtgataaatctgg  
 agccggtgagcgtgggtctcgcggatcatgtcagcactggggccagatggttaagccctcccgatcgtagtattatcac  
 gacggggagtcaggcaactatggatgaacgaatagacagatcgtgagataggtgcctcactgattaagcattggtaact  
 gtcagaccaagttaactatatactttagattgatttaaaacttcaatttaaaaggatctagggtgaagatccttttgata  
 atctcatgacaaaatcccttaacgtgagtttctgctcactgagcgtcagaccccgtagaaaagatcaaggatcttctgag  
 atccttttttctgcgcgtaactgtgcttgcacaaaaaaaccaccgctaccagcgggtgtttgttggcggatcaagagct  
 accaactcttttccgaaggtaactggctcagcagagcgcagataccaatactgtccttctagttagccgtagttaggcc  
 accacttcaagaactctgtgacccgctacatcctgcctctgtaactctgttaccagtggtgctgctgagtgccgataag  
 tctgtcttaccgggttgactcaagacgatagttaccggataaggcgcagcggctgggtgaacgggggggtcgtgcac  
 acagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaagcggccacgcttccc  
 gaaggggagaaaggcggacaggtatccgtaagcggcagggctcggaaacagagagcgcacgagggagcttccaggg  
 ggaacgcttggatcttatactctgtcgggttcgccaccttgcacttgcagcgtcgtattttgtgactcgtcagggggg  
 cggagcctatgaaaaacgccagcaacgcggccttttacggcttgccttggccttttgccttctgctcacatgttcttctg  
 cgtatccctgattctgtgataaccgtattaccgctttagtgagctgataccgctcgcgcagcgaacgaccgagcgc  
 cagcggagtcagtgagcgaaggagcgggaagcgcaccaatagcaaacccctctcccgcgcgttggccgattcattaa  
 tgcagctggcacgacaggttcccgactggaaagcgggcagtgagcgcgaacgaattaatgtgagttagctcactcattag  
 gcaccccagcgttaccattatgcttccggctcgtatgtgtgtggaattgtgagcggataacaattcacacaggaacagc  
 tatgaccatgattacgccaagcgcgaattaaccctcactaaagggaacaaaagctggagctgcaagcttaattgtatctta  
 tgcataactctttagtcttgaacatgtaacgatgagtttagcaacatgccttacaaggagagaaaaagcaccgtcatgc  
 cgattgggtgaagtaaggtggtacgatcgtgccttattaggaaggcaacagacgggtctgacatggattggacgaaccact  
 gaattggcgcattgcagagatattgtattaaagtcctagctcgtacataataaacgggtctctgtgttagaccagatctgagc  
 ctgggagctctctggctaaactaggggaaccactgcttaagcctcaataaagccttgccttgagtgcttcaagtagtgtgtgccc  
 gtctgttgtgactctgtaactagagatccctcagaccctttagtcagtggtgaaaatctctagcagtggtgcgccgaaca  
 gggacctgaagggaagggaaccagagctctcgcagcagactcggcttgcgaagcgcgcacggcaagagggc  
 gagggggcggcactggtgagtagcgcacaaaattttgactagcggagctagaaggagagagatgggtgcgagagcgtc  
 agtattaagcgggggagaaattagatcgcgatgggaaaaaattcggtaaggccagggggaagaaaaaataataaaa  
 acatatagtatgggcaagcagggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaagcgttagaca  
 aatactgggacagctacaaccatccctcagacaggatcagaagaacttagatcattatataatacagtagcaaccctctatt  
 gtgtgcatcaaggatagagataaaagacaccaaggagccttagacaagatagaggaagagcaaaacaaaagtaagac  
 caccgcacagcaagcggcgcgtgatctcagacctggaggaggagatatagggacaattggagaagtgaattatataaa  
 tataaagtagtaaaaattgaaccattaggagtagcaccaccaaaggcaagagaagagtggtgcagagagaaaaagag  
 cagtggggaataggagccttgttcttgggttcttgggagcagcaggaagcactatgggcgcagcctcaatgacgctgacgg  
 tacaggccagacaattattgtctgtatagtgacgagcagaacaatttgcaggggctattgaggcgcaacagcatctgtt  
 gcaactcacagctctgggcatcaagcagctccaggcaagaatcctggctgtgaaagatacctaaaggatcaacagctcc  
 tggggatttgggttctctggaactcatttgcaccactgctgtgccttggatgctagtggagtaataatctctggaac  
 agattggaatcacacgacctggatggagtgggacagagaaattaacaattacacaagcctaatacactcctaattgaagaa  
 tcgcaaaaccagcaagaaaagaatgaacaaagatttgaattagataaatgggcaagtttgggaattgttaacataac  
 aaattggctgtgtatataaaattatcataatgatagtaggagccttgtaggttaagaatagttttgctgtacttctatagtg  
 aatagagttaggcagggatattaccattatcgtttacagccacctcccaaccccgaggggaccogacaggcccgaagg

aatagaagaagaagggtggagagagagacagacagacatccattcgattagtgaacggatctcgacgggtatcggttaacttt  
taaaaagaaaaggggggattgggggggtacagtgcagggggaaagaatagttagacataatagcaacagacatacaaaactaaa  
gaattacaaaaacaattacaaaaattcaaaattttatcgtacacgagactagcctcgagagatctgtatcataatcagccatac  
cacattgttagagggtttacttctttaaaaaacctcccacacctcccctgaaacctgaaacataaaatgaatgcaattgttggtt  
ttaacttgtttattgcagcttataatggttacaataagggcaatagcafcacaaatttcacaaataagggcaattttttacttgcattc  
tagttttggtttgtccaaactcataatgtatcttataatgtctgtgatctcaaatcccctcggaagctgcgcctgtcttaggttggag  
tgatacatttttatcacttttaccctgtctttggattaggcagtagtctgtacggccctcctgtcttaggttagtgaanaatgtcact  
ctcttaccctgctattggctgtccagcttagctcgcaggggagggtggtctgtgatccctggatatcaagaattcgtctcaggct  
cagatcctctagaattacacggcgatcttccgcccttcttggcctttatgaggalctctgtattttcttgcgtcgagtttccgg  
taagacctttcgggtacttctgccaaaaacacaaactcctccggcgaactttttcggggttgaacttgaactggccacgtaaccac  
gatctctttttcgcgtcgtcttccgtgtctcaaaaacaacacggcgggcggaagtaccggcggtcatcgtcgggaaga  
cctgcgacacctgcgtcgaagatgttgggggtgttggagcaagatgattccaattcagcggggagccacgtatagcctttgt  
acttaacagagacttcaggcggtcgaacgatgaagaagtgttcgtcttcgtcccagtaagctatgtctccagtagtagcctgat  
ccatcctgtcaatcaaggcgttggctgttccggattgtttacataaacggacataataataggaacctctcacacaggttcg  
cctctgttataacgccctggttttccgggtatgcacgatcccaaccttcgcataaaatgggaacaaactttaccgaccggc  
cccggttattaccccccggtgtgaatcagaatagctatgtagtctcagtgagcccatccttgcctgatacctggcaga  
tggaaacctcttggcaaccgtctcccgaactccttagagaggggagcgccaccagaagcaatttctgttaaattagataaat  
cgtatttgtcaatcagagtgtcttttggcgaaagaaggagaatagggttggcaccagcagcgcactttgaatcttgaatcctga  
aggctcctcagaanaacagctcttcttcaaatctatacattaagacgactcgaatccacataatcaataatccgagtgtagtaaac  
attccaaaaccgtgatggaatggaacaacacttaaatcgcagtatccgggaatgatttgattgcaaaaataggaatctctggc  
atgcgagaatctcacgcaggcagttctatgaggcagagcgacaccttaggcagaccagtagatccagaggaggtcatgat  
cagtgcaattgtcttgcctatcgaaggactctggcacaanaatcgtattcattaaaccgggaggtagatgagatgtgacga  
acgtgtacatcgactgaaatccctggttaatccgttttagaatccatgataataatttttggatgattgggagcttttttgcacgtt  
caaaatttttgaacccctttttgaaacgaacaccacggtaggctgcgaatgccatactgttgagcaattcacgttctatta  
taaatgtcgttcggggcgcaactgcaactccgataataacgcgcccaacaccggcataaagaattgaagagaggtttca  
ctgcatacgacgattctgtgatttgaatcagccccatctgtttcatagcttctgccaacggaacggacatttcgaagtactcag  
cgtaaagtgtgtccacctcgaatgtgcactgttaaaggaattgttccagggaaccaggcggtatctctcatagaccttatgca  
gttgtctccagcgggttcatcttccagcggatagaatggcgccggggccttttttattgttttggcgcttccatggtgaattcc  
gatccccctgggggagagaggtcgggtgattcgggtcaacgaggggagccgactgccgacgtgcgtccggagggcttgcaga  
atggcggaacaccgcgcggggcagggaacaggggccacactaccgccccacaccccgcttccgcaccgcccccttccgg  
ccgctgtctcggcgcgccccgtgtgacgagccgctattggccacagcccatcgcggcggcgcgctgccattgtcctctg  
gcgctgtccgtctgcgagggtactagtgaagactgtcgggttccgtttgtacgtccggcacgccggaaccgcaagggaac  
cttcccgacttaggggcgggagcagggaagcgtcggcgggggggcccaagggtagcggcgaagatccgggtgacgctg  
cgaaacggacgtgaagaatgtgcgagaccaggggtcggcgccgctgtcgtttccgggaaccacgccagagcagccgcg  
tccctgcgcaaacccagggtcgccttggaaaaggcgcaaccccaaccccggtgggaattcgatatcaagcttgctatgttc  
ttttggaatctatcaaagtcttatgtaaatcttatgtaaacataataaaaagagtgtgatttttgagtaaaactgcaacagtc  
ctaacttcttctcgtgtgtttgtgtctgttcgccatcccgctccgctcgtcacttatccttacttttcagaggggtcccccg  
agatccgggtcacctcaggctgggtcgacaacctggtgtgagcaaggcgaggagctgttcaccgggggtgtgtgccatc  
ctggctgagctggacggcgacgtaaacggccacaaggttcagcgttccggcgaggggcgaggggcgatgccacctacgg  
caagctgaccttgaagttcatctgcaccaccggcgaagctgccctgtcccggccacccttctgaccacctgtacctacg  
gcgtgcagtgcttaccgcgtaccccgaccacatgaagcagcagcagcttctcaagtccgcatcccggaaggctacgtc  
cagggagcgtccatcttctcaaggagacgagcaactacagacaccttccggttgaggttgaagttcggggcgacacctg  
gtgaaccgcatcgagctgaaggggcatcgacttcaaggaggagggcaacatcctggggcgacaagctgtgagtacaactaca  
acagccacaacgtctatataatggccgacaagcagaagaacggcatcaaggtaacttcaagatccgccacaacatcgag  
gacggcagcgtgcagctcggcgaccactaccagcagaacacccccatcggcgacggccccgtgctgtcggcgacaac  
cactacctgagcaccaccgtccgctgagcaaaagaccccaacgagaagcgcgatcatcatggtctgtgaggatctgtga  
ccggcgccgggatcactctcggcatggacgagctgtacaagtaaaaggcgctcgcacaatcaacctctggattacaaaatt  
gtgaagaattgactggtattcttaactatgttctcctttttacgctatgtggatacgtcgttttaatgcottigtatcatgctattgct

Fig. 9b (3 of 3)

tcccgtatggctttcattttctcctcctgtataaatcctgggtgctgtctctttatgaggagttgtggcccgttgcaggcaacgtg  
 gcgtgggtgactgtgttgctgacgcaacccccactgggtggggcattgccaccacctgtcagctccttccgggacttgc  
 gctttcccccctcctattgccacggcggaactcatcgccgcctgcttggccgctgctggacaggggctcggctgttgggc  
 actgacaattccgtgggtgtgtcggggaagctgacgtcctttccatggctgctgcctgtgttccacctggattctgcgcgg  
 gacgtccttctgtacgtccctcggccctcaatccagcggaccttccctccgcggcctgctgcgggctctgcggcctcttc  
 cgcgtcttcgcttcgcccagacgagtcggatctcccttggggccgctcccgccctggaattcagctcggtaacttaa  
 gaccaatgacttacaaggcagctgtatcttagccacttttaaaagaaaaggggggactggaaggctaatcactccca  
 acgaagacaagatctgttttgcctgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagg  
 gaacccactgcttaagcctcaataaagccttgccttgagtgtctcaagtagtgtgtgccctgtctgtgtgactctggttaactag  
 agatccctcagacccttttagtcagtggtgaaaatctctagcagtagtagtcatgtcatctattattcagtatttataacttcaa  
 agaaatgaatatcagagagtgaagggaacttggtattgcagcttataatgggtacaaataaagcaatagcatcacaaatttca  
 caaataaagcattttttcactgcattctagttgtgtgttgcacaaactcatcaatgtatcttatcatgtctggctctagctatccgc  
 ccctaactccgcccagttccgcccattctccgcccctatggctgactaatttttttattatgcagaggccgaggccgctcgg  
 cctctgagctattccagaagtagtgaggaggctttttggaggcctaggcctttgcgtcgagacgtacccaattcggcctatag  
 tgagtcgtattacgcgcgtcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttaccacaacttaactgcc  
 ttgcagcacatcccccttccgagctggcgtaatagcgaaggagcccgaccgatcgccctcccaacagttgcgcagc  
 ctgaatggcggaatggcgcgacgcgccctgtagcggcgcatagcgcggcggtgtgtgtgttacgcgcagcgtgacc  
 gctacacttgcagcggcctagcgcggcgtccttctgcttctccttctccttctcgcacgttcggcggttccccgtcaag  
 ctctaaatcgggggctccctttaggggtccgatttagtgccttacggcacctcgaccccaaaaaacttgattagggtgatggtt  
 cacgtagtggggcctcgcctgatagacgggttttcgccccttgacgttggagtccacgttcttataataggactctgttcca  
 aactggaacaacactcaaccctatctcggctattcttttgattataagggttttgcgatttcggcctattggttaaaaaatga  
 gctgatttaacaaaaattaacgcgaattttaacaaaataataacgtttacaatttc




Fig. 10a

Fig. 10b (1 of 3)

cagggtggcacttttcggggaaatgtgcgcggaaccctatttgittatttttctaaatacattcaaatatgtatccgctcatgaga  
 caataacctgataaatgcttcaataatattgaaaaaggaagagatgagttatcaacatttccgtgctgcccattatcccttttt  
 ggggcatittgcttctgttttgcacccagaaacgctgggtgaaagttaaagatgctgaagatcagttgggtgcacgagt  
 ggggtacatcgaactggatcacaacgggtaagatccttgagagtttgcggcgaagaacgttttcaatgatgagcactti  
 taaagtctgctatgtggcgcggtaattatcccgtattgacggcgggcaagagcaacgcggcgcgcatacactatctcaga  
 atgacttgggtgagttactaccagtcacagaaaagcatcttaccggtggcagacagtaagagaattatgcagtctgccat  
 aacctgagtgataacactgcggccaacttacttgcacaacgacggaggaccgaaggagctaaccgctttttgcacaac  
 atgggggatcatgtaactgccttgatcgttgggaaccggagctgaatgaagccataccaacgacgagcgtgacaccac  
 gatgctgtgagcaatggcaacaacgttgcgcaactattaactggcgaactacttactctagcttccggcaacaattaatag  
 actggatggaggcgggataaagtgcaggaccacttctgcgctggcccttccgctggctggttattgctgataaacttgg  
 agcgggtgagcgtgggtctgcgggtatcattgcagcactggggccagatggtaagccctcccgatcgtagtattctacac  
 gacggggagtcaggcaactatggatgaacgaatagacagatcgtgagataggtgcctcactgattaagcattggtaact  
 gtcagaccaagttactatatacattagattgatttaaaacttattttaatttaaaaggatctaggtgaagatcccttttgata  
 atctcatgaccaaactccctaacgtgagtttctgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgag  
 atcccttttttgcgcgtaatctgctgcttgcacaacaaaaaacaccgctaccagcgggtggttgggtggcggatcaagagct  
 accaactcttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtcttctagtgtagccgtagttaggcc  
 accacttcaagaactctgtagcaccgcctacatacctgcctctgtaactctgttaccagtgctgctgccagtgccgataag  
 togtgtcttaccgggttgactcaagacgatagttacoggataagggcgcagcggctgggctgaacgggggggttcgtgcac  
 acagcccagcttggagcgaacgacacacacgaactgagatacctacagcgtgagctatgagaagcggcacgcttccc  
 gaaggggagaaaggcgacaggtatccggtaagcggcagggtcggaaacaggagagcgcacgaggagcttccagggg  
 ggaacgccttgatctttatagctctgcgggttgcacacctctgactgagcgtcgattttgtgatgctcgtcagggggg  
 cggagcctatggaanaacggcagcaacggccttttaccggcttctggccttttgccttggccttttgcacatgttcttctg  
 cgttatccctgattctgtgataaccgtattaccgctttagtgagctgataccgctcggcgcagccgaacgaccgagcg  
 cagcgagtcagtgagcgagggaagcggaaagcggcccaatagcgaacccgctctccccgcggttggccgattcattaa  
 tgcagctggcagcagaggttcccactggaagcggcgagtgagcgcaacgcaattaatgtgagttagctcactcattag  
 gcaccccaggctttacattatgcttccggctcgtatgttgggtggaattgtgagcgataacaatttcaacaggaacagc  
 tatgacatgattacgccaagcgcgaattaacctcactaaagggaacaaaagctggagctgcaagcttggccattgcat  
 acgttgtatccatacataatattgacattatattgctcatgtccaactaccgccatgttgacattgatttactagttatta  
 atagtaatcaattacgggtcattagttcatagcccatatattggagttccggttacataacttacggtaaatggcccgctgg  
 ctgacggcccaacgacccccgccattgacgtcaataatgacgtatgttccatagtaacgccaatagggaatttccattga  
 cgtcaatgggtggagattttacggtaaaactggccacttggcagctacatcaagtgatcatatgccaaagtagccccctattga  
 cgtcaatgacggtaaatggcccgctggcattatgccagctacatgacatttgggacttctacttggcagctacatctacgt  
 attagtcatcgtattaccatggtgatgcgggtttggcagctacatcaatggcggtggatagcgggttgactcacgggatttcc  
 aagcttccacccattgacgtcaatgggagtttgggttggcaccacaaatcaacgggacttccaaaatgtcgtacaactccg  
 cccattgacgcaaatggcggttaggcgtgtacgggtgggaggtctatataagcagagctcgttagtgaaccggggtctct  
 ctgggttagaccagatctgagcctgggagctctctggctaactagggaaccactgcttaagcccaataaagcttgccttga  
 gtgcttcaagtagtgtgtcccgtctgtgtgtgactctggtaactagagatccctcagaccccttttagtcagttgtgaaaatct  
 ctgacagtggtgccggaacaggacgtgaaagcgaagggaacagagctctctcagcgcaggactcggcttctga  
 agcgcgcacggcaagaggcgaggggcgactgggtgagtagcccaaaattttagtagcggagggtagaaggaga  
 gagatgggtgagagcgtcagttatagcgggggagaattagatcgcatgggaaaaaattcggtaaggccagggggg  
 aaagaaaaataataataaacataatagttggcgaagcaggagctagaacgattcgcagttaatctggcctgttagaa  
 acatcagaaggctgtagacaaactgggacagctacaacctccctcagacaggatcagaagaacttagatcattatata  
 atacagtagcaacctctattgtgtcatcaaaaggatagagataaaagacaccaagggaagcttagacaagatagaggag  
 agcaaaacaaaagtaagaccaccgcacagcaagcggcgtgatcttcagacctggaggaggagatataggggacaat  
 tggagaagtgaattatataataaagttagtaaaattgaaccattaggagtagcaccaccaaggcaagagagagtg  
 gtgcagagagaaaaagagcagtggtgaataggagcttggcttgggttgggagcagcagggaagcactatggggc  
 agcctcaatgacgctgacggtacaggccagacaattattgtctgtatagtgacgagcagagaacaatttctgagggtatt  
 gaggcgcaacagcatctgttgaactcacagcttggggcatcaagcagctccaggcaagaatctggctgtggaagata

Fig. 10 b (2 of 3)

cctaaggatcaacagctcctggggatttgggggtgctctggaaactcatttgcaccactgctgtgcttggaatgctagt  
 gagtaataaactctggaaacagatttgaatcacacgacctggatggagtgaggacagagaaataacaattacacaagctta  
 atacactccttaattgaagaatcgcaaaaccagcaagaaagaatgaacaagaattattggaattagataaatggcaagttt  
 gtggaattgtttaacatacaaaattggctgtgtatataaaattatcataatgatatagaggagcttgtaggtttaagaatag  
 ttttgcgtacttctatagtgaatagagttaggcaggatattaccattatcgtttcagaccacctcccaaccccgagggg  
 acccgacaggcccggaaggaaatagaagaagggtggagagagagacagagacagatccattcgtattgtgaacggatc  
 tcgacggatcgggttaacttttaaagaaaagggggattgggggtacagtgcaggggaaagaatagtagacataatag  
 caacagacatacaaaactaaagaattacaaaaacaaattacaaaaattcaaaattttatcgtacagagactagcctcgagga  
 gatctgatcataatcagccataccacattgtagagggtttacttcttataaaaaacctccacacctcccccgaacctgaac  
 ataaaaatgaatgcaattgttgttgaactgtttattgcagcttataatggttacaataaggcaatagcatcacaatttcaaa  
 ataaggcaatttttctactgcattctagtttgggtgtccaaactatcaatgtatcttcatgcttgatctcaaatccctcggaa  
 gctgcgcctgtcttaggttggagtatacattttatcatttaccctgtcttggattaggcagtagctctgacggccctcctgt  
 cttaggttagtgaataatgtcactcttaccctgtcattggctgtccagcttagctcgcaggggagggtggctgtggtaccat  
 gtctagagaataggaacttcggaataggaacttcggccgctttactgtacagctcgtccatgccgagagtgatcccgcc  
 ggccgttcacgaactccagcaggaccatgtgatcgccttctgttggggcttctgctcaggccggactgggtgctcaggta  
 gtgggtgtcggggcagcagcagggggccgtccgatgggggtgtctgctggttagtggctggcgagctgcacgctcgg  
 tctcgtatgttggcggatcttgaagttcaccttgatgccgttctgtctgtcggcatgatataagactgttgggtgttga  
 gttgtactccagcttggcccgaggatgttgcgtctccttgaagtcgatgcccttcagctcgtatgggttcacagggtgtc  
 gccctcgaacttcacctcggcgcgggtctttagtggcgtcgtccttgaagaagatgggtgcgtcctggacgtagccttcg  
 ggcatggcggacttgaagaagtcgtgctgtctatgtgtcgggtagcggctgaagcactgcacgccgttaggtcagggt  
 ggtcacgagggtggggccaggccagggcagcttgcgggtgggtgcagatgaacttcagggtcagcttggcgttaggtggc  
 atcggccctcggccctcggcgacacgctgaacttggccgtttacgtcggcgtccagctcgtaccaggatggggcaccaccc  
 cgggtgaacagctcctcggccttgcctcaccatggtgtcgaaccgacctgagggtgaccgggactcgtcggggggacccct  
 gaaaagtgaaggataagtgacgagcggagacgggatggcgaacagacacaaacacacgagagaagaatgttaggact  
 gttgcaagtttaactcaaaaaatcagcactctttatattatgtgttacataagcatttacataagacttggatagattcaaaaga  
 cataggcaagcttgatacgaattccacgggggttgggggttgcgccttttcaaggcagccctgggttgcgcaggagcgc  
 ggctgctctgggctggttccgggaacgcagcggcggcggccctgggtctcgcacattcttcacgtcgttgcagcgt  
 caccggatcttcggcgtacccttgttggcccccggcgacgcttctgctcggccctaaagtcgggaaggttcttgcg  
 gticggcgctgcccggacgtgacaacgggaagccgcacgtctcactagttaccctcgcagacggacagcggcaggagc  
 aatggcagcgcgcggaccgcgatgggtgtggccaatagcggctgctcagcggggcgccggcggagagcagcggccgg  
 gaagggggggtgcccggagggcgggggtgtggggcggttagtggggccctgttctcggccggcggtgttcgcattctgca  
 agcctccggagcgcacgtcggcagtcggctccctgttgaccgaatcaccgacctctctccagggggatccccgggg  
 ctgcaggaattcggccgcggccagctcggcgggcagggggggcgctggagcgcagcgcagcgcagcccatcag  
 tccgcaaagcggaccgagctggaagtcgagcgtcggcggggagggcggtggggggcaggtgccaccggccgc  
 gccatggacggggcgccctgctgctgttctgtcttctgggggtgtcccttggaggtgccaaaggaggcatccccacagg  
 cctgtacacacacagcgggtgagtgctgcaaaagcctgcaacctggggcagggtgtggccagccttgggagccaaccag  
 accgtgtgtgagccctgcctggacagcgtgacgttctccgacgtgggtgagcgcgaccgagccgtgcaagccgtgcaccg  
 agtgcgtgggggtccagagcatgtcggcgccgtgctggaggccgacgacgcccgtgtgcccgtgcgcctacggctact  
 accaggatgagacgactggcgctgcgagggcgtccgcgtgtgcgagggcggtcggccctgtgttctctgcccagg  
 acaagcagaacaccgtgtgcgaggagtccccgacggcacgtattccgacgagggccaaccacgtggacccgtgcctgc  
 cctgcaccgtgtgcgaggacaccgagcggcagctccgcgagtgacacagctggggccgacggcgagtgagaggatc  
 cctggccgttggattacacggtccacacccccagagggtcggacagcacagccccagcaccagggagcctgaggga  
 cctccagaacaagacctcatagccagcaggtggcaggtgtgtgtgaccacagtgtgggagctccagcccggtgtga  
 cccgaggcaccaccgacaacctatcccgtctattgtctcctcgtgctgtgtgtgtggcccttggccctacatagcc  
 ttaagagggtggaacagggggatcctctagctgagctagagtcgacaatcaacctctggattacaaaattgtgaaaga  
 ttgactggtattcttaactatgttgccttttacgctatgttgatagcgtctttaaagccttctgtatcatgctattgtccgtatg  
 gtttcaatttctcctctgtataaatcctgtgtgtgtcttctttagaggagttgtggccgtgtgtcaggcaacgtggcggtgtg  
 tgcactgtgttgcgtgacgcaacccccactggttggggcattgccaccacctgtcagctccttccgggacttccgtttcccc

Fig. 10b (3 of 3)

ctccctattgccacggcggaactcatcgccgcctgccttgcctgctggacaggggctcggctgttgggcaactgacaat  
 tccgtgggtgtgtcggggaagctgacgtcctttccatggctgctgcctgtgttggccacctggattctgcgcgggacgtcctt  
 ctgctacgtcccttcggccctcaatccagcggaccttccctcccgccctgctgcccggctctgcggcctctccgcgtctc  
 gccttcgccctcagacgagtcggatctcccttggggccgcctccccgcctggaattcgagctcggtaaccttaagaccaatg  
 acctacaaggcagctgtagatctagccacttttaaaagaaaaggggggactggaagggctaattcacaccaacgaaga  
 caagatctgcttttgcctgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaaacca  
 ctgctaagcccaataaagcttgccttgagtgctcaagtagtgtgtgcccgtctgtgtgtgactctggttaactagagatccc  
 tcagacccttttagtcagtggtgaaaatctctagcagtagtagttcatgtcatcttattattcagttattataacttgcaaagaaatg  
 aatacagagagtgagaggaactgtttattgcagcttataatggttacaaataaagcaatagcatcacaaattcacaaataa  
 agcattttttcaactgcattctagttgtgtgtgtccaaactcatcaatgtatcttatcatgtctggctctagctatccggccctaac  
 tccggccagttccgcccattctccgcccctatggctgactaatttttttatttatgcagaggccgagggccgctcggcctctga  
 gctattccagaagtagtgaggaggctttttggaggcctagggcttttgcgtcgagacgtacccaattcgcctatagtgagtc  
 gtattacgcgcgtcactggcgtcgtttacaacgtcgtgactgggaaaaccctggcgtacccaacttaatgccttgcag  
 cacatcccccttgcagctggcgtatagcgaagaggcccgcaccgatacgccttcccaacagttgcgcagcctgaat  
 ggcgaatggcgcgacgcgcctgtagcggcgcattaaagcggcggtgtgtgtgttacgcgcagcgtgaccgctaca  
 ctggcagcgccttagcggcgcctcttgccttttcccttcccttctcgcacgttcggcggttccccgtcaagctctaa  
 atcgggggctcccttaggggtccgatttagtgccttacggcacctcgcacccaaaaaacttgattagggtaggttcacgta  
 gtgggccatcgccctgatagacgggttttgcctttgacgttggagtcacgttcttataatagtgagctctgttccaaactgg  
 aacaacactcaacctatctcggctatcttcttattataagggaatttggcgatttcggcctattgggtaaaaaatgagctgatt  
 taacaaaaattaacgcgaatttaacaaaatattaacgtttacaatttc




Fig. 11a

Fig. 11b (1 of 3)

cagggtggacatttccgggaaatgtgcgcggaacccctattgtttattttttaaatacatcaaatatgtatccgctcatgaga  
 caataacccgtataaatgcttcaataatgaaaaaggaaagatgagttatcaacatttccgtgccccttattcccttttt  
 ggggcatittgcttctgttttgcacccagaaacgctggtagaaagtaaaagatgctgaagatcagttgggtgcacgagt  
 ggggtacatgaactggatcacaacagcggtaagatccttgagagttttcccccgaagaacgtttccaatgatgagcattt  
 taaagtctgctatgtggcgcgggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactatctcaga  
 atgacttggtagtactaccagtcacagaaagcatttaccgtaggcatgacagtaagagaattatgagtgctgccat  
 aaccatgagtgataacactgcggccaacttactctgacaacgatcggaggaccgaaggagctaaccgctttttgcacaac  
 atgggggacatgtaactgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccac  
 gatgcctgtagcaatggcaacaacgttgcgcaactattactggcgaactacttactctagcttccgggcaacaattaatag  
 actggatggaggcggataaagtgcaggaccacttctgcgctcggcccttcgggctggctgttttattgctgataaatctgg  
 agccggtgagcgtgggtctcgcgggtatcattgcagcactggggccagatgtaagccctccgtatcgtatctacac  
 gacggggagtcaggcaactatggatgaacgaatagacagatcgcctgagataggtgcctcactgattaagcattgtaact  
 gtcagaccaagttaactatatactttagattgatttaaaacttcaatttaatttaaaaggatctagtgaaagatccttttgata  
 atctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaggatctcttgag  
 atccttttttctgcgcgtaactctgctgttgcacacaaaaaacaccgcctaccagcgggtgtttgttgcggatcaagagct  
 accaactctttttccgaagtaactggcttcagcagagcgcagataccaatactgtccttctagtgtagccgtagtagggc  
 accacttcaagaactctgtagcaccgcctacatacctcgtctgtaactcgttaccagtggtcgtcgtcagtgagcgaataag  
 tctgttctaccgggttgactcaagacgatagttaccggataaggcgcagcgggtcgggtgaacgggggggtcgtgcac  
 acagcccagcttgagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaagcggccacgcttccc  
 gaaggagaaaggcggacaggtatccgtaagcggcaggggtcggaaaggagagcgcacgaggggagcttccagggg  
 ggaaacgcctgtatcttatagtcctgtcgggttcggccaccttacttgagcgtcgattttgtgatgctcgtcagggggg  
 cggagcctatggaaaaacggcagcaacgcggcctttttacgggtcctggccttttgccttttgcacatgttcttctg  
 cgttatccctgtattctgtggataaccgtattaccgctttagtgagctgataccgctcggcgcagccgaacgaccgagcg  
 cagcgagtgagtgagcgggaagcgggaagcggccaatacgaacacgccttctcccgcgcgttggccgattcattaa  
 tgcagctggcagcagaggttcccgactggaagcggggcagtgagcgaacgaatfaatgtgagtgatgctcactcattag  
 gcaccccaggctttacatttatgcttccggctcgtatgttggtaattgtgagcgggataacaatttcacacaggaacacagc  
 tatgacatgattacgccaagcgcgcaattaacccctactaaagggaacaaaagctggagctgcaagcttgccattgcat  
 acgttgtatccatataatataatgtacattatattggtcatgtccaactaccgccatgttgacattgattatgactagtatta  
 atagtaataattacggggctcattagttcatagcccatatattggagttccgcgttacataacttacggtaaatggcccgctgg  
 ctgacccgccaacgacccccgccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattga  
 cgtcaatgggtggagattttacggtaaactgcccacttggcagttacatcaaggtatcatatgccaaagtagccccctattga  
 cgtcaatgacggttaaatggcccgcttggcattatgcccagttacatgaccttattgggactttcctacttggcagttacatcagct  
 attagtcacgctattaccatgggtgatcgggttttggcagttacatcaatgggcgttggatagcgggttgactcaggggatttcc  
 aagtcctcccccattgacgtcaatgggagttgttttggcaccaaaatcaacgggactttccaaaatgtcgttaacaactccg  
 cccattgacgcaaatgggcggtaggcgtgtacgggtgggaggtctatataagcagagcgtcgttagtgaaacgggggtctct  
 ctggtagaccagatctgagcctgggagctctctgcttaactagggaacccactgcttaagcctcaataaagcttgccttga  
 gtgctcaagtagtgttgcctgtctgttgtgtgactctggttaactagatccctcagacccttttagtcagtggtgaaatct  
 ctgacagtgaggcggcgaacagggacctgaaagcgaagggaacagagctctctcagcagggactcggcttgcgtga  
 agcgcgcagcggcgaagaggcggggggcggcagtggtgagtagcgaacaaattttagtagcggaggttagaaggaga  
 gagatgggtgcgagagcgtcagttatgaagcgggggagaatagatcgcgatgggaaaaaaltcgggttaaggccagggggg  
 aaagaaaaataataaataaataatagatgtgggcaagcaggagctagaacgatttcgagttaatcctggcctgttagaa  
 acatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacaggatcagaagaacttagatcattatata  
 atacagtagcaaccctctattgtgtgcatcaagagtagagataaaagacaccaagggaagcttttagacaagatagagggaag  
 agcaaaacaaaagttaagaccaccgcacagcaagcggcgctgacttccagacctggaggagagatagagggaacat  
 tggagaagtgaattatataataaataaagtagtaaaatgaaccattaggagtagcaccaccaaaggcaagagaagagtg  
 gtgcagagagaaaaaagcagtggtgaataggagcttgttcttgggttcttgggagcagcaggaagcactatggcgcc  
 agcctcaatgacgctgacggtacagggcagacaattatgtctgtatagtgacgagcagaacaatttgcgtgagggtatt  
 gagggcgaacagcatctgttgaactcacagcttggggcatcaagcagctccaggcaagaatcctggtgtggaaagata

Fig. 11 b (2 of 3)

cctaaggatcaacagctcctggggatttggggttgccttggaaaactcatttgcaccactgctgtgccttggatgctagt  
 gtagtaataatctcttgaacagattggaatcacacgacctggatggagtgaggacagagaataaacaattacacaagctta  
 atacactccttaattgaagaatcgcaaaaccagcaagaaaaaatgaacaagaattattggaattagataaatgggcaagttt  
 gtggaattggttaacataacaattggctgtgtatataaaattattcataatgatagtaggagccttggtaggtttaagaatag  
 ttttgcctgactttctatagtgaatagagtttaggcagggaatattcaccattatcgttcagaccacctcccaaccccgagggg  
 acccgacaggcccgaaaggaaatagaagaaggagggtggagagagagacagagacagatccattcgttagtgaaaggatc  
 tcgacggatcgggttaacttttaaaagaaaaaggggggttgggggggtacagtgccaggggaaagaatagtagacataatag  
 caacagacatacaaaactaaagaattacaaaaacaattacaaaaattcaaaatttatcgtacagagactagcctcgagag  
 atcgtatcataatcagccataccacattttagtagaggtttacttgccttaaaaaaccccccacacccctccctgaacctgaaaca  
 taaaaatgaatgcaattgttggtaacttgtttatgcagcttataatggttacaataaggcaatagcatcacaaattcacaaa  
 taaggcattttttcacigcattcgttttgggttgcctaaactcatcaatgtatcttatcatgtctggatcctcaatccctcggaag  
 ctgcgcctgtcttaggttggagtgatacattttatcactttaccctgttggattaggcagtagctctgacggccctcctgtct  
 taggttagtgaaaaatgtcactcttaccctgtcattggctgtccagcttagctcgcaggggaggtggtctggatccgagctc  
 gaattggccgcttacttgcagctcgtccatgccgagagtgatccggcgggcggtcacgaactccagcaggaccatgtg  
 atcgcccttctcgttggggcttctgtcagggcggtggtggtcaggtagtggttgcgggcagcagcagggggccgtc  
 gccgatgggggtgttctgtcgttagtggtcgccgagctgcacgctgcctcctcgtggttgcgggagcttgaagttacc  
 ttgatccgttcttctgtcgttgcggcagatagacgttgggtgtttagttgtactcagcttgcggccaggtgttgc  
 gtctccttgaagtcgatgcccttcagctcgtatgcgggtcaccagggtgtcggccctgaactcaccctggcgccgggtcttgt  
 agttgccgtcgtccttgaagaagatggtgcgctcctggacgtatgcctcgggcatggcggttgaagaagtcgtgctgtt  
 catgtggtcggggtagcgggtgaagcactgcacgccgttaggtcaggggtgttcacgaggggtggccaggggcacgggca  
 gcttgcgggtgtgagatgaactcagggtcagcttgcgttaggtggcatcggccctcggccctcggcgacacgtgaaat  
 tgtggccgtttacgtcggcgtccagctcagccaggtgggacaccccggtgaacagctcctcggccctgtcaccatgg  
 tgaattccgcggaggctggatcggctccgggtgtcttctatggaggtcaaaacagcgtggatggcgtcctcagggcatctga  
 cgggtcactaaacagctcgtctatagggcctccaccgtacacgctaccctcagagaagcttgattaaaccgtgtcggct  
 ccagatctggcctccggccgggtttggcgccctccggcgcccccctcctcagggcgagcgtgcccacgtcagac  
 gaaggcgccagcagcgtcctgacccctccggcgacgctcagggacagcggcccgctgctcataagactcggccttag  
 aacccagctatcagcagaaggacattttaggacgggacttgggtgactctagggcactggttttcttccagagagcggaaac  
 aggcgaggaagtagtcccttctcggcgattctgcggagggtatcctcgtggggcggtgaacgccgatgattatataagg  
 acgcccgggtgtggcacagctagtctcgcagccgggatttgggtcgggtctgttggatcgtgtgacgtca  
 ctgtgtgagttggggctgtcgggtcggccggggcttctgtggccggcgggcgctcgtgggacggaagcgtgtggag  
 agaccgccaaaggcgtgtagctgtgggtccgcgagcaagggttgcctgaactgggggttggggggagcgcacaaatggc  
 ggctgttcccgagcttgaatggaagacgttgaaggcggggtgtgaggtcgttgaacaagggtggggggcagcgtgtggg  
 cggcaagaaccgaaggcttggggccttcgtaatgcgggaaagcttattcgggtgagatgggctggggcaccatctg  
 gggaccctgacgtgaagtttgcactgactggagaactcgggttgcgtcgtgtggttgcggggcgggcagttatgcgggtgcc  
 gttgggagtgacccgtaccttggggagcgcgcctcgtcgtgacgtcaccgttctgttggcttataatgcagg  
 gtggggccacctgccggtaggtgtgcggtaggcttctcgtcgcaggacgaggggtcgggcttagggtaggtctcct  
 gaatcgacaggcgccggacctctgtgtggggagggagataagtgaggcgtcagtttcttggctgggtttatgtacctatctc  
 ttaagtagctgaagctccgggtttgaactatgcgtcgggggttggcgaggtgttttgaagtttttaggcaccttttgaatgt  
 aatcatttgggtcaatatgtaatttcagttgttagactagtaaatgtccgctaaattctggccgtttttggtttttgttagacgaa  
 gcttgggtcagcgaattcggggccggccagctccggcgggcagggggggcgctggagcgcagcgcagcgcagcc  
 ccatcagctccaaaggacggagctggaagtcgagcgtcggcgggagggcgatggggcgaggtgccacc  
 ggccgcgcatggagggccgcgcctgctgctgttgccttctgggggtgtcccttggaggtgccaaggaggcatgcc  
 ccacaggcctgtacacacacagcgtgagtgctgcaaaagcctgcaacctgggcgaggggtgtggccagccttgtggagc  
 caaccagaccgtgtgtgagccctgcctggacagcgtgacgttctccagcgtgtgagcgcgaccgagcgtgcaagccg  
 tgcaccgagtgctgtgggctccagagcatgtcggcgccgtgcgtggagggcgacgacgccgtgtccgctgcgctac  
 ggctactaccaggtgagacgactggcgctgcgagggcgtgccgctgtgcgagggcgggctcgggctcgtgttctcct  
 gccaggacaagcagaaccgtgtgtcgagggagtgcggcgacggcacgtattccgacgagggccaaccacgtggaccgg  
 tgcctcggctgcacgtgtgcgagggacaccgagcggcagctccgcgagtgacacgctggggcgacggcgagtgcca

Fig. 11b (3 of 3)

ggagatccctggccgttgattacacgggtccacacccccagagggctcggacagcacagccccagcaccagggagcc  
 tgaggcacctccagaacaagacctcatagccagcacgggtggcaggtgtggtgaccacagtgtatgggcagctcccagccc  
 gtggtgacccgaggcaccaccgacaacctcaccctgtctattgtccatcctggctgtgtggttggggccttgggccta  
 catagccctcaagaggtggaacaggggagtcctctagagtcgagtcctagagtcgacaatcaacctciggattacaaaatttg  
 tgaagattgactggtattcttaactatgttgctcctttacgctatgtggatacgtgctttaatgccttgtatcatgctattgcttc  
 ccgtatggctttcatittctcctcctgtataaatcctggtgtgtctctttatgaggagttgtggcccgtgtcaggcaacgtgg  
 cgtggtgtgcactgtgttgtgacgcaacccccactggttggggcattgccaccacctgtcagctccttccgggactttcg  
 ctttccccctccctattgccacggcggaactcaicgccgctgcttggccgctgtgtggacaggggctcggctgttgggca  
 ctgacaattccgtgtgtgtgtcggggaagctgacgtcctttccatggctgtctgcctgtgttggccacctggattctgcgggg  
 acgtccttctgtacgtccctcggccctcaatccagcggaccttccctcccgccgctgtgtccggctctgcggcctctcc  
 gcgtcttcgcttcgccctcagacgagtcggatcctccttggggccgctccccgcctggaattcagctcgggtacctttaag  
 accaatgacttacaaggcagctgtagatcttagccacttttaaaagaaaaggggggactggaagggttaattcactcccaa  
 cgaagacaagatctgttttgcctgtactgggtctctctgtttagaccagatctgagcctgggagctctctggctaactaggg  
 aaccactgcttaagcccaataaagcctgacctgagtgcttcaagtagtgtgtgcccgtctgtgtgtgactctgtaactaga  
 gatccctcagacccttttagtcagtggtgaaaatctctagcagtagtagtcatctattattcagttattataacttgcaaa  
 gaaatgaatatcagagagtgagaggaactgtttattgcagcttataatggttacaataaagcaatagcatcacaaattcac  
 aaataaagcattttttcactgcattctagtgtgtgttgcctcaactcaatgtatcttatcatgtctgtgctctagctatccgccc  
 cctaactccgcccagttccgccattctccgcccatggtgactaattttttttatgacagaggccgagggccgctcggc  
 ctctgagctattccagaagtagtgaggaggctttttggaggcctaggcttttgcgtcagacgtacccaattcggccctatagt  
 gagtctgtattacgcgcgtcactggccgtcgtttacaacgtcgtgactgggaaaaccctggcgttaccacaacttaatcgct  
 tgcagcacatccccctttcggcagctggcgttaatagcgaaggcccgaccgatcggccttccaacagttgcgcagcc  
 tgaatggcgaatggcgcgacgcgccctgtagcggcgcatfaagcgcggcggtgtgtgtgttacgcgcagcgtgaccg  
 ctacacttgccagcgccctagcggccgctccttgccttctccttctccttctcggcacgttcggcgcttccccgtcaagc  
 tctaaatcgggggctcctttaggggtccgatttagtgccttacggcacctcgaacccaaaaaacttgattaggggtgatggttc  
 acgtagtggggccatcgccctgatagacggttttgcctttgacgttggagtcacacgttctttaatagtgactcttgttcaa  
 actggaacaacactcaacctatctcgggtctattctttgattataagggaatttgcgatttcggcctattgggttaaaaatgag  
 ctgatttaacaaaaatttaacgcgaattttaacaaaataaataacgtttacaatttc

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 02064804 A [0006]
- US 6388170 B [0008] [0009] [0009]
- WO 0134825 A [0010]
- IT 2004000227 W [0064]

## Non-patent literature cited in the description

- KAY, M.A. ; GLORIOSO, J.C. ; NALDINI, L. *Nat Med*, 2001, vol. 7, 33-40 [0063]
- NEFF, T. et al. *J Clin Invest*, 2003, vol. 112, 1581-1588 [0063]
- BORDIGNON, C. ; RONCAROLO, M.G. *Nat. Immunol.*, 2002, vol. 3, 318-321 [0063]
- SADELAIN, M. *J Gene Med*, 2002, vol. 4, 113-121 [0063]
- BONINI, C. et al. *Science*, 1997, vol. 276, 1719-1724 [0063]
- HACEIN-BEY-ABINA, S. et al. *Science*, 2003, vol. 302, 415-419 [0063]
- BURTON, E.A. ; GLORIOSO, J.C. ; FINK, D.J. *Gene Ther*, 2003, vol. 10, 1721-1727 [0063]
- SADELAIN, M. ; RIVIERE, I. ; BRENTJENS, R. *Nat Rev Cancer*, 2003, vol. 3, 35-45 [0063]
- MILLER, A.D. *Retroviruses*. Cold Spring Harbor Laboratory Press, 2000, 437-474 [0063]
- EMERMAN, M. ; TEMIN, H.M. *Mol Cell Biol*, 1986, vol. 6, 792-800 [0063]
- ZHU, Y. et al. *Mol Ther.*, 2001, vol. 4, 375-382 [0063]
- KLUMP, H. et al. *Gene Ther.*, 2001, vol. 8, 811-817 [0063]
- FURLER, S. et al. *Gene Ther*, 2001, vol. 8, 864-873 [0063]
- MARTINEZ-SALAS, E. *Curr Opin Biotechnol.*, 1999, vol. 10, 458-464 [0063]
- FOLLENZI, A. et al. *Nat Genet*, 2000, vol. 25, 217-222 [0063]
- GHATTAS, I.R. ; SANES, J.R. ; MAJORS, J.E. *Mol Cell Biol.*, 1991, vol. 11, 5848-5859 [0063]
- QIAO, J. et al. *Hum Gene Ther*, 2002, vol. 13, 881-887 [0063]
- LOIS, C. et al. *Science*, 2002, vol. 295, 868-872 [0063]
- BARON, U. ; BUJARD, H. *Methods Enzymol.*, 2000, vol. 327, 401-421 [0063]
- BRAY, M. et al. *Proc Natl Acad Sci USA*, 1994, vol. 91, 1256-1260 [0063]
- ZUFFEREY, R. et al. *J Virol.*, 1999, vol. 73, 2886-2892 [0063]
- AILLES, L. et al. *Mol Ther*, 2002, vol. 6, 615-626 [0063]
- CAVALIERI, S. et al. *Blood*, 2003, vol. 102, 497-505 [0063]
- NALDINI, L. et al. *Proc Natl Acad Sci U SA*, 1996, vol. 93, 11382-11388 [0063]
- BAEKELANDT, V. et al. *Hum Gene Ther*, 2002, vol. 13, 841-853 [0063]
- DEGLON, N. et al. *Hum. Gene Ther.*, 2000, vol. 11, 179-190 [0063]
- SOKOLIC, R.A. et al. *Blood*, 1996, vol. 87, 42-50 [0063]
- WONG, E.T. ; NGOI, S.M. ; LEE, C.G. *Gene Ther*, 2002, vol. 9, 337-344 [0063]
- KOZAK, M. *Gene*, 2003, vol. 318, 1-23 [0063]
- MIZUGUCHI, H. et al. *Mol Ther*, 2000, vol. 1, 376-382 [0063]
- HENNECKE, M. et al. *Nucleic Acids Res*, 2001, vol. 29, 3327-3334 [0063]
- MAZURIER, F. et al. *Blood*, 2004, vol. 103, 545-552 [0063]
- VIGNA, E. ; NALDINI, L. *J Gene Med*, 2000, vol. 2, 308-316 [0063]
- GARDINER-GARDEN, M. ; FROMMER, M. *J Mol Biol*, 1987, vol. 196, 261-282 [0063]
- LAVIA, P. ; MACLEOD, D. ; BIRD, A. *EMBO J*, 1987, vol. 6, 2773-2779 [0063]
- JOHNSON, P. ; FRIEDMANN, T. *Gene*, 1990, vol. 88, 207-213 [0063]
- SCACHERI, P.C. et al. *Genesis*, 2001, vol. 30, 259-263 [0063]
- VIGNA, E. et al. *Mol Ther*, 2002, vol. 5, 252-261 [0063]
- BARON, U. et al. *Nucleic Acids Res.*, 1995, vol. 23, 3605-3606 [0063]
- UNSINGER, J. et al. *Mol Ther*, 2001, vol. 4, 484-489 [0063]
- FUX, C. et al. *J Gene Med*, 2003, vol. 5, 1067-1079 [0063]
- XIE, M. ; HE, Y. ; GAN, S. *Nat Biotechnol*, 2001, vol. 19, 677-679 [0063]
- TRINKLEIN, N.D. et al. *Genome Res*, 2004, vol. 14, 62-66 [0063]
- TAKAI, D. ; JONES, P.A. *Mol Biol Evol*, 2004, vol. 21, 463-467 [0063]

**EP 1 616 012 B1**

- **ADACHI, N. ; LIEBER, M.R.** *Cell*, 2002, vol. 109, 807-809 [0063]
- **FARSON, D. et al.** *Hum Gene Ther*, 2001, vol. 12, 981-997 [0063]
- **DE PALMA, M. et al.** *Nat Med*, 2003, vol. 9, 789-795 [0063]
- **FOLLENZI, A. et al.** *Hum Gene Ther*, 2002, vol. 13, 243-260 [0063]